Uterotonic agents for preventing postpartum haemorrhage::a network meta-analysis by Gallos, Ioannis D et al.
 
 
Uterotonic agents for preventing postpartum
haemorrhage:
Gallos, Ioannis D; Williams, Helen M; Price, Malcolm J; Merriel, Abi; Gee, Harold; Lissauer,
David; Moorthy, Vidhya; Tobias, Aurelio; Deeks, Jonathan J; Widmer, Mariana; Tunçalp,
Özge; Gülmezoglu, Ahmet Metin; Hofmeyr, G Justus; Coomarasamy, Arri
DOI:
10.1002/14651858.CD011689.pub2
License:
None: All rights reserved
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Gallos, ID, Williams, HM, Price, MJ, Merriel, A, Gee, H, Lissauer, D, Moorthy, V, Tobias, A, Deeks, JJ, Widmer,
M, Tunçalp, Ö, Gülmezoglu, AM, Hofmeyr, GJ & Coomarasamy, A 2018, 'Uterotonic agents for preventing
postpartum haemorrhage: a network meta-analysis' Cochrane Library.
https://doi.org/10.1002/14651858.CD011689.pub2
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility:17/05/2018
Gallos ID, Williams HM, Price MJ, Merriel A, Gee H, Lissauer D, Moorthy V, Tobias A, Deeks JJ, Widmer M, Tunçalp Ö, Gülmezoglu AM,
Hofmeyr GJ, Coomarasamy A. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database of
Systematic Reviews 2018, Issue 4. Art. No.: CD011689. DOI: 10.1002/14651858.CD011689.pub2.
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 13. Aug. 2019
Cochrane Database of Systematic Reviews
Uterotonic agents for preventing postpartum haemorrhage: a
network meta-analysis (Review)
Gallos ID, Williams HM, Price MJ, Merriel A, Gee H, Lissauer D, Moorthy V, Tobias A, Deeks JJ,
Widmer M, Tunçalp Ö, Gülmezoglu AM, Hofmeyr GJ, Coomarasamy A
Gallos ID, Williams HM, Price MJ, Merriel A, Gee H, Lissauer D, Moorthy V, Tobias A, Deeks JJ, Widmer M, Tunçalp Ö, Gülmezoglu AM, Hofmeyr
GJ, Coomarasamy A.
Uterotonic agents for preventing postpartum haemorrhage: a networkmeta-analysis.
Cochrane Database of Systematic Reviews 2018, Issue 4. Art. No.: CD011689.
DOI: 10.1002/14651858.CD011689.pub2.
www.cochranelibrary.com
Uterotonic agents for preventing postpartumhaemorrhage: a networkmeta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
16RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Figure 7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Figure 8. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Figure 9. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Figure 10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
Figure 11. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Figure 12. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
Figure 13. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Figure 14. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
Figure 15. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Figure 16. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Figure 17. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Figure 18. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Figure 19. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Figure 20. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Figure 21. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Figure 22. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Figure 23. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Figure 24. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Figure 25. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Figure 26. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Figure 27. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Figure 28. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Figure 29. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Figure 30. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Figure 31. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Figure 32. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Figure 33. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
Figure 34. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
Figure 35. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
Figure 36. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
Figure 37. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Figure 38. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
Figure 39. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
Figure 40. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
Figure 41. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
Figure 42. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
Figure 43. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
iUterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 44. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
Figure 45. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
Figure 46. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Figure 47. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
Figure 48. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
Figure 49. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
Figure 50. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Figure 51. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
Figure 52. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
Figure 53. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
Figure 54. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
Figure 55. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
Figure 56. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
Figure 57. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
Figure 58. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
Figure 59. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
Figure 60. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Figure 61. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
Figure 62. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
Figure 63. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
Figure 64. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
Figure 65. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
Figure 66. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Figure 67. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
Figure 68. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
Figure 69. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
Figure 70. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
Figure 71. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Figure 72. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
Figure 73. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
Figure 74. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
Figure 75. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
Figure 76. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
Figure 77. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
93DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
95AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
95ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
96REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
125CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
353APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
354CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
354DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
355SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
356DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
iiUterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Uterotonic agents for preventing postpartum haemorrhage: a
network meta-analysis
Ioannis D Gallos1, Helen M Williams1, Malcolm J Price2, Abi Merriel3, Harold Gee4, David Lissauer5 , Vidhya Moorthy6, Aurelio
Tobias1 , Jonathan J Deeks7, Mariana Widmer8, Özge Tunçalp8 , Ahmet Metin Gülmezoglu8, G Justus Hofmeyr9, Arri Coomarasamy1
1Tommy’s National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, University of Birmingham, Birm-
ingham, UK. 2School of Health and Population Sciences, University of Birmingham, Birmingham, UK. 3Bristol Medical School, Uni-
versity of Bristol, SouthmeadHospital, UK. 4Birmingham, UK. 5School of Clinical and ExperimentalMedicine, University of Birming-
ham, Birmingham, UK. 6Department of Obstetrics and Gynaecology, Sandwell and West Birmingham NHS Trust, Birmingham, UK.
7Institute of Applied Health Research, University of Birmingham, Birmingham, UK. 8UNDP/UNFPA/UNICEF/WHO/World Bank
Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive
Health and Research, World Health Organization, Geneva, Switzerland. 9Walter Sisulu University, University of the Witwatersrand,
Eastern Cape Department of Health, East London, South Africa
Contact address: Ioannis D Gallos, Tommy’s National Centre for Miscarriage Research, Institute of Metabolism and Systems Research,
University of Birmingham, C/o Academic Unit, 3rd Floor, Birmingham Women’s Hospital Foundation Trust, Mindelsohn Way,
Birmingham, B15 2TG, UK. i.d.gallos@bham.ac.uk, gallosioannis@gmail.com.
Editorial group: Cochrane Pregnancy and Childbirth Group.
Publication status and date: New, published in Issue 4, 2018.
Citation: Gallos ID, Williams HM, Price MJ, Merriel A, Gee H, Lissauer D, Moorthy V, Tobias A, Deeks JJ, Widmer M, Tunçalp Ö,
Gülmezoglu AM, Hofmeyr GJ, Coomarasamy A. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.
Cochrane Database of Systematic Reviews 2018, Issue 4. Art. No.: CD011689. DOI: 10.1002/14651858.CD011689.pub2.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Postpartum haemorrhage (PPH) is the leading cause of maternal mortality worldwide. Prophylactic uterotonic drugs can prevent PPH,
and are routinely recommended. There are several uterotonic drugs for preventing PPH but it is still debatable which drug is best.
Objectives
To identify the most effective uterotonic drug(s) to prevent PPH, and generate a ranking according to their effectiveness and side-effect
profile.
Search methods
We searchedCochrane Pregnancy and Childbirth’s Trials Register (1 June 2015), ClinicalTrials.gov and theWorld Health Organization
(WHO) International Clinical Trials Registry Platform (ICTRP) for unpublished trial reports (30 June 2015) and reference lists of
retrieved studies.
Selection criteria
All randomised controlled comparisons or cluster trials of effectiveness or side-effects of uterotonic drugs for preventing PPH.
Quasi-randomised trials and cross-over trials are not eligible for inclusion in this review.
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Data collection and analysis
At least three review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy.
We estimated the relative effects and rankings for preventing PPH≥ 500 mL and PPH≥ 1000 mL as primary outcomes. We performed
pairwise meta-analyses and network meta-analysis to determine the relative effects and rankings of all available drugs. We stratified our
primary outcomes according to mode of birth, prior risk of PPH, healthcare setting, dosage, regimen and route of drug administration,
to detect subgroup effects.The absolute risks in the oxytocin are based on meta-analyses of proportions from the studies included in
this review and the risks in the intervention groups were based on the assumed risk in the oxytocin group and the relative effects of the
interventions.
Main results
This network meta-analysis included 140 randomised trials with data from 88,947 women. There are two large ongoing studies. The
trials were mostly carried out in hospital settings and recruited women who were predominantly more than 37 weeks of gestation
having a vaginal birth. The majority of trials were assessed to have uncertain risk of bias due to poor reporting of study design. This
primarily impacted on our confidence in comparisons involving carbetocin trials more than other uterotonics.
The three most effective drugs for prevention of PPH ≥ 500 mL were ergometrine plus oxytocin combination, carbetocin, and
misoprostol plus oxytocin combination. These three options weremore effective at preventing PPH≥ 500 mL compared with oxytocin,
the drug currently recommended by the WHO (ergometrine plus oxytocin risk ratio (RR) 0.69 (95% confidence interval (CI) 0.57 to
0.83), moderate-quality evidence; carbetocin RR 0.72 (95% CI 0.52 to 1.00), very low-quality evidence; misoprostol plus oxytocin RR
0.73 (95% CI 0.60 to 0.90), moderate-quality evidence). Based on these results, about 10.5% women given oxytocin would experience
a PPH of ≥ 500 mL compared with 7.2% given ergometrine plus oxytocin combination, 7.6% given carbetocin, and 7.7% given
misoprostol plus oxytocin. Oxytocin was ranked fourth with close to 0% cumulative probability of being ranked in the top three for
PPH ≥ 500 mL.
The outcomes and rankings for the outcome of PPH ≥ 1000 mL were similar to those of PPH ≥ 500 mL. with the evidence for
ergometrine plus oxytocin combination being more effective than oxytocin (RR 0.77 (95% CI 0.61 to 0.95), high-quality evidence)
being more certain than that for carbetocin (RR 0.70 (95% CI 0.38 to 1.28), low-quality evidence), or misoprostol plus oxytocin
combination (RR 0.90 (95% CI 0.72 to 1.14), moderate-quality evidence)
There were no meaningful differences between all drugs for maternal deaths or severe morbidity as these outcomes were so rare in the
included randomised trials.
Two combination regimens had the poorest rankings for side-effects. Specifically, the ergometrine plus oxytocin combination had the
higher risk for vomiting (RR 3.10 (95% CI 2.11 to 4.56), high-quality evidence; 1.9% versus 0.6%) and hypertension [RR 1.77 (95%
CI 0.55 to 5.66), low-quality evidence; 1.2% versus 0.7%), while the misoprostol plus oxytocin combination had the higher risk for
fever (RR 3.18 (95% CI 2.22 to 4.55), moderate-quality evidence; 11.4% versus 3.6%) when compared with oxytocin. Carbetocin
had similar risk for side-effects compared with oxytocin although the quality evidence was very low for vomiting and for fever, and was
low for hypertension.
Authors’ conclusions
Ergometrine plus oxytocin combination, carbetocin, and misoprostol plus oxytocin combination were more effective for preventing
PPH ≥ 500 mL than the current standard oxytocin. Ergometrine plus oxytocin combination was more effective for preventing PPH
≥ 1000 mL than oxytocin. Misoprostol plus oxytocin combination evidence is less consistent and may relate to different routes and
doses of misoprostol used in the studies. Carbetocin had the most favourable side-effect profile amongst the top three options; however,
most carbetocin trials were small and at high risk of bias.
Amongst the 11 ongoing studies listed in this review there are two key studies that will inform a future update of this review. The first
is a WHO-led multi-centre study comparing the effectiveness of a room temperature stable carbetocin versus oxytocin (administered
intramuscularly) for preventing PPH in women having a vaginal birth. The trial includes around 30,000 women from 10 countries.
The other is a UK-based trial recruiting more than 6000 women to a three-arm trial comparing carbetocin, oxytocin and ergometrine
plus oxytocin combination. Both trials are expected to report in 2018.
Consultation with our consumer group demonstrated the need for more research into PPH outcomes identified as priorities for women
and their families, such as women’s views regarding the drugs used, clinical signs of excessive blood loss, neonatal unit admissions
and breastfeeding at discharge. To date, trials have rarely investigated these outcomes. Consumers also considered the side-effects of
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uterotonic drugs to be important but these were often not reported. A forthcoming set of core outcomes relating to PPH will identify
outcomes to prioritise in trial reporting and will inform futures updates of this review. We urge all trialists to consider measuring these
outcomes for each drug in all future randomised trials. Lastly, future evidence synthesis research could compare the effects of different
dosages and routes of administration for the most effective drugs.
P L A I N L A N G U A G E S U M M A R Y
Which drug is best for reducing excessive blood loss after birth?
What is the issue?
The aim of this Cochrane review was to find out which drug is most effective in preventing excessive blood loss at childbirth and has
the least side-effects. We collected and analysed all the relevant studies to answer this question.
Why is this important?
Bleeding after birth is the most common reason why mothers die in childbirth worldwide. Although most healthy women can cope
well with some bleeding at childbirth, others do not, and this can pose a serious risk to their health and even life. To reduce excessive
bleeding at childbirth, the routine administration of a drug to contract the uterus (uterotonic) has become standard practice across the
world. The aim of this research was to identify which drug is most effective in preventing excessive bleeding after childbirth with the
least side-effects.
Different drugs given routinely at childbirth have been used for preventing excessive bleeding. They include oxytocin, misoprostol,
ergometrine, carbetocin, and combinations of these drugs, each with different effectiveness and side-effects. Some of the side-effects
identified include: vomiting, high blood pressure and fever. We analysed all the available evidence to compare all of these drugs and
calculated a ranking among them, providing robust effectiveness and side-effect profiles for each drug.
What evidence did we find?
We searched for evidence in June 2015 and found 140 studies involving a total of 88,947 women. The results suggest that an ergometrine
plus oxytocin combination, carbetocin, and amisoprostol plus oxytocin combination are themost effective drugs for preventing excessive
bleeding after childbirth and are more effective than the drug oxytocin currently recommended by the World Health Organization
(WHO). However, ergometrine plus oxytocin and misoprostol plus oxytocin were the worst drugs for side-effects, with carbetocin
having themost favourable side-effect profile (less vomiting, high blood pressure and fever).More effective drugs could probably prevent
one out of three women from bleeding excessively after childbirth compared to oxytocin. However, existing carbetocin studies were
small and of poor quality.
What does this mean?
We found that ergometrine plus oxytocin, misoprostol plus oxytocin, and carbetocin were more effective drugs for reducing excessive
bleeding at childbirth than oxytocin which is the current standard drug used to prevent this condition. Carbetocin has the least side-
effects among the top three drug options, but to date studies of carbetocin were small and of poor quality.
There are some ongoing studies that are not yet complete, including two key studies. One is a large study (involving around 30,000
women across 10 different countries) comparing the effectiveness of carbetocin versus oxytocin for preventing PPH among women
having a vaginal birth. The other is aUK-based trial (involvingmore than6000women) comparing carbetocin, oxytocin and ergometrine
plus oxytocin combination. Both trials are expected to report in 2018 and these results will be incorporated when this review is updated.
Consultation with our consumer group has demonstrated a need for more research into PPH outcomes identified as priorities for
women and their families, such as women’s views regarding the drugs used, clinical signs of excessive blood loss, neonatal unit admissions
and breastfeeding at discharge. Trials to date have rarely investigated these outcomes. Consumers also considered the side-effects of
uterotonic drugs to be important and these were often not reported. A set of standardised PPH outcomes are being developed and
will be incorporated in future updates of this review. We would hope that future trials would also consider adopting those outcomes.
Finally, future systematic reviews could compare the effects of different doses and ways of administering the most effective drugs.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Effects of uterotonic drugs for preventing postpartum haemorrhage: a network meta-analysis
Patient or population: Women giving birth and at the third stage of labour
Settings: Hospital sett ing
Intervention: Ergometrine plus oxytocin, Carbetocin, M isoprostol plus oxytocin
Comparison: Oxytocin
Outcomes Effects and 95% confidence intervals in the effects. Main comparator is oxytocin. Comments
Risk with ergometrine plus
oxytocin*
Risk with carbetocin* Risk with misoprostol plus
oxytocin*
Risk with oxytocin* *
PPH ≥500 mL 7.2% (6 to 8.7) for vaginal
births
51 .7% (42.7 to 62.2) for cae-
sareans
7.6% (5.5 to 10.5) for vagi-
nal births
53 .9% (38.9 to 74.9) for cae-
sareans
7 .7% (6.3 to 9.5) for vaginal
births
54 .7% (44.9 to 67.4) for cae-
sareans
10 .5% (9.8 to 11.3) for vagi-
nal births
74 .9% (65.7 to 85.4) for cae-
sareans
There was evidence of
global inconsistency in this
analysis ( P = 0.046). How-
ever, the comparisons in
this table were consistent
except for the comparison
of ergometrine versus no
treatment not included in
this table-based on a single
study
RR 0.69 (0.57 to 0.83)
(NMA)
RR 0.72 (0.56 to 0.92) (Pair-
wise)
RR 0.72 (0.52 to 1.00)
(NMA)
RR 0.69 (0.45 to 1.07) (Pair-
wise)
RR 0.73 (0.60 to 0.90)
(NMA)
RR 0.74 (0.62 to 0.88) (Pair-
wise)
1
⊕⊕⊕© moderate conf i-
dence in est imate due to
inconsistency based on 10
studies (13,138 women, I2=
57.4%)
⊕©©© very low conf i-
dence in est imate due to
risk of bias, imprecision and
inconsistency based on 8
studies (917 women, I2 =
49.9%)
⊕⊕⊕© moderate conf i-
dence in est imate due to
inconsistency based on 12
studies (9651 women, I2 =
60.5%)
PPH ≥1000 mL 2 .8% (2.2 to 3.4) for vaginal
births
10 .7% (8.5 to 13.2) for cae-
sareans
2 .5% (1.4 to 4.6) for vaginal
births
9 .7% (5.3 to 17.8) for cae-
sareans
3 .2% (2.6 to 4.1) for vaginal
births
12 .5% (10 to 15.8) for cae-
sareans
3 .6% (3.4 to 3.9) for vaginal
births
13 .9% (11.7 to 16.6) for cae-
sareans
There was no evidence of
global inconsistency (P = 0.
345) in this analysis
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RR 0.77 (0.61 to 0.95)
(NMA)
RR 0.73 (0.57 to 0.93) (Pair-
wise)
RR 0.70 (0.38 to 1.28)
(NMA)
RR 0.71 (0.38 to 1.35) (Pair-
wise)
RR 0.90 (0.72 to 1.14)
(NMA)
RR 0.89 (0.71 to 1.12) (Pair-
wise)
1
⊕⊕⊕⊕ high conf idence in
est imate based on 9 studies
(13,038 women, I2 = 0%)
⊕⊕©© low conf idence in
est imate due to risk of bias
and imprecision based on 7
studies (1026 women, I2 =
0%)
⊕⊕⊕© moderate conf i-
dence in est imate due to im-
precision based on 14 stud-
ies (9897 women, I2 = 0%)
Vomiting 1.9% (1.3 to 2.7) for vaginal
births
16.1% (11 to 23.7) for cae-
sareans
0.5% (0.3 to 0.9) for vaginal
births
4.6% (2.9 to 7.4) for cae-
sareans
1.3% (0.8 to 2) for vaginal
births
11.2% (7.1 to 17.6) for cae-
sareans
0.6% (0.5 to 0.6) for vaginal
births
5.2% (4.9 to 5.5) for cae-
sareans
There was no evidence of
global inconsistency (P = 0.
06) in this analysis
RR 3.10 (2.11 to 4.56)
(NMA)
RR 3.15 (1.72 to 5.78) (Pair-
wise)
RR 0.89 (0.55 to 1.42)
(NMA)
RR 0.88 (0.39 to 1.99) (Pair-
wise)
RR 2.16 (1.37 to 3.39)
(NMA)
RR 2.25 (1.45 to 3.48) (Pair-
wise)
1
⊕⊕⊕⊕ high conf idence in
est imate based on 8 studies
(9811 women, I2 = 48.1%)
⊕©©© very low conf i-
dence in est imate due to
risk of bias, inconsistency
and imprecision based on
10 studies (1939 women, I2
= 59.2%)
⊕⊕⊕⊕ high conf idence in
est imate due to imprecision
based on 9 studies (5015
women, I2 = 30.1%)
Hypertension 1.2% (0.4 to 4) for vaginal
births
29.6% ( to ) for caesareans
0.6% (0.1 to 3.3) for vaginal
births
14.2% (2.5 to 79.7) for cae-
sareans
Risks not available as no
studies report this outcome
0.7% (0.7 to 0.8) for vaginal
births
16.7%(11.2 to 24.9) for cae-
sareans
There was no evidence of
global inconsistency (P = 0.
481) in this analysis
RR 1.77 (0.55 to 5.66)
(NMA)
RR 0.95 (0.10 to 8.38) (Pair-
wise)
RR 0.85 (0.15 to 4.77)
(NMA)
RR not available as no stud-
ies reported this outcome
1
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⊕⊕©© low conf idence in
est imate due to incon-
sistency and imprecision
based on 2 studies (1039
women, I2 = 73.2%)
⊕⊕©© low conf idence in
est imate due to imprecision
and based only on indirect
evidence
Quality of the evidence can-
not be assessed as no stud-
ies report this outcome
Fever 3% (1.5 to 6) for vaginal
births
11.7% (6.5 to 23.2) for cae-
sareans
3.1% (0.8 to 12.1) for vagi-
nal births
12% (3.1 to 46.6) for cae-
sareans
11.4% (8 to 16.4) for vaginal
births
44.2%(30.9 to 63.2) for cae-
sareans
3 .6% (3.4 to 3.9) for vaginal
births
13 .9% (11.7 to 16.6) for cae-
sareans
There was no evidence of
global inconsistency (P = 0.
352) in this analysis
RR 0.84 (0.42 to 1.67)
(NMA)
RR 1.07 (0.47 to 2.43) (Pair-
wise)
RR 0.86 (0.22 to 3.35)
(NMA)
RR 2.11 (0.18 to 24.40)
(Pairwise)
RR 3.18 (2.22 to 4.55)
(NMA)
RR 2.96 (1.95 to 4.51) (Pair-
wise)
1
⊕⊕⊕© moderate conf i-
dence in est imate due to im-
precision based on 2 stud-
ies (1591 women, I2 = 0%)
⊕©©© very low conf i-
dence in est imate due to
risk of bias, inconsistency
and imprecision based on
3 studies (292 women, I2 =
40.9%)
⊕⊕⊕© moderate conf i-
dence in est imate due to
inconsistency based on 15
studies (8209 women, I2 =
77.8%)
*The risks in the ergometrine plus oxytocin, carbetocin, misoprostol plus oxytocin groups (and their 95% conf idence interval) are based on the assumed risk in the oxytocin
group and the relative effects of the intervent ions (and its 95% CI).
* *The risk in the oxytocin group (and its 95% conf idence interval) is based on a meta-analysis of proport ions f rom the studies included in this review for this group.
RR: Risk rat io
GRADE Working Group grades of evidence
High quality:
We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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B A C K G R O U N D
Description of the condition
An estimated 303,000 women died during childbirth in 2015
(Alkema2016). Postpartumhaemorrhage (PPH) accounted for up
to a third of all thesematernal deaths (Say 2014). Almost all deaths
occurred in low- or middle-income countries. Even when death
fromPPHis avoided, the need for blood transfusion, hysterectomy
and additional care place a huge burden on health services (Penney
2007; Souza 2013).
The third stage of labour, defined as the period of time from birth
until the delivery of the placenta, and the immediate postpartum
period are the most hazardous periods of childbirth due to the
risk of PPH. The World Health Organization (WHO) defines
PPH as blood loss after birth exceeds 500 mL in the first 24 hours
(WHO 2012). Even though healthy women can easily cope with
this amount of blood loss, for those who may be malnourished
and/or anaemic it can cause considerable morbidity and mortal-
ity. The most common cause of PPH is uterine atony (failure of
the uterus to contract after delivery), which accounts for 75% of
cases (Weekes 1956). Even though risk factors for adversematernal
outcomes from severe haemorrhage have been identified (Souza
2013), often PPH is unpredictable as it occurs in the absence of
identifiable clinical or historical risk factors (Combs 1991). There-
fore, effective prevention of PPH is advocated for all women dur-
ing childbirth (WHO 2012). The administration of uterotonic
drugs routinely in the third stage of labour is the key interven-
tion that prevents PPH, although there is uncertainty about which
drug may be the most effective.
Description of the intervention
The administration of uterotonic drugs to prevent PPH is part
of the active management of the third stage of labour, which can
prevent two out of three events of PPH (Begley 2015). The active
management of the third stage of labour refers to the adminis-
tration of a uterotonic drug, early cord clamping, and controlled
cord traction until delivery of the placenta. The WHO guideline
development group recently revisited the evidence underpinning
each component of active management of third stage of labour
and considered the use of uterotonics as the main intervention
within this package (WHO 2012). Uterotonics are also essential
for the treatment of PPH, but this is not considered in this review.
How the intervention might work
Several different uterotonic drugs have been used for preventing
PPH. These drugs include ergometrine, misoprostol, carbetocin,
oxytocin, and the combinations of misoprostol plus oxytocin and
ergometrine plus oxytocin.
Oxytocin
Oxytocin (Syntocinon®) is themost widely used uterotonic drug.
At low doses, it produces rhythmic uterine contractions that are
indistinguishable in frequency, force and duration from those ob-
served during spontaneous labour, but at higher dosages, it causes
sustained uterine contractions (MEDICINES.ORG.UK). It has a
short half-life, approximately three tofiveminutes, and canbe used
as an infusion to maintain uterine contraction. When used intra-
muscularly, the latent phase lasts two to five minutes, but the uter-
ine activity can last two to three hours (MEDICINES.ORG.UK).
However, oxytocin cannot be used orally. It is unstable in ambi-
ent temperatures and it requires a cold chain through storage and
transport. It should also not be given intravenously as a large bo-
lus, because it can cause severe hypotension (Thomas 2007). Be-
cause of its anti-diuretic effect, water intoxication can occur with
prolonged infusion of oxytocin (MEDICINES.ORG.UK). Oxy-
tocin has a favourable side-effect profile and it is not significantly
worse than placebo for common side-effects such as nausea and
vomiting, but the evidence is scarce (Westhoff 2013).
Ergometrine
Ergometrine and methylergometrine are ergot alkaloids that in-
crease the uterine muscle tone by causing sustained uterine con-
tractions. They have a latent phase of two to five minutes after in-
tramuscular injection and the plasma half-life is 30 to 120 minutes
(de Groot 1998). However, ergometrine and methylergometrine
are unstable in heat with an unpredictable bioavailability, which
precludes oral use (de Groot 1996a). They are vasoconstrictive
and increase the risk of hypertension postpartum (Liabsuetrakul
2007). Other side-effects with ergot alkaloids are pain after birth,
nausea and vomiting (Liabsuetrakul 2007).
Misoprostol
Misoprostol is a prostaglandin E1 analogue, which is licensed for
the prevention and treatment of gastric ulcers. It is well known for
its off-label use as a uterotonic agent (Tuncalp 2012). It is water-
soluble and heat stable (Davies 2001). It is absorbed after nine
to 15 minutes after sublingual, oral, vaginal, and rectal use. The
half-life is about 20 to 40 minutes. Oral and sublingual routes
have the advantage of rapid onset of action, while the vaginal and
rectal routes result in prolonged activity and greater bioavailability
(Schaff 2005). However, it is associated with side-effects such as
diarrhoea, abdominal pain, nausea and vomiting, shivering and
pyrexia (Tuncalp 2012).
Carbetocin
Carbetocin is a newer long-acting synthetic analogue of oxytocin
with agonist properties. After intravenous injection, it produces
sustained uterine contractions within two minutes, lasting for ap-
proximately six minutes followed by rhythmic contractions for 60
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minutes (Hunter 1992). When carbetocin is administered by an
intramuscular injection, the sustained uterine contractions last for
approximately 11 minutes and the rhythmic contractions for 120
minutes (Hunter 1992). Carbetocin is heat stable and the side-
effect profile appears to be similar to oxytocin (Su 2012).
Combination drugs
The use of combinations of uterotonic drugs is also popular and
themost commonly used preparation is ergometrine plus oxytocin
(Syntometrine®). This combination is associated with a statis-
tically significant reduction of PPH ≥ 500 mL when compared
with oxytocin alone, attributable to the additive ergometrine effect
(odds ratio (OR) 0.82, 95% confidence interval (CI) 0.71 to 0.95)
(McDonald 2004). Another combination is misoprostol plus oxy-
tocin that is also found to be associated with a small reduction
in PPH ≥ 500 mL (risk ratio (RR) 0.71, 95% CI 0.53 to 0.95)
(Tuncalp 2012). However, both these combinations are associated
with significant side-effects and despite the difference in PPH ≥
500 mL, there was no difference found for more severe PPH when
compared to oxytocin defined as PPH ≥ 1000 mL. Hence, the
WHO guideline recommends oxytocin over these combinations
(WHO 2012).
The WHO recommends that all women giving birth should be
offered uterotonics during the third stage of labour for the pre-
vention of PPH; oxytocin (intramuscular/intravenous, 10 interna-
tional units (IU)) is the uterotonic drug of choice (WHO 2012).
Other injectable uterotonics and misoprostol are recommended
as alternatives for the prevention of PPH in settings where oxy-
tocin is not available. Carbetocin is found to reduce the need for
additional uterotonics (RR 0.62, 95% CI 0.44 to 0.88), but it is
more expensive and not better than oxytocin for preventing PPH
≥ 1000 mL (WHO 2012).
Why it is important to do this review
Cochrane reviews have compared individual uterotonic agents
against another uterotonic agent, placebo or no treatment (Begley
2015; Liabsuetrakul 2007; McDonald 2004; Su 2012; Tuncalp
2012;Westhoff 2013). Such pairwise meta-analyses can only com-
pare two agents that have been compared directly in head-to-
head trials (direct evidence). In the absence of a single randomised
controlled trial comparing all available uterotonic agents, uncer-
tainty remains over their relative effectiveness and ranking. We
conducted a network meta-analysis synthesizing all direct and in-
direct trial evidence of relative treatment effects in a single co-
herent analysis for all the competing agents. Indirect evidence is
obtained when the relative effectiveness of two competing drugs
is inferred through a common comparator, even though this pair
may not have been compared directly (Caldwell 2005; Lumley
2002). Our networkmeta-analysis provides effectiveness and side-
effect profiles, along with the ranking for each uterotonic agent.
O B J E C T I V E S
Primary
To identify the most effective uterotonic drug(s) to prevent post-
partum haemorrhage (PPH) with a favourable side-effect profile,
and to generate a clinically useful ranking of all available utero-
tonics.
Secondary
To provide the relative effectiveness and side-effect profile of each
drug for our primary outcomes within: a) population subgroups
(prior risk of PPH, mode of birth and healthcare setting) and
b) treatment subgroups (different dosages, routes or regimens of
administration of each uterotonic drug).
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled comparisons or cluster trials of effec-
tiveness or side-effects of uterotonic drugs for preventing postpar-
tum haemorrhage (PPH) were included. Quasi-randomised trials
and cross-over trials were excluded.
Types of participants
The review included studies of pregnant women following a vagi-
nal or caesarean birth in hospital or community settings.
Types of interventions
Trials were eligible if they administered uterotonic agents of any
dosage, route or regimen systemically at birth for preventing PPH,
and compared them against other uterotonic agents, placebo or
no treatment. Trials evaluating uterotonic drugs administered lo-
cally or not immediately after birth, or exclusively comparing dif-
ferent dosages, routes or regimens of the same uterotonic agent
were excluded. We included trials in which non-pharmacologic
co-interventions such as controlled cord traction, cord clamping,
or uterine massage was performed as a randomised intervention in
all arms of the trial and the effects of such co-interventions were
tested through a sensitivity analysis.
We classified drugs into oxytocin, carbetocin, misoprostol, er-
gometrine (included also ergonovine, methylergonovine), er-
gometrine plus oxytocin (Syntometrine, oxytocin combined with
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ergometrine, ergonovine, or methylergonovine), and misoprostol
plus oxytocin. We excluded synthetic prostaglandin analogues of
PGF2α (carboprost), and PGE2 (prostin, sulprostone), because
these drugs are usually used for treating (and not preventing) PPH,
and are not currently recommended by the WHO as alternatives
(WHO 2012).
For this review, we assumed that any woman who meets the in-
clusion criteria is, in principle, equally likely to be randomised to
any of the eligible uterotonic drugs.
Types of outcome measures
We estimated the relative effects and rankings of the competing
interventions according to the following outcomes.
Primary outcomes
The primary outcomes of the review were:
1. PPH ≥ 500 mL; and
2. PPH ≥ 1000 mL.
Secondary outcomes
The secondary outcomes of the review were:
1. maternal deaths;
2. maternal deaths or severe morbidity events adapted from
WHO “near miss” criteria (WHO 2011) to include major
surgery (laparotomy, uterine artery ligation, internal iliac artery
ligation, B-Lynch suture, hysterectomy, extensive vaginal repair,
admission to the intensive care unit, or vital organ failure
(temporary or permanent);
3. additional uterotonics requirement;
4. transfusion requirement;
5. manual removal of the placenta;
6. mean volumes of blood loss (mL);
7. mean durations of the third stage of labour (minutes);
8. change in haemoglobin measurements before and after
birth (g/L);
9. clinical signs of excessive blood loss (as defined by the
trialists);
10. neonatal unit admission requirement;
11. breastfeeding at discharge; and
12. side-effects such as nausea, vomiting, hypertension,
headache, tachycardia, hypotension, abdominal pain, fever and
shivering in the first 24 hours postpartum.
Search methods for identification of studies
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Regis-
ter by contacting their Information Specialist (1 June 2015). We
updated this search on 27 October 2017 and added the results to
Studies awaiting classification to be assessed and incorporated at
the next update.
The Register is a database containing over 23,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter including the detailed search strategies for CENTRAL, MED-
LINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings; and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about the Cochrane Pregnancy and Childbirth
in the Cochrane Library and select the ‘Specialized Register ’ sec-
tion from the options on the left side of the screen.
Briefly, the Cochrane Pregnancy and Childbirth’s Trials Register
is maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of
all relevant trial reports identified through the searching activi-
ties described above is reviewed. Based on the intervention de-
scribed, each trial report is assigned a number that corresponds
to a specific Pregnancy and Childbirth review topic (or topics),
and is then added to the Register. The Information Specialist
searches the Register for each reviewusing this topic number rather
than keywords. This results in a more specific search set that has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies; Studies awaiting classification; Ongoing
studies).
In addition, we searched ClinicalTrials.gov and the WHO Inter-
national Clinical Trials Registry Platform (ICTRP) for unpub-
lished, planned and ongoing trial reports using the terms given in
Appendix 1 (30 June 2015).
Searching other resources
We retrieved additional relevant references cited in papers identi-
fied through the above search strategy and we did search for the
full texts of trials initially identified as abstracts. We sought infor-
mation from primary authors to investigate whether these studies
met our eligibility criteria, and to obtain outcome and study data.
Trials that compared at least two of the drugs were eligible and
we searched for all possible comparisons formed by the drugs of
interest. We did not apply any language or date restrictions.
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Data collection and analysis
Selection of studies
Three review authors retrieved and independently assessed for in-
clusion all the potential studies we identified (IDG, AM, HW).
We resolved any disagreements through discussion or, if required,
in consultation with a third person (AC). We created a study flow
diagram to map out the number of records identified, included
and excluded (Figure 1).
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Figure 1. Study flow diagram.
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Data extraction and management
We designed an electronic form on ©Microsoft Access to extract
data. For eligible studies, at least three review authors indepen-
dently extracted the data using a blank electronic form (IDG,HW,
AM, DL, HG, OT). We resolved discrepancies through discus-
sion or, if required, we consulted another person (AC). We en-
tered data into STATA and Review Manager software (RevMan
2014) and checked for accuracy. When information was unclear,
we attempted to contact authors of the original reports to provide
further details. The following data were extracted.
Outcome data
From each included study we extracted: the number of partici-
pants, the gestational age and the parity of participants, and any
exclusion criteria. We also extracted: the interventions being com-
pared, and their respective primary and secondary outcomes. All
relevant arm level data were extracted (e.g. number of events and
number of patients for binary outcomes).
Data on potential effect modifiers
From each included study we extracted the following study, in-
tervention and population characteristics that may act as effect
modifiers:
1. mode of delivery (vaginal or caesarean birth);
2. prior risk of PPH (as defined by trialists and categorised as
low, high, mixed or not stated);
3. dosage, regimen, and route of drug administration
(sublingual, subcutaneous, intramuscular, rectal, oral,
intravenous bolus and/or infusion); and
4. setting of the study (community or hospital).
Other data
From each included study we extracted the following additional
information:
1. country or countries in which the study was performed;
2. date of publication;
3. type of publication (full-text publication, abstract
publication, unpublished data); and
4. trial registration reference.
Assessment of risk of bias in included studies
At least three (IDG, HW, AM, DL, HG, OT) review authors
independently assessed the risk of bias for each study using the
criteria outlined in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). Any disagreements were resolved
by discussion or by involving another assessor (AC).
(1) Random sequence generation (checking for possible
selection bias)
Studieswere excluded if found tobe at high risk for bias for random
sequence generation (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number). We described for
each included study the method used to generate the allocation
sequence in sufficient detail to allow an assessment of whether it
should produce comparable groups.
We assessed the methods as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator); or
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth); or
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding would be unlikely to have affected the results.
We assessed the methods as:
• low, high or unclear risk of bias for participants; and
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received.
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We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study the completeness of data
including attrition and exclusions from the analysis. We stated
whether attrition and exclusions were reported and the numbers
included in the analysis at each stage (compared with the total
randomised participants), reasons for attrition or exclusion where
reported, and whether missing data were balanced across groups
or were related to outcomes. Where sufficient information was
reported, or supplied by the trial authors, we re-included missing
data in the analyses. We assessed methods to handle incomplete
outcome data as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups and less than 10% of
missing outcome data);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation or more than 10% of missing outcome data); or
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported); or
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns
about other possible sources of bias, such as the source of funding
and potential conflicts of interest.
We assessed these interests as:
• low risk of other bias (public funding or no funding and no
significant conflicts of interest identified);
• high risk of other bias (industry funding or significant
conflicts of interest identified); or
• unclear risk of other bias.
Another source of bias was generated by the method of measuring
blood loss. We assessed the method described in each study and
classified it as at:
• low risk of other bias (objective measurements such as
weighing sponges, measurements in drapes, volumetric
assessment, tagged red cells, etc);
• high risk of other bias (subjective measurement such as
clinical or visual estimates); or
• unclear risk of other bias (unspecified methods of
measurement).
(7) Overall risk of bias
We made explicit judgements about whether studies are at high
risk of bias, according to the criteria given in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). With
reference to (1) to (6) above, we assessed the likely magnitude
and direction of the bias and whether we considered it was likely
to have impacted on the findings. For our primary outcomes, we
combined quality items and judged trials as “low risk of bias” if
they were double-blinded, had allocation concealment and with
little loss to follow-up (less than 10%). Trials were judged as “in-
termediate risk of bias” if they demonstrated adequate allocation
concealment, with assessor blinding and little loss to follow-up
(less than 10%). Alternatively, trials were considered to be at “high
risk of bias”. We explored the impact of the level of bias through
undertaking sensitivity analyses - see Sensitivity analysis for infor-
mation about how the risk of bias was incorporated in the sensi-
tivity analysis.
Summary of findings
A “Summary of findings” table is presented as described by Puhan
et al (Puhan 2014). This table shows the overall quality of the
body of evidence for the primary review outcomes and important
side-effects, using GRADE criteria. GRADE ratings were deter-
mined on the basis of risk of bias, inconsistency, indirectness and
imprecision. The risks of bias was assessed conventionally for each
included trial. A judgement was made to downgrade the quality
of the evidence if the majority of the trials for each outcome or
each direct comparison were at high risk of bias. The evidence
was also downgraded in quality if we found inconsistency between
estimates produced by the network meta-analysis and direct esti-
mates obtained from pairwise comparisons. Heterogeneity across
studies for each pairwise meta-analysis was assessed using I2. The
evidence was downgraded for indirectness if the included trials for
specific direct comparisons were considered to be more restrictive
or different than the overall review question. Lastly, evidence was
downgraded if there was imprecision. Imprecision relates to the
overall level of confidence that may be placed in the estimated
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treatment effects. Each quality element considered to have ‘seri-
ous’ or ‘very serious’ limitations was rated down one or two levels
respectively. GRADE assessments were made for the most effec-
tive drugs (ergometrine plus oxytocin, carbetocin, and misopros-
tol plus oxytocin) in comparison with the most frequently used
and recommended drug (oxytocin) as a comparison for the pri-
mary outcomes and important side-effects. The risk calculated in
the comparison group (oxytocin) (and its 95% confidence interval
(CI)) was based on ameta-analysis of proportions from the studies
included in this review. The risks (and their 95% CIs) calculated
in the intervention groups were based on the assumed risk in the
comparison group and the relative effects of the interventions (and
their 95% CIs). The risks differed significantly by the mode of
birth subgroup and they are presented separately for vaginal births
and caesareans. Assessments were carried out by IDG and checked
by AC.
Measures of treatment effect
Relative treatment effects
We summarised relative treatment effects for dichotomous out-
comes as risk ratios (RR) and for continuous outcomes as mean
difference (MD) with 95% CIs (Dias 2013).
Relative treatment ranking
We estimated the cumulative probabilities for each treatment be-
ing at each possible rank and obtained a treatment hierarchy us-
ing the surface under the cumulative ranking curve (SUCRA); the
larger the SUCRA the higher its rank among all available drug op-
tions (Salanti 2011). The probabilities to rank the treatments are
estimated under a Bayesian model with flat priors, assuming that
the posterior distribution of the parameter estimates is approxi-
mated by a normal distribution with mean and variance equal to
the frequentist estimates and variance-covariance matrix (White
2015).
Unit of analysis issues
Cluster-randomised trials
For the only cluster-randomised trial included in this review
(Stanton 2013), we used the unadjusted standard errors as the clus-
ters and the Intracluster Correlation Co-efficient (ICC) was small
(ICC = 0.012). We considered it reasonable to combine the results
from the cluster-randomised and the individually-randomised tri-
als as there was little heterogeneity between the study designs and
any interaction between the relative effects of agents and the choice
of randomisation unit was considered to be unlikely. The effect of
the unit of randomisation was also assessed in sensitivity analysis
(Higgins 2011).
Cross-over trials
This type of trial was not deemed appropriate for this intervention.
Multi-arm trials
Multi-arm trials were included and we accounted for the corre-
lation between the effect estimates in the network meta-analysis.
We treated multi-arm studies as multiple independent compar-
isons in pairwise meta-analyses and these were not combined in
any analysis.
Dealing with missing data
For included studies, we noted the levels of attrition. We explored
the impact of including studies with high levels of missing data
in the overall assessment of treatment effect by using sensitivity
analysis. For all outcomes, we carried out analyses, as far as possible,
on an intention-to-treat basis, i.e. we included all participants
randomised to each group in the analyses, and all participants were
analysed in the group to which they were allocated, regardless of
whether or not they received the allocated intervention. We used
the number randomised minus any participants whose outcomes
were known to be missing as the denominator for each outcome
in each trial.
Assessment of clinical and methodological
heterogeneity within treatment comparisons
To evaluate the presence of clinical heterogeneity, we described
the study population characteristics across all included trials. We
assessed the presence of clinical heterogeneity by comparing these
characteristics.
Assessment of transitivity across treatment
comparisons
In this context we expect that the transitivity assumption holds
assuming the following: 1) the common treatment used to com-
pare different uterotonics indirectly is similar when it appears in
different trials (e.g. oxytocin is administered in a similar way in
oxytocin versus misoprostol trials and in oxytocin versus oxytocin
plus ergometrine trials); 2) all pairwise comparisons do not differ
with respect to the distribution of effect modifiers (e.g. the de-
sign and study characteristics of oxytocin versus misoprostol trials
are similar to oxytocin versus oxytocin plus ergometrine trials).
The assumption of transitivity was evaluated epidemiologically by
comparing the clinical and methodological characteristics of sets
of studies from the various treatment comparisons.
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Assessment of reporting biases
We assessed potential reporting bias for the primary outcomes by
assessing the sensitivity of results to exclusion of studies with fewer
than 400 participants.
Data synthesis
Methods for direct treatment comparisons
Initially, we performed pairwise meta-analyses using a random-
effects model in Stata for every treatment comparison with at least
two studies (DerSimonian 1986).
Methods for indirect and mixed comparisons
We performed the network meta-analysis within a frequentist
framework using multivariate meta-analysis estimated by re-
stricted maximum likelihood. All analyses were done using Stata
statistical software, release 14 (StataCorp, College Station, TX).
We used the network suite of Stata commands designed from this
purpose (White 2012; White 2015).
Assessment of statistical heterogeneity
Assumptions when estimating the heterogeneity
In pairwise meta-analyses we estimated the heterogeneity for each
comparison. In network meta-analysis we assumed a common es-
timate for the heterogeneity variance across all of the different
comparisons.
Measures and tests for heterogeneity
We assessed statistically the presence of heterogeneity within each
pairwise comparison for the primary outcomes using the I2 statis-
tic that measures the percentage of variability that cannot be at-
tributed to random error (Higgins 2002). The assessment of sta-
tistical heterogeneity in the entire network was based on the mag-
nitude of the heterogeneity variance parameter estimated from the
multivariate meta-analysis.
Assessment of statistical inconsistency
To check the assumption of consistency in the entire network we
used the “design-by- treatment” interaction model as described
by Higgins (Higgins 2012). This method accounts for a different
source of inconsistency that can occur when studies with different
designs (two-arm trials versus three-arm trials) give different results
aswell as disagreement betweendirect and indirect evidence.Using
this approachwe inferred about the presence of inconsistency from
any source in the entire network based on a Chi2 test.
Investigation of heterogeneity and inconsistency
Where we found important heterogeneity and/or inconsistency,
we explored the possible sources for primary outcomes. Where
sufficient studies were available, we performed multivariate meta-
analyses or subgroup analyses by using the following potential ef-
fect modifiers as possible sources of inconsistency and/or hetero-
geneity.
1. Population: prior risk of PPH (high versus low), mode of
delivery (vaginal versus caesarean birth), setting (hospital versus
community).
2. Intervention: dose of misoprostol ( ≥ 600 mcg versus < 600
mcg), and regimen of oxytocin (bolus versus bolus plus infusion
versus infusion only).
3. Risk of bias of the studies: studies are ranked as “low risk of
bias” if they are double-blinded, and have allocation concealment
with little loss to follow-up (less than 10%). The concealed
studies with assessor blinding and little loss to follow-up (less
than 10%) are ranked as “intermediate risk of bias” and the rest
as “high risk of bias”. We considered that assessor blinding was
likely to be very important, in order to eliminate any risk of bias
in subjective measurements or estimates of blood loss (not all
studies measure this outcome objectively). We considered
protocol publication in advance of the results to be an unsuitable
criterion for sensitivity analyses, because protocol publication
only became widespread in recent years.
4. Funding source (high versus low risk of bias).
5. Whether an objective method of outcome assessment was
employed (objective versus subjective). Objective methods of
blood loss measurement were considered to be all methods that
employed a measurement of the blood loss. This is in contrast to
subjective methods where a healthcare professional is estimating
the blood loss, usually visually.
6. Trial size (excluding small studies, in recognition of the
greater likelihood for small studies than large or multi-centre
studies to suffer publication bias). In terms of trial size, there is
evidence that smaller studies can exaggerate estimated benefits
(Nüesch 2010). However, the cut-off for deciding the definition
of a small study can vary between research topics. For this topic,
it appears that trials with more than 400 participants are more
likely to be of higher quality, prospectively registered and overall
at low risk of bias.
7. Randomisation unit (cluster versus individual).
Subgroup analysis
For the primary outcomes we carried out the following subgroup
analyses.
1. Population: prior risk of PPH (high versus low), mode of
delivery (vaginal versus caesarean birth), setting (hospital versus
community).
2. Intervention: dose of misoprostol (≥ 600 mcg versus < 600
mcg), and regimen of oxytocin (bolus versus bolus plus infusion
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versus infusion only).
We assessed subgroup differences by firstly comparing the network
diagram for each subgroup. Next, we performed a network meta-
analysis for each subgroup and we compared their relative treat-
ment effects and their relative treatment ranking..
Sensitivity analysis
For the primary outcomes we performed sensitivity analysis for
the following.
1. Risk of bias of the studies as described previously.
2. Funding source as described previously.
3. Whether an objective method of outcome assessment was
employed (objective versus subjective).
4. Trial size as described previously.
5. Trials that also randomised participants to co-interventions
such as uterine massage or controlled cord traction.
6. Trials with more than 10% missing data.
7. Trials published before 1990.
8. Randomisation unit (cluster versus individual).
9. Choice of relative effect measure (RR versus OR).
10. Use of fixed-effect versus random-effects model.
Differences were assessed by evaluating the relative effects and
assessment of model fit.
R E S U L T S
Description of studies
Results of the search
The results of the search strategy are summarised in the PRISMA
(PreferredReporting Items for SystematicReviews andMeta-Anal-
yses) flow diagram (Figure 1).
The search of Cochrane Pregnancy and Childbirth’s (CPC) Trials
Register in June 2015 retrieved 469 trial reports. A further 137
records were retrieved from additional author searches andmanual
searching of reference lists. In October 2017, an updated search
of the CPC Register retrieved an additional 85 trial reports. After
exclusion of duplicates, we assessed for eligibility 378 trials by full-
text evaluation. We have included in this systematic review 140
randomised trials (192 trial reports) involving 88,947 women,
From these, 137 trials involving 87,466 women, comparing six
active drugs contributed data to the network meta-analysis.
We have contacted the authors from 95 primary randomised trials
for additional data or clarifications and were able to add in this re-
view data not reported in the published reports for 40 randomised
trials.
We excluded 238 trials (267 trial reports) and 11 trials are ongoing
(Ongoing studies). We also have 94 trial reports that are awaiting
further classification and we plan to assess these at the next update
(see: Studies awaiting classification).
Included studies
Most studies were reported in English;nine translations were ob-
tained (four Spanish, two French, two Turkish and one Chinese).
The studies were conducted in various countries and often in-
volved more than one country. The UK was the country where
most studies were conducted (11 studies). A number of multi-arm
trials were identified: two five-arm trials, six four-arm trials and
15 three-arm trials. The median size of the trials was around 248
participants (interquartile (IQR) 136 to 622).
Most trials (96.4%, 135/140) were performed in a hospital setting
with only four community trials (2.9%) and one (0.7%) in amixed
setting. The majority of the trials included women undergoing a
vaginal birth (74.3%, 104/140), and 36 trials (25.7%) involved
women undergoing elective or emergency caesareans. Women in-
cluded in the trials were judged to be at high risk for postpartum
haemorrhage (PPH) in 43 of 140 trials (30.7%), low risk in 42
trials (30%) and 50 trials (35.7%) included women both at high
or low risk for PPH. The risk for PPH was not specified in five
trials (3.6%).
The gestational age of women included in the trials was not speci-
fied in 70 of 140 trials (50%). Thirty-two trials (22.9%) included
womenwith termpregnancies and the remaining 38 trials (27.1%)
included women with both pre-term or term pregnancies. Eighty-
two trials (58.6%) included women with a singleton pregnancy,
23 trials (16.4%) included women with either singleton or mul-
tiple pregnancies and 35 trials (25%) did not specify this crite-
rion. Four trials (2.9%) included only nulliparous or primigravida
women, one trial included only multiparous women (0.7%), 35
trials (25%) included women of all parities and 100 trials (71.4%)
did not specify the parity of the women included in the trials.
Exclusion criteria varied significantly and usually encompassed
womenwith significantmedical comorbidities. See Characteristics
of included studies for details.
Excluded studies
We excluded 238 randomised trials (for details see Characteristics
of excluded studies).
Risk of bias in included studies
We present summaries of the methodological quality of the in-
cluded studies for each of the domains we assessed across all studies
(Figure 2) and for each included study (Figure 3).
16Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Trials with evidence of inadequate random sequence generation
were excluded from this review. As a result 100 of 140 included
trials (71.4%) were found to have used an adequate method gener-
ating the random sequence and were at low risk of bias. However,
40 trials (28.6%) did not report the method used in sufficient
detail and the risk of bias was judged to be unclear. Seventy-one
of 140 trials (50.7%) reported adequate methods for allocation
concealment and were judged to be at low risk of bias. Sixty-nine
trials (49.3%), did not provide enough information to assess allo-
cation concealment and the risk of bias was judged to be unclear.
Blinding
In total, 61 of 140 trials (43.6%) reported adequate methods for
blinding both participants and personnel to treatment allocation.
Twenty-eight trials (20.0%) were judged to be at high risk of bias
for blinding of participants and personnel. Fifty-one trials (36.4%)
did not provide enough information to assess the blinding of par-
ticipants and personnel and the risk of bias was judged to be un-
clear. Fifty-eight of 140 trials (41.47%) reported adequate meth-
ods for blinding the assessment of the primary outcomes. Twelve
trials (8.6%) were judged to be at high risk of bias for blinding
the assessment of the primary outcomes. Seventy trials (50.0%)
did not provide enough information for blinding the assessment
of the primary outcomes and the risk of bias was judged to be
unclear.
Incomplete outcome data
Ninety-four of 140 trials (67.1%) were judged to be at a low risk
of bias. In these trials, missing outcome data were less than 10%
and balanced in numbers across intervention groups with similar
reasons for missing data across groups. In 10 trials (7.1%), more
than 10% of patients dropped out or were not analysed as per the
“intention-to-treat” principles following randomisation, indicat-
ing a high risk of bias. Thirty-six trials (25.7%) did not provide
enough information to assess so that it was uncertain whether or
not the handling of incomplete data was appropriate and the risk
of bias was judged to be unclear in these trials.
Selective reporting
Only 16 of 140 trials (11.4%) pre-specified all outcomes in pub-
licly available study protocols and were judged to be at low risk of
bias. Five trials (3.6%) did not report all pre-specified outcomes as
reported in their published protocols or methodology within the
main report and were judged to be at high risk of bias for selective
reporting. For most trials (119 trials; 85.0%), we were unable to
trace a published protocol and the risk of bias was judged to be
unclear.
Other potential sources of bias
We found that 47 of 140 trials (33.6%) were either conducted
with public or no funding and did not declare potential conflicts
of interest. Eight trials (5.7%) were judged to be at high risk of
bias as they were funded directly by the pharmaceutical industry.
Eighty-five trials (60.7%) did not provide enough information to
assess the source of funding or potential conflicts of interest and
the risk of bias was judged to be unclear.
Among all the studies, 64 of 140 trials (45.7%) reported rela-
tively objective methods for measuring blood loss such as weighing
sponges, measurements in drapes or volumetric assessment and
were judged to be at low risk of bias. Forty trials (28.6%) were
judged to be at high risk of bias for measuring blood loss as they
used subjective measurement such as clinical or visual estimates.
Thirty-six trials (25.7%) did not measure blood loss or did not
provide enough information to assess the method for measuring
blood loss, and the risk of bias was judged to be unclear. Three
included studies did not report useable blood loss data and were
not included in the networkmeta-analysis (Fawole 2011, Kikutani
2006, Ramirez 2001).
For the purpose of sensitivity analysis we analysed howmany trials
were judged to be at low, intermediate or high overall risk of bias.
For PPH ≥ 500 mL, 29 of 100 trials (29%) were found to be
at low overall risk of bias. Seventy-one of 100 trials (71%) were
judged to be at high risk of bias as they were judged to be either
at high risk or unclear risk of bias for at least one of the domains
mentioned above. There were no trials judged as intermediate risk
of bias - see Sensitivity analysis for information about how this
risk of bias has impacted the results.
Effects of interventions
See: Summary of findings for the main comparison
Primary outcomes
Postpartum haemorrhage (PPH) ≥ 500 mL
The network diagram for PPH ≥ 500 mL is presented in Figure
4. Oxytocin was themost frequently investigated uterotonic agent
(82%, 82 of 100 trials) (Figure 4).
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Figure 4. Network diagram for PPH ≥ 500 mL. The nodes represent an intervention and their size is
proportional to the number of trials comparing this intervention to any other in the network. The lines
connecting each pair of interventions represent a direct comparison and are drawn proportional to the
number of trials making each direct comparison. Numbers on the lines represent the number of trials and
participants for each comparison. The colour of the line is green when more than 50% of the trials involved in
the specific direct comparison are judged to be at “low risk of bias” if they were double-blinded, and had
allocation concealment with little loss to follow-up (less than 10%). The colour is red when less than 50% of the
trials are at “low risk of bias”. Multi-arm trials contribute to more than one comparison.
Pooled effect sizes from the network meta-analysis of 100 trials
suggested that all drugs were effective for preventing PPH ≥ 500
mL when compared with placebo or no treatment (Figure 5).
The three most effective options for prevention of PPH ≥ 500
mL were ergometrine plus oxytocin combination, carbetocin, and
misoprostol plus oxytocin combination. All three drugs more ef-
fectively reduced the risk of PPH ≥ 500 mL than oxytocin (er-
gometrine plus oxytocin risk ratio (RR) 0.69 (95% confidence
interval (CI) 0.57 to 0.83); carbetocin RR 0.72 (95% CI 0.52 to
1.00); misoprostol plus oxytocin RR 0.73 95% CI (0.60 to 0.90),
(Figure 5). Ergometrine plus oxytocin, carbetocin and misopros-
tol plus oxytocin were also found to be more effective when com-
pared with misoprostol and ergometrine when used alone. There
was evidence of global inconsistency in this analysis, where the
direct and network (combining direct and indirect) randomised
evidence were not in agreement (P = 0.046). The inconsistency
was driven by a single unblinded study of ergometrine versus no
treatment (Begley 1990).
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Figure 5. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise analyses
for prevention of PPH ≥ 500 mL.
The cumulative probabilities for each agent being at each possible
rank for preventing PPH ≥ 500 mL are shown in Figure 6. Rank-
ing indicates the cumulative probability of being the best drug, the
second best, the third best, etc. The highest ranked agents were er-
gometrine plus oxytocin combination, carbetocin, and misopros-
tol plus oxytocin combination with an almost 100% probability
of these three agents being ranked first, second or third best. Oxy-
tocin was ranked fourth and its probability of being ranked in the
top three agents was close to 0%.
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Figure 6. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 500 mL.
Ranking indicates the cumulative probability of being the best drug, the second best, the third best, etc. The x-
axis shows the relative ranking and the y-axis the cumulative probability of each ranking. We estimate the
SUrface underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among
all available drug options.
According to GRADE, the quality of evidence was rated as mod-
erate due to inconsistency for the comparisons of ergometrine plus
oxytocin versus oxytocin andmisoprostol plus oxytocin versus oxy-
tocin (Summary of findings for the main comparison). However,
the quality of evidence was ranked very low for the comparison
of carbetocin versus oxytocin due to the risk of bias in the stud-
ies comparing the two uterotonics, inconsistency and imprecision
(Summary of findings for the main comparison).
Postpartum haemorrhage (PPH) ≥ 1000 mL
The network diagram for PPH ≥ 1000 mL is presented in Figure
7. Oxytocin was themost frequently investigated uterotonic agent
(85.6%, 77 of 90 trials) (Figure 7).
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Figure 7. Network diagram for PPH ≥ 1000 mL.
Pooled effect estimates from the network meta-analysis of 90 tri-
als suggested that all agents except ergometrine were effective for
preventing PPH ≥ 1000 mL when compared with placebo or no
treatment (Figure 8). Ergometrine plus oxytocin combination was
the only agent found to be more effective when compared with
the standard agent oxytocin (RR 0.77, 95% CI 0.61 to 0.95) al-
though carbetocin (RR 0.70, 95%CI 0.38 to 1.28) and misopros-
tol plus oxytocin combination (RR 0.90, 95% CI 0.72 to 1.14)
demonstrated a trend towards reduction in this outcome (Figure
8). There was no evidence of global inconsistency (P = 0.345).
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Figure 8. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise analyses
for prevention of PPH ≥ 1000 mL.
The cumulative probabilities for each agent being at each possible
rank for PPH ≥ 1000 mL are shown in Figure 9. The highest
ranked agents were ergometrine plus oxytocin combination, car-
betocin, and misoprostol plus oxytocin combination. Oxytocin
was still ranked fourth and its probability of being ranked in the
top three agents was approximately 20%.
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Figure 9. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 1000
mL.
According toGRADE, the quality of evidence was rated as high for
the comparison of ergometrine plus oxytocin combination versus
oxytocin (Summary of findings for the main comparison). How-
ever, the quality of evidence was ranked moderate for the com-
parison of misoprostol plus oxytocin combination versus oxytocin
due to imprecision in the confidence intervals. The quality of evi-
dence for carbetocin versus oxytocin was ranked as low due to the
risk of bias in the studies comparing the two uterotonics and the
imprecision (Summary of findings for the main comparison).
Secondary outcomes
Maternal death
The network diagram for maternal death is presented in Appendix
2. Pooled effect estimates from the network meta-analysis of 50
trials suggested that there were no meaningful differences between
all uterotonic agents formaternal deaths as this outcomewas so rare
(Figure 10). There was no evidence of global inconsistency in this
analysis (P = 0.999). Figure 11 shows the cumulative probabilities
for each agent being at each possible rank for maternal death. No
reliable ranking could be derived for this outcome.
25Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 10. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for maternal death.
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Figure 11. Cumulative rankograms comparing each of the uterotonic drugs for prevention of maternal
death.
Maternal deaths or severe morbidity
The network diagram for maternal death or severe morbidity is
presented in Appendix 2. Pooled effect estimates from the network
meta-analysis of 37 trials suggested that there were no detectable
differences between all agents for maternal deaths or severe mor-
bidity as this outcome was still so rare (Figure 12). There was no
evidence of global inconsistency in this analysis (P = 0.884). Figure
13 shows the cumulative probabilities for each agent being at each
possible rank for maternal death or severe morbidity. No sensible
ranking could be derived for this outcome due to limited data.
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Figure 12. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for maternal death or severe morbidity.
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Figure 13. Cumulative rankograms comparing each of the uterotonic drugs for prevention of maternal
deaths or severe morbidity events.
Additional uterotonics
The network diagram for the requirement of additional utero-
tonics is presented in Appendix 2. Pooled effect estimates from
the network meta-analysis of 107 trials suggested that all agents
were effective at reducing the requirement of additional utero-
tonics when compared with placebo or no treatment (Figure 14).
Ergometrine plus oxytocin, carbetocin and misoprostol plus oxy-
tocin were found to be more effective when compared with the
standard agent oxytocin (Figure 14). Ergometrine plus oxytocin,
carbetocin and misoprostol plus oxytocin were also found to be
more effective when compared with misoprostol and ergometrine
when used alone. There was no evidence of global inconsistency
in this analysis (P = 0.275). Figure 15 shows the cumulative prob-
abilities for each agent being at each possible rank for the require-
ment of additional uterotonics. The highest ranked agents were
carbetocin, misoprostol plus oxytocin and ergometrine plus oxy-
tocinwith an almost 100% probability of these three agents be-
ing ranked in the top three. Oxytocin was ranked fourth and its
probability in being ranked in the top three agents was close to
0%. The lowest ranked agents were misoprostol, ergometrine and
placebo or no treatment.
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Figure 14. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for the requirement of additional uterotonics.
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Figure 15. Cumulative rankograms comparing each of the uterotonic drugs for the requirement of
additional uterotonics.
Transfusion
The network diagram for blood transfusion is presented in
Appendix 2. Pooled effect estimates from the network meta-anal-
ysis of 92 trials suggested that all agents except ergometrine were
effective for preventing blood transfusion when compared with
placebo or no treatment (Figure 16). Misoprostol plus oxytocin
was the only agent found to be more effective when compared
with the standard agent oxytocin. Carbetocin and ergometrine
plus oxytocin demonstrated a trend towards reduction of this out-
come (Figure 16). There was no evidence of global inconsistency
in this analysis (P = 0.061). Figure 17 shows the cumulative prob-
abilities for each agent being at each possible rank for preventing
blood transfusion. The highest ranked agents were misoprostol
plus oxytocin, carbetocin and ergometrine plus oxytocin. Oxy-
tocin was ranked fifth behind misoprostol and its probability of
being ranked in the top three agents was less than 10%.
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Figure 16. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for the requirement of blood transfusion.
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Figure 17. Cumulative rankograms comparing each of the uterotonic drugs for the requirement of blood
transfusion.
Manual removal of the placenta
The network diagram for the requirement of manual removal of
placenta is presented in Appendix 2. Pooled effect estimates from
the network meta-analysis of 67 trials suggested that there are no
clear differences between all agents for this outcome (Figure 18).
There was evidence of global inconsistency in this analysis (P =
0.025). However, we note that the CIs for both the network meta-
analysis and direct evidence were overlapping across all compar-
isons suggesting locally-consistent results except for ergometrine
versus placebo or no treatment and carbetocin versus oxytocin
based on single studies. Figure 19 shows the cumulative probabil-
ities for each agent being at each possible rank for prevention of
themanual removal of placenta. No clear ranking could be derived
for this outcome with all agents being comparable, except for car-
betocin that appeared to have the highest probability in being the
top ranked agent with a probability close to 80%.
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Figure 18. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for the requirement of manual removal of placenta.
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Figure 19. Cumulative rankograms comparing each of the uterotonic drugs for the requirement of manual
removal of placenta.
Mean volumes of blood loss
The network diagram for blood loss (mL) as a continuous out-
come is presented in Appendix 2. Pooled effect estimates from the
network meta-analysis of 102 trials suggested that all agents are
effective for reducing blood loss as a continuous outcome when
compared with placebo or no treatment (Figure 20). Carbetocin
and misoprostol plus oxytocin were found to be more effective
when compared with the standard agent oxytocin. Ergometrine
plus oxytocin also demonstrated a trend towards reduction of this
outcome (Figure 20). Carbetocin and misoprostol plus oxytocin
were more effective than ergometrine plus oxytocin in reducing
blood loss. Carbetocin and misoprostol plus oxytocin were also
found to be more effective when compared with misoprostol and
ergometrine when used alone. There was no evidence of global
inconsistency in this analysis (P = 0.111). Figure 21 shows the
cumulative probabilities for each agent being at each possible rank
for preventing blood loss (mL) as a continuous outcome. The
highest ranked agents were carbetocin, misoprostol plus oxytocin
and ergometrine plus oxytocin. Oxytocin was ranked fourth and
its probability in being ranked in the top three agents was less than
10%. The lowest ranked agents were misoprostol, ergometrine
and placebo or no treatment.
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Figure 20. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for blood loss (mL).
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Figure 21. Cumulative rankograms comparing each of the uterotonic drugs for blood loss (mL).
Mean durations of the third stage of labour
The network diagram for the duration of the third stage (minutes)
as a continuous outcome is presented in Appendix 2. Pooled effect
estimates from the network meta-analysis of 58 trials suggested
that all agents are effective for reducing the duration of the third
stage as a continuous outcome when compared with placebo or
no treatment except for carbetocin and misoprostol plus oxytocin
that demonstrated a similar trend towards reduction of this out-
come (Figure 22). There were no significant differences between
all active agents for this outcome (Figure 22). There was evidence
of global inconsistency in this analysis (P = 0.011) and these results
need to be interpreted with caution. Figure 23 shows the cumula-
tive probabilities for each agent being at each possible rank for the
reduction of the duration of the third stage. No sensible ranking
could be derived for this outcome with all agents being compara-
ble. The exception was ergometrine plus oxytocin that appeared
to have the highest probability in being the top ranked agent with
a probability close to 60% and the placebo or no treatment that
appeared to have the lowest ranking.
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Figure 22. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for duration of third stage (minutes).
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Figure 23. Cumulative rankograms comparing each of the uterotonic drugs for duration of third stage
(minutes).
Change in haemoglobin
The network diagram for the change in haemoglobin measure-
ments before and after birth (g/L) is presented in Appendix 2.
Pooled effect estimates from the network meta-analysis of 74 trials
suggested that misoprostol plus oxytocin and carbetocin are effec-
tive for reducing the change in haemoglobin measurements when
compared with placebo or no treatment (Figure 24). Misoprostol
plus oxytocin was the only agent found to be more effective when
compared with the standard agent oxytocin (Figure 24). The com-
bination of misoprostol plus oxytocin was also more effective than
misoprostol and ergometrine when used alone. Carbetocin was
more effective than ergometrine when used alone. However, there
was evidence of substantial global inconsistency in this analysis (P
= 0.001). Figure 25 shows the cumulative probabilities for each
agent being at each possible rank for change in haemoglobin mea-
surements before and after birth (g/L). The highest ranked agents
were misoprostol plus oxytocin, carbetocin and ergometrine plus
oxytocin. Oxytocin was ranked fourth and its probability in be-
ing ranked in the top three agents was just over 20%. The lowest
ranked agents were misoprostol, ergometrine and placebo or no
treatment.
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Figure 24. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for change in haemoglobin measurements before and after birth (g/L).
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Figure 25. Cumulative rankograms comparing each of the uterotonic drugs for change in haemoglobin
measurements before and after birth (g/L).
Clinical signs of blood loss
There were no trials reporting clinical signs of acute blood loss.
Neonatal unit admission
The network diagram for neonatal unit admissions is presented
in Appendix 2. Pooled effect estimates from the network meta-
analysis of only six trials did not point towards any meaningful
differences between all agents for this outcome (Figure 26). There
was no evidence of global inconsistency in this analysis (P = 0.989).
Figure 27 shows the cumulative probabilities for each agent being
at each possible rank for neonatal unit admissions. No sensible
ranking could be derived for this outcome because of too few
studies reporting this outcome.
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Figure 26. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for neonatal unit admissions.
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Figure 27. Cumulative rankograms comparing each of the uterotonic drugs for neonatal unit admissions.
Breastfeeding at discharge
The network diagram for breastfeeding at discharge is presented
in Appendix 2. Pooled effect estimates from the network meta-
analysis of only five trials did not point towards any meaningful
differences between agents for this outcome (Figure 28). There was
no evidence of global inconsistency in this analysis (P = 0.167).
Figure 29 shows the cumulative probabilities for each agent be-
ing at each possible rank for breastfeeding at discharge. No clear
ranking could be derived for this outcome with all agents being
comparable again because of too few studies.
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Figure 28. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for breastfeeding at discharge.
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Figure 29. Cumulative rankograms comparing each of the uterotonic drugs for breastfeeding at discharge.
Side-effects
Nausea
The network diagram for nausea is presented in Appendix 2.
Pooled effect estimates from the network meta-analysis of 74 tri-
als suggested that ergometrine and ergometrine plus oxytocin are
worse than placebo or no treatment in causing nausea (Figure 30).
Ergometrine, ergometrine plus oxytocin, misoprostol and miso-
prostol plus oxytocin were found to be worse in causing nausea
when compared with the standard agent oxytocin (Figure 30). Er-
gometrine, ergometrine plus oxytocin and misoprostol plus oxy-
tocin were significantly worse in causing nausea than carbetocin.
There was evidence of global inconsistency in this analysis (P =
0.005). However, we note that the CIs for both the network meta-
analysis and direct evidence were overlapping across all compar-
isons suggesting locally-consistent results except for ergometrine
versus placebo or no treatment based on a single study. Figure
31 shows the cumulative probabilities for each agent being at
each possible rank for causing nausea. The highest ranked and the
agents with the least risk of nausea were carbetocin, oxytocin and
placebo or no treatment. The lowest ranked andmost likely agents
to cause nausea were ergometrine plus oxytocin and ergometrine.
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Figure 30. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for nausea.
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Figure 31. Cumulative rankograms comparing each of the uterotonic drugs for nausea.
Vomiting
The network diagram for vomiting is presented in Appendix 2.
Pooled effect estimates from the network meta-analysis of 83 tri-
als suggested that ergometrine and ergometrine plus oxytocin are
worse than placebo or no treatment in causing vomiting (Figure
32). Ergometrine, ergometrine plus oxytocin, misoprostol and
misoprostol plus ocytocin were found to be worse in causing vom-
itingwhen comparedwith the standard agent oxytocin (Figure 32).
Ergometrine, ergometrine plus oxytocin, misoprostol and miso-
prostol plus oxytocin were significantly worse in causing vomiting
than carbetocin. There was no evidence of global inconsistency in
this analysis (P = 0.06). Figure 33 shows the cumulative probabili-
ties for each agent being at each possible rank for causing vomiting.
The highest ranked agents were carbetocin, oxytocin and placebo
or no treatment with an almost 100% probability of these three
agents being ranked in the top three. The lowest ranked agents
were ergometrine plus oxytocin and ergometrine.
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Figure 32. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for vomiting.
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Figure 33. Cumulative rankograms comparing each of the uterotonic drugs for vomiting.
Hypertension
The network diagram for hypertension is presented inAppendix 2.
Pooled effect estimates from the network meta-analysis of 15 trials
suggested that ergometrine is worse than placebo or no treatment
in causing hypertension (Figure 34). Ergometrine was found to
be worse in causing hypertension when compared with the stan-
dard agent oxytocin (Figure 34). Ergometrinewas also significantly
worse in causing hypertension than carbetocin and misoprostol.
There was no evidence of global inconsistency in this analysis (P
= 0.481). Figure 35 shows the cumulative probabilities for each
agent being at each possible rank for causing hypertension. The
lowest ranked agents were ergometrine and ergometrine plus oxy-
tocin. However, not all agents could be ranked because of too few
studies in this analysis.
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Figure 34. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for hypertension.
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Figure 35. Cumulative rankograms comparing each of the uterotonic drugs for hypertension.
Headache
The network diagram for headache is presented in Appendix 2.
Pooled effect estimates from the network meta-analysis of 45 trials
suggested that ergometrine is worse than placebo or no treatment
in causing headache (Figure 36). Ergometrine was found to be
worse in causingheadachewhen comparedwith the standard agent
oxytocin (Figure 36). Ergometrine was also significantly worse in
causing headache than carbetocin and misoprostol. There was no
evidence of global inconsistency in this analysis (P = 0.826). Figure
37 shows the cumulative probabilities for each agent being at each
possible rank for causing headache. The lowest ranked agents were
ergometrine, misoprostol plus oxytocin and ergometrine plus oxy-
tocin. The highest ranked agents were placebo or no treatment,
carbetocin and oxytocin.
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Figure 36. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for headache.
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Figure 37. Cumulative rankograms comparing each of the uterotonic drugs for headache.
Fever
The network diagram for fever is presented in Appendix 2. Pooled
effect estimates from the network meta-analysis of 64 trials sug-
gested that misoprostol and misoprostol plus oxytocin are worse
than placebo or no treatment in causing fever (Figure 38). Miso-
prostol and misoprostol plus oxytocin were found to be worse in
causing fever when compared with the standard agent oxytocin
(Figure 38). Misoprostol and misoprostol plus oxytocin were also
significantly worse in causing fever than carbetocin, ergometrine
and ergometrine plus oxytocin with the exception of the compar-
ison carbetocin versus misoprostol plus oxytocin which fell just
short of being statistically significant. There was no evidence of
global inconsistency in this analysis (P = 0.352). Figure 39 shows
the cumulative probabilities for each agent being at each possible
rank for causing fever. The highest ranked agents were carbetocin,
oxytocin and placebo or no treatment. The lowest ranked agents
were misoprostol and misoprostol plus oxytocin. The rest of the
agents were similar in ranking to the placebo or no treatment
group.
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Figure 38. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for fever.
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Figure 39. Cumulative rankograms comparing each of the uterotonic drugs for fever.
Shivering
The network diagram for shivering is presented in Appendix 2.
Pooled effect estimates from the network meta-analysis of 87 tri-
als suggested that misoprostol and misoprostol plus oxytocin are
worse than placebo or no treatment in causing shivering (Figure
40). Misoprostol and misoprostol plus oxytocin were found to
be worse in causing shivering when compared with the standard
agent oxytocin (Figure 40).Misoprostol andmisoprostol plus oxy-
tocin were also significantly worse in causing shivering than car-
betocin, ergometrine and ergometrine plus oxytocin. There was
no evidence of global inconsistency in this analysis (P = 0.923).
Figure 41 shows the cumulative probabilities for each agent being
at each possible rank for causing shivering. The highest ranked
agents were carbetocin and oxytocin. The lowest ranked agents
were misoprostol and misoprostol plus oxytocin. Ergometrine and
ergometrine plus oxytocin were similar in ranking to the placebo
or no treatment group.
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Figure 40. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for shivering.
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Figure 41. Cumulative rankograms comparing each of the uterotonic drugs for shivering.
Tachycardia
The network diagram for tachycardia is presented in Appendix 2.
Pooled effect estimates from the network meta-analysis of seven
trials suggested only that carbetocin is worse than oxytocin and
ergometrine plus oxytocin in causing tachycardia, but most of the
comparisons were based on single studies (Figure 42). There was
no evidence of global inconsistency in this analysis (P = 0.361).
Figure 43 shows the cumulative probabilities for each agent being
at each possible rank for causing tachycardia. No clear ranking
emerged and not all agents could be ranked because of the lack of
studies in this analysis.
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Figure 42. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for tachycardia.
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Figure 43. Cumulative rankograms comparing each of the uterotonic drugs for tachycardia.
Hypotension
The network diagram for hypotension is presented in Appendix 2.
Pooled effect estimates from the network meta-analysis of 8 trials
suggested a lack of evidence that any agent is worse or better than
any other as most of the comparisons were based on single studies
(Figure 44). There was no evidence of global inconsistency in this
analysis (P = 0.304). Figure 45 shows the cumulative probabilities
for each agent being at each possible rank for causing hypotension.
The highest ranked agents were misoprostol and placebo or no
treatment. For the rest of the agents no clear ranking emerged and
not all agents could be ranked because of the lack of studies in this
analysis.
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Figure 44. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for hypotension.
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Figure 45. Cumulative rankograms comparing each of the uterotonic drugs for hypotension.
Abdominal pain
The network diagram for abdominal pain is presented inAppendix
2. Pooled effect estimates from the networkmeta-analysis of 25 tri-
als suggested that misoprostol plus oxytocin is worse than placebo
or no treatment in causing abdominal pain (Figure 46). No ac-
tive agent was found to be worse or better than any other. There
was evidence of global inconsistency in this analysis (P = 0.035).
However, we note that the CIs for both the network meta-analysis
and direct evidence were overlapping across all comparisons sug-
gesting locally fairly consistent results. Figure 47 shows the cumu-
lative probabilities for each agent being at each possible rank for
causing abdominal pain. The highest ranked agent was placebo or
no treatment. For the rest of the agents no clear ranking emerged
because of the lack of studies in this analysis.
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Figure 46. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for abdominal pain.
62Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 47. Cumulative rankograms comparing each of the uterotonic drugs for abdominal pain.
Subgroup analyses
Mode of birth
Vaginal birth
PPH ≥ 500 mL
The network diagram for PPH≥ 500mL for the subgroup includ-
ing only vaginal births is presented in Appendix 2. Pooled effect
estimates from the network meta-analysis of 85 trials suggested
that all agents are effective for preventing PPH ≥ 500 mL when
compared with placebo or no treatment (Figure 48). Ergometrine
plus oxytocin, and misoprostol plus oxytocin were found to be
more effective when compared with the standard agent oxytocin.
Carbetocin also demonstrated a trend towards reduction of this
outcome (Figure 48). Ergometrine plus oxytocin, carbetocin and
misoprostol plus oxytocin were also found to be more effective
when compared with misoprostol and ergometrine when used
alone. There was no evidence of global inconsistency in this anal-
ysis (P = 0.06). Figure 49 shows the cumulative probabilities for
each agent being at each possible rank for PPH ≥ 500 mL for the
subgroup including only vaginal births. The highest ranked agents
were ergometrine plus oxytocin, carbetocin, and misoprostol plus
oxytocin with an almost 100% probability of these three agents
being ranked first, second or third. Oxytocin was ranked fourth
and its probability of being ranked in the top three agents was
close to 0%.
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Figure 48. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for prevention of PPH ≥ 500 mL by mode of birth (vaginal birth).
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Figure 49. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 500
mL by mode of birth (vaginal birth).
PPH ≥ 1000 mL
Pooled effect estimates from the network meta-analysis of 71 trials
suggested that all agents except carbetocin and ergometrine are
effective for preventing PPH ≥ 1000 mL when compared with
placebo or no treatment (Appendix 3). Ergometrine plus oxytocin
was the only agent found to be more effective when compared
with the standard agent oxytocin.Carbetocin andmisoprostol plus
oxytocin demonstrated a trend towards reduction of this outcome
(Appendix 3). There was no evidence of global inconsistency in
this analysis (P = 0.206). Appendix 3 shows the cumulative proba-
bilities for each agent being at each possible rank for PPH≥ 1000
mL for the subgroup including only vaginal births. The highest
ranked agents were carbetocin, ergometrine plus oxytocin, and
misoprostol plus oxytocin. Oxytocin was ranked fourth and its
probability in being ranked in the top two agents was close to 0%.
Caesarean section
PPH ≥ 500 mL
Pooled effect estimates from the network meta-analysis of 15 tri-
als suggested that only misoprostol plus oxytocin is better than
oxytocin alone in preventing PPH ≥ 500 mL for women under-
going caesareans, but most of the comparisons were based on sin-
gle studies (Figure 50). There was no evidence of global inconsis-
tency in this analysis (P = 0.249). Figure 51 shows the cumulative
probabilities for each agent being at each possible rank for PPH
≥ 500 mL for the subgroup including only caesareans. The high-
est ranked agents were misoprostol plus oxytocin and carbetocin.
Oxytocin was ranked third and its probability in being ranked in
the top two agents was close to 5%. Ergometrine and ergometrine
plus oxytocin could not be ranked as there were no studies found
comparing those with any other agents in the network.
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Figure 50. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for prevention of PPH ≥ 500 mL by mode of birth (caesarean).
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Figure 51. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 500
mL by mode of birth (caesarean).
PPH ≥ 1000 mL
Pooled effect estimates from the network meta-analysis of 19 trials
suggested a lack of evidence that any agent is worse or better than
any other in preventing PPH ≥ 1000 mL in women undergo-
ing caesareans, but many of the comparisons were based on single
studies (Appendix 3). There was no evidence of global inconsis-
tency in this analysis (P = 0.86). Appendix 3 shows the cumulative
probabilities for each agent being at each possible rank for PPH
≥ 1000 mL for the subgroup including only caesareans. No clear
ranking emerged in this analysis. Ergometrine and ergometrine
plus oxytocin could not be ranked as there were no studies found
comparing those with any other agents in the network.
Prior risk of PPH
Low risk for PPH
PPH ≥ 500 mL
Pooled effect estimates from the network meta-analysis of 35 trials
suggested that only ergometrine plus oxytocin andmisoprostol are
better than placebo or no treatment in preventing PPH ≥ 500
mL in women at low risk for PPH, but most of the comparisons
were based on single studies (Figure 52). There was no evidence of
global inconsistency in this analysis (P = 0.236). Figure 53 shows
the cumulative probabilities for each agent being at each possible
rank for PPH ≥ 500 mL for the subgroup including only trials
with women at low risk for PPH. The highest ranked agents were
ergometrine plus oxytocin and carbetocin. Oxytocin was ranked
fourth behind misoprostol and its probability in being ranked in
the top two agents was close to 10%. Misoprostol plus oxytocin
could not be ranked as there were no studies found comparing this
agent with any other agents in the network.
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Figure 52. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for prevention of PPH ≥ 500 mL by prior risk for PPH (low risk).
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Figure 53. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 500
mL by prior risk for PPH (low risk).
PPH ≥ 1000 mL
Pooled effect estimates from the network meta-analysis of 32 trials
suggested that ergometrine plus oxytocin, oxytocin, ergometrine
andmisoprostol are better thanplaceboor no treatment in prevent-
ing PPH≥ 1000 mL in women at low risk for PPH (Appendix 3).
The comparisons between active agents appeared to be underpow-
ered to detect differences between them. There was no evidence of
global inconsistency in this analysis (P = 0.477). Appendix 3 shows
the cumulative probabilities for each agent being at each possible
rank for PPH ≥ 1000 mL for the subgroup including only trials
with women at low risk for PPH. No clear ranking emerged in this
analysis. Ergometrine could not be ranked as there were no studies
found comparing those with any other agents in the network.
High risk for PPH
PPH ≥ 500 mL
Pooled effect estimates from the network meta-analysis of 21 trials
suggested that only isoprostol plus oxytocin is better than oxytocin
in preventing PPH ≥ 500 mL and carbetocin showed a similar
trend towards prevention of this outcome for women at high risk
for PPH, but most of the comparisons were based on single studies
(Figure 54). There was no evidence of global inconsistency in this
analysis (P = 0.211). Figure 55 shows the cumulative probabilities
for each agent being at each possible rank for PPH ≥ 500 mL for
the subgroup including only trials with women at high risk for
PPH. The highest ranked agents were misoprostol plus oxytocin
and carbetocin. Oxytocin was ranked third closely followed by
misoprostol and its probability in being ranked in the top two
agents was close to 0%.
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Figure 54. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for prevention of PPH ≥ 500 mL by prior risk for PPH (high risk).
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Figure 55. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 500
mL by prior risk for PPH (high risk).
PPH ≥ 1000 mL
Pooled effect estimates from the network meta-analysis of 22 trials
suggested a lack of evidence that any agent is worse or better than
any other in preventing PPH ≥ 1000 mL in women at high risk
for PPH; many of the comparisons were based on single studies
(Appendix 3). There was no evidence of global inconsistency in
this analysis (P = 0.851). Appendix 3 shows the cumulative proba-
bilities for each agent being at each possible rank for PPH≥ 1000
mL for the subgroup including only trials with women at high risk
for PPH. No clear ranking emerged in this analysis. Ergometrine
and ergometrine plus oxytocin could not be ranked as there were
no studies found comparing those with any other agents in the
network.
Healthcare setting
Hospital setting
PPH ≥ 500 mL
The network diagram for PPH ≥ 500 mL for the subgroup in-
cluding trials carried out in the hospital setting is presented in
Appendix 2. Pooled effect estimates from the network meta-anal-
ysis of 95 trials suggested that all agents are effective for prevent-
ing PPH ≥ 500 mL when compared with placebo or no treat-
ment (Figure 56). Ergometrine plus oxytocin, and misoprostol
plus oxytocin were found to be more effective when compared
with the standard agent oxytocin. Carbetocin also demonstrated a
trend towards reduction of this outcome (Figure 56). Ergometrine
plus oxytocin, carbetocin and misoprostol plus oxytocin were also
found to be more effective when compared with misoprostol and
ergometrine when used alone. There was evidence of global in-
consistency in this analysis (P = 0.0448). However, we note that
the CIs for both the network and direct evidence were overlapping
across all comparisons suggesting locally-consistent results except
for ergometrine versus placebo or no treatment based on a single
study. Figure 57 shows the cumulative probabilities for each agent
being at each possible rank for PPH ≥ 500 mL for the subgroup
including only trials carried out in the hospital setting. The high-
est ranked agents were ergometrine plus oxytocin, carbetocin, and
misoprostol plus oxytocin with an almost 100% probability of
these three agents being ranked first, second or third. Oxytocin
was ranked fourth and its probability in being ranked in the top
three agents was close to 0%.
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Figure 56. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for prevention of PPH ≥ 500 mL by healthcare setting (hospital setting).
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Figure 57. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 500
mL by healthcare setting (hospital setting).
PPH ≥ 1000 mL
Pooled effect estimates from the network meta-analysis of 85 tri-
als suggested that all agents except ergometrine are effective for
preventing PPH ≥ 1000 mL when compared with placebo or no
treatment for the subgroup including only trials carried out in the
hospital setting (Appendix 3). Ergometrine plus oxytocin was the
only agent found to be more effective when compared with the
standard agent oxytocin. Carbetocin and misoprostol plus oxy-
tocin demonstrated a trend towards reduction of this outcome
(Appendix 3). There was no evidence of global inconsistency in
this analysis (P = 0.389). Appendix 3 shows the cumulative proba-
bilities for each agent being at each possible rank for PPH≥ 1000
mL for the subgroup including trials carried out in the hospital
setting. The highest ranked agents were carbetocin, ergometrine
plus oxytocin and misoprostol plus oxytocin. Oxytocin was still
ranked fourth and its probability in being ranked in the top three
agents was close to 20%.
Community setting
PPH ≥ 500 mL
Pooled effect estimates from the network meta-analysis of four
trials suggested that only oxytocin and misoprostol are effective
for preventing PPH ≥ 500 mL when compared with placebo or
no treatment for the subgroup including only trials carried out in
the community setting (Figure 58). There was evidence of global
inconsistency in this analysis (P = 0.03), but most of the compar-
isons were based on a small number of studies. Figure 59 shows
the cumulative probabilities for each agent being at each possible
rank for PPH ≥ 500 mL for the subgroup including trials carried
out in the community setting. No clear ranking emerged in this
analysis. Carbetocin, misoprostol plus oxytocin, ergometrine and
ergometrine plus oxytocin could not be ranked as there were no
studies found comparing those with any other agents in the net-
work.
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Figure 58. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for prevention of PPH ≥ 500 mL by healthcare setting (community setting).
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Figure 59. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 500
mL by healthcare setting (community setting).
PPH ≥ 1000 mL
Pooled effect estimates from the network meta-analysis of four tri-
als suggested that only misoprostol is more effective for preventing
PPH ≥ 1000 mL when compared with placebo or no treatment.
Oxytocin also demonstrated a trend towards reduction of this out-
come for the subgroup including trials carried out in the commu-
nity setting (Appendix 3). There was evidence of global inconsis-
tency in this analysis (P = 0.004), but most of the comparisons
were based on single studies. Appendix 3 shows the cumulative
probabilities for each agent being at each possible rank for PPH≥
1000 mL for the subgroup including trials carried out in the com-
munity setting. No clear ranking emerged in this analysis. Car-
betocin, misoprostol plus oxytocin, ergometrine and ergometrine
plus oxytocin could not be ranked as there were no studies found
comparing those with any other agents in the network.
Intervention: dose, regimen or route
Low-dose misoprostol
PPH ≥ 500 mL
The network diagram for PPH ≥ 500 mL for the subgroup in-
cluding only misoprostol studies that used a low dose (< 600 mcg)
is presented in Appendix 2. Pooled effect estimates from the net-
work meta-analysis of 72 trials suggested that all agents are effec-
tive for preventing PPH ≥ 500 mL when compared with placebo
or no treatment (Figure 60). Ergometrine plus oxytocin, carbe-
tocin and misoprostol plus oxytocin were found to be more effec-
tive when compared with the standard agent oxytocin (Figure 60).
Ergometrine plus oxytocin, carbetocin and misoprostol plus oxy-
tocin were also found to be more effective when compared with
misoprostol and ergometrine when used alone. There was evidence
of global inconsistency in this analysis (P = 0.016). However, we
note that the CIs for both the network and direct evidence were
overlapping across all comparisons suggesting locally-consistent
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results except for ergometrine versus control or no treatment based
on a single study. Figure 61 shows the cumulative probabilities for
each agent being at each possible rank for PPH ≥ 500 mL for the
subgroup restricted to misoprostol trials that used a low dose. The
highest ranked agents were ergometrine plus oxytocin, carbetocin,
and misoprostol plus oxytocin with almost 100% probability of
these three agents being ranked first, second or third. Oxytocin
was ranked fourth and its probability in being ranked in the top
three agents was close to 0%.
Figure 60. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for prevention of PPH ≥ 500 mL restricted to misoprostol studies that use a low dose (less or equal to
500 mcg).
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Figure 61. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 500
mL restricted to misoprostol studies that use a low dose (less or equal to 500 mcg).
PPH ≥ 1000 mL
Pooled effect estimates from the network meta-analysis of 69 tri-
als suggested that all agents except ergometrine are effective for
preventing PPH ≥ 1000 mL when compared with placebo or no
treatment for the subgroup including only misoprostol trials that
used a low dose (Appendix 3). Ergometrine plus oxytocin was the
only agent found to be more effective when compared with the
standard agent oxytocin. Carbetocin also demonstrated a trend to-
wards reduction of this outcome (Appendix 3). There was no evi-
dence of global inconsistency in this analysis (P =0.401). Appendix
3 shows the cumulative probabilities for each agent being at each
possible rank for PPH ≥ 1000 mL for the subgroup restricted to
misoprostol trials that used a low dose. The highest ranked agents
were carbetocin, ergometrine plus oxytocin and misoprostol plus
oxytocin. Oxytocin was still ranked fourth and its probability in
being ranked in the top three agents was close to 20%.
High-dose misoprostol
PPH ≥ 500 mL
The network diagram for PPH≥ 500mL for the subgroup includ-
ing only misoprostol studies that used a high dose (≥ 600 mcg) is
presented in Appendix 2. Pooled effect estimates from the network
meta-analysis of 83 trials suggested that all agents are effective for
preventing PPH ≥ 500 mL when compared with placebo or no
treatment for the subgroup including only misoprostol trials that
used a high dose (Figure 62). Ergometrine plus oxytocin andmiso-
prostol plus oxytocin were found to be more effective when com-
pared with the standard agent oxytocin. Carbetocin also showed a
trend towards reduction of this outcome (Figure 62). Ergometrine
plus oxytocin, carbetocin and misoprostol plus oxytocin were also
found to be more effective than misoprostol when used alone.
There was no evidence of global inconsistency in this analysis (P
= 0.322). Figure 63 shows the cumulative probabilities for each
agent being at each possible rank for PPH ≥ 500 mL for the sub-
group including only misoprostol trials that used a high dose. The
highest ranked agents were ergometrine plus oxytocin, carbetocin,
and misoprostol plus oxytocin with more than 80% probability
of these three agents being ranked first, second or third. Oxytocin
was ranked fifth behind ergometrine and its probability in being
ranked in the top three agents was close to 0%.
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Figure 62. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise analyses
for prevention of PPH ≥ 500 mL restricted to misoprostol studies that use a high dose (600 mcg or more).
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Figure 63. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 1000
mL restricted to misoprostol studies that use a high dose (600 mcg or more).
PPH ≥ 1000 mL
Pooled effect estimates from the network meta-analysis of 62 tri-
als suggested that all agents except ergometrine are effective for
preventing PPH ≥ 1000 mL when compared with placebo or no
treatment for the subgroup including only misoprostol trials that
used a high dose (Appendix 3). Ergometrine plus oxytocin was the
only agent found to be more effective when compared with the
standard agent oxytocin. Carbetocin also demonstrated a trend
towards reduction of this outcome (Appendix 3). Ergometrine
plus oxytocin, carbetocin, misoprostol plus oxytocin and oxytocin
when used alone were found to be more effective than misoprostol
despite misoprostol being used at a high dose. There was no evi-
dence of global inconsistency in this analysis (P =0.625). Appendix
3 shows the cumulative probabilities for each agent being at each
possible rank for PPH ≥ 1000 mL for the subgroup restricted
to misoprostol trials that used a high dose. The highest ranked
agents were carbetocin, ergometrine plus oxytocin, ergometrine
and misoprostol plus oxytocin. Oxytocin was still ranked fifth and
its probability in being ranked in the top three agents was less than
20%.
Oxytocin bolus only
PPH ≥ 500 mL
The network diagram for PPH ≥ 500 mL for the subgroup is
presented in Appendix 2. This subgroup includes all trials, but for
trials including oxytocin as an arm, this analysis is restricted to
oxytocin studies that used an intravenous or intramuscular bolus
of any dose and excluded studies that used a bolus plus infusion
or infusion only of oxytocin. Pooled effect estimates from the
network meta-analysis of 84 trials suggested that all agents are
effective for preventing PPH ≥ 500 mL when compared with
placebo or no treatment for the subgroup including trials that
only used an intramuscular or intravenous bolus of oxytocin at
any dose (Figure 64). Ergometrine plus oxytocin was the only
agent found to bemore effective when comparedwith the standard
agent oxytocin. Carbetocin and misoprostol plus oxytocin also
demonstrated a trend towards reduction of this outcome (Figure
64). Ergometrine plus oxytocin was also found to bemore effective
thanmisoprostol whenused alone.Therewas no evidence of global
inconsistency in this analysis (P = 0.134). Figure 65 shows the
cumulative probabilities for each agent being at each possible rank
for PPH ≥ 500 mL for the subgroup including trials that used an
intramuscular or intravenous bolus of oxytocin at any dose. The
highest ranked agentswere ergometrine plus oxytocin,misoprostol
plus oxytocin and carbetocin with more than 80% probability of
these three agents being ranked first, second or third. Oxytocin
was still ranked fourth and its probability in being ranked in the
top three agents was less than 20%.
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Figure 64. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for prevention of PPH ≥ 500 mL restricted to oxytocin studies that used an intramuscular or
intravenous bolus of any dose.
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Figure 65. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 500
mL restricted to oxytocin studies that used an intramuscular or intravenous bolus of any dose.
PPH ≥ 1000 mL
The network diagram for PPH ≥ 1000 mL for the subgroup in-
cluding all trials, but restricted to trials that used an intravenous
or intramuscular bolus of oxytocin at any dose is presented in
Appendix 2. Pooled effect estimates from the network meta-anal-
ysis of 68 trials suggested that all agents except carbetocin and
ergometrine are effective for preventing PPH ≥ 500 mL when
compared with placebo or no treatment for the subgroup includ-
ing only trials that used an intramuscular or intravenous bolus
of oxytocin at any dose (Appendix 3). None of the agents was
found to bemore effective when comparedwith the standard agent
oxytocin (Appendix 3). Ergometrine plus oxytocin and oxytocin
when used alone were found to be more effective than misopros-
tol. There was no evidence of global inconsistency in this analysis
(P = 0.468). Appendix 3 shows the cumulative probabilities for
each agent being at each possible rank for PPH ≥ 1000 mL for
the subgroup restricted to oxytocin studies that used an intramus-
cular or intravenous bolus of any dose. The highest ranked agent
was ergometrine plus oxytocin with less clear ranking amongst the
other agents.
Oxytocin bolus plus infusion
PPH ≥ 500 mL
The network diagram for PPH≥ 500 mL for this subgroup is pre-
sented in Appendix 2. This subgroup includes all trials, but when
oxytocin was used as an arm in the trial this analysis is restricted
only to studies that used an intravenous bolus with an intravenous
infusion of oxytocin at any dose and excluded studies that used
an intravenous or intramuscular bolus or an intravenous infusion
only of oxytocin. Pooled effect estimates from the network meta-
analysis of 31 trials suggested that all agents except oxytocin and
misoprostol plus oxytocin are effective for preventing PPH≥ 500
mLwhen comparedwith placebo or no treatment for the subgroup
including oxytocin trials that used an intravenous bolus plus an in-
fusion of any dose (Figure 66). The active agents were comparable
between them, but most of the comparisons were underpowered
to detect a difference. There was no evidence of global inconsis-
tency in this analysis (P = 0.081). Figure 67 shows the cumulative
probabilities for each agent being at each possible rank for PPH
≥ 500 mL for the subgroup including only trials of oxytocin that
used an intravenous bolus plus an infusion of any dose. No clear
ranking emerged in this analysis.
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Figure 66. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for prevention of PPH ≥ 500 mL restricted to oxytocin studies that used an intravenous bolus plus an
infusion of any dose.
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Figure 67. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 500
mL restricted to oxytocin studies that used an intravenous bolus plus an infusion of any dose.
PPH ≥ 1000 mL
The network diagram for PPH ≥ 1000 mL for this subgroup is
presented in Appendix 2. This subgroup includes all trials, but
it is restricted to studies that used an intravenous bolus with an
intravenous infusion of oxytocin at any dose. Pooled effect esti-
mates from the network meta-analysis of 29 trials suggested that
all agents demonstrated a similar trend for reducing occurrence of
this outcome, but only ergometrine, misoprostol and ergometrine
plus oxytocin reached statistical significance when compared with
placebo or no treatment for this subgroup (Appendix 3). The
active agents were comparable between them, but most of the
comparisons were underpowered to detect a difference. There was
no evidence of global inconsistency in this analysis (P = 0.315).
Appendix 3 shows the cumulative probabilities for each agent be-
ing at each possible rank for PPH ≥ 1000 mL for the subgroup
including oxytocin studies that used an intravenous bolus plus an
infusion of any dose. No clear ranking emerged in this analysis.
Oxytocin infusion only
PPH ≥ 500 mL
The network diagram for PPH ≥ 500 mL for this subgroup is
presented in Appendix 2. This subgroup includes all trials, but
when oxytocin was used as an arm in the trial this analysis is re-
stricted to studies that used an intravenous infusion only of oxy-
tocin at any dose and excluded studies that used an intravenous or
intramuscular bolus or an intravenous bolus plus an intravenous
infusion of oxytocin. Pooled effect estimates from the network
meta-analysis of 48 trials suggested that all agents are effective
for preventing PPH ≥ 500 mL when compared with placebo or
no treatment for the subgroup including oxytocin trials that used
an intravenous infusion only of any dose (Figure 68). The active
agents were comparable between them, but most of the compar-
isons were underpowered to detect a difference. There was no ev-
idence of global inconsistency in this analysis (P = 0.135). Figure
69 shows the cumulative probabilities for each agent being at each
possible rank for PPH≥ 500 mL for the subgroup including oxy-
tocin trials that used an intravenous infusion only of any dose. The
highest ranked agents were carbetocin, ergometrine plus oxytocin
and misoprostol plus oxytocin with almost 100% probability of
these three agents being ranked first, second or third. Oxytocin
was ranked fourth and its probability in being ranked in the top
three agents was almost 0%.
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Figure 68. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for prevention of PPH ≥ 500 mL restricted to oxytocin studies that used an intravenous infusion only
of any dose.
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Figure 69. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 500
mL restricted to oxytocin studies that used an intravenous infusion only of any dose.
PPH ≥ 1000 mL
The network diagram for PPH ≥ 1000 mL for the subgroup
including all trials, but restricted to oxytocin trials that used an
intravenous infusion only of any dose is presented in Appendix
2. Pooled effect estimates from the network meta-analysis of 41
trials suggested that all agents except oxytocin and ergometrine
are effective for preventing PPH ≥ 500 mL when compared with
placebo or no treatment for the subgroup including only oxytocin
trials that used an intravenous infusion only of any dose (Appendix
3). Ergometrine plus oxytocin and carbetocin were found to be
more effective when compared with the standard agent oxytocin
(Appendix 3). Ergometrine plus oxytocin and carbetocin were also
found to be more effective than misoprostol. There was no evi-
dence of global inconsistency in this analysis (P =0.232). Appendix
3 shows the cumulative probabilities for each agent being at each
possible rank for PPH ≥ 1000 mL for the subgroup including
oxytocin studies that used an intravenous infusion only of any
dose. The highest ranked agent was carbetocin. There is less clear
ranking for the rest of the agents but on this analysis oxytocin was
ranked sixth lower than ergometrine and misoprostol with 0%
probability of being ranked in the top three.
Sensitivity analyses
Low risk of bias studies
PPH ≥ 500 mL
The network diagram for PPH ≥ 500 mL for low risk of bias
trials (double-blinded, adequately concealed with less than 10%
loss to follow-up) is presented in Appendix 2. Pooled effect es-
timates from the network meta-analysis of 29 low risk of bias
trials suggested that all agents except carbetocin are effective for
preventing PPH ≥ 500 mL when compared with placebo or no
treatment. Carbetocin demonstrated a similar trend towards re-
duction of this outcome (Figure 70). Ergometrine plus oxytocin,
and ergometrine were found to be more effective when compared
with the standard agent oxytocin (Figure 70). Ergometrine plus
oxytocin and ergometrine were also found to be more effective
when compared with misoprostol when used alone. There was
no evidence of global inconsistency in this analysis (P = 0.844).
Figure 71 shows the cumulative probabilities for each agent being
at each possible rank for PPH ≥ 500 mL for the low risk of bias
trials. The highest ranked agents were ergometrine, ergometrine
plus oxytocin andmisoprostol plus oxytocin.Oxytocinwas ranked
fourth and its probability in being ranked in the top three agents
was less than 10%. Carbetocin dropped its ranking from second
in the global analysis for PPH ≥ 500 mL to fifth behind oxytocin
in this analysis including only low risk of bias trials. The ranking
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of ergometrine is an extreme outlier in this analysis and is based
on a single study.
Figure 70. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for prevention of PPH ≥ 500 mL restricted to low risk of bias studies only.
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Figure 71. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 500
mL restricted to low risk of bias studies only.
PPH ≥ 1000 mL
The network diagram for PPH ≥ 1000 mL for low risk of bias
trials is presented in Appendix 2. Pooled effect estimates from the
network meta-analysis of 30 high-quality trials suggested that all
agents except carbetocin are effective for preventing PPH ≥ 1000
mL when compared with placebo or no treatment. Carbetocin
demonstrated a similar trend towards reduction of this outcome
(Appendix 3). Oxytocin was found to be better than misoprostol
when used alone (Appendix 3). Ergometrine plus oxytocin was
also found to be more effective when compared with misoprostol
when used alone. There was no evidence of global inconsistency
in this analysis (P = 0.802). Appendix 3 shows the cumulative
probabilities for each agent being at each possible rank for PPH
≥ 1000 mL for the low risk of bias trials. The highest ranked
agent was ergometrine plus oxytocin. The ranking for carbetocin,
oxytocin and misoprostol plus oxytocin was very close without a
clear hierarchy.
Studies with funding source at low risk of bias (public or no
funding)
PPH ≥ 500 mL
The network diagram for PPH ≥ 500 mL for studies with pub-
lic or no funding is presented in Appendix 2. Pooled effect esti-
mates from the network meta-analysis of 32 trials suggested that
all agents except carbetocin and ergometrine are effective for pre-
venting PPH≥ 500 mL when compared with placebo or no treat-
ment. All other agents demonstrated a similar trend towards re-
duction of this outcome (Figure 72). There were no significant
differences between the active agents. There was evidence of global
inconsistency in this analysis (P = 0.0003). However, we note that
the CIs for both the network and direct evidence were overlapping
across all comparisons suggesting locally-consistent results except
for ergometrine versus misoprostol based on a single study. Figure
73 shows the cumulative probabilities for each agent being at each
possible rank for PPH≥ 500 mL for trials with public or no fund-
ing. The highest ranked agent was ergometrine plus oxytocin. The
ranking for carbetocin, oxytocin and misoprostol plus oxytocin
was very close without a clear hierarchy.
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Figure 72. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for prevention of PPH ≥ 500 mL restricted to studies with funding source at low risk of bias (public or
no funding).
88Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 73. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 500
mL restricted to studies with funding source at low risk of bias (public or no funding).
PPH ≥ 1000 mL
The network diagram for PPH ≥ 1000 mL for trials with pub-
lic or no funding is presented in Appendix 2. Pooled effect esti-
mates from the network meta-analysis of 35 trials suggested that
all agents except carbetocin are effective for preventing PPH ≥
1000 mL when compared with placebo or no treatment. Carbe-
tocin demonstrated a similar trend towards reduction of this out-
come (Appendix 3). No agent was found to be significantly better
or worse than oxytocin (Appendix 3). Ergometrine was found to
be more effective when compared with misoprostol. There was
no evidence of global inconsistency in this analysis (P = 0.739).
Appendix 3 shows the cumulative probabilities for each agent be-
ing at each possible rank for PPH ≥ 1000 mL for the trials with
public or no funding. The highest ranked agents were ergometrine
and ergometrine plus oxytocin. The ranking for carbetocin, oxy-
tocin and misoprostol plus oxytocin was very close without a clear
hierarchy. The ranking of ergometrine was an outlier in this anal-
ysis and was based on a single study.
Studies with an objective method of measuring blood loss
PPH ≥ 500 mL
The network diagram for PPH ≥ 500 mL for the trials that
used an objective method for measuring blood loss is presented
in Appendix 2. Pooled effect estimates from the network meta-
analysis of 56 trials suggested that all agents except ergometrine
are effective for preventing PPH ≥ 500 mL when compared with
placebo or no treatment (Figure 74). Ergometrine plus oxytocin
and misoprostol plus oxytocin were found to be more effective
when compared with the standard agent oxytocin with carbetocin
also demonstrating a similar trend (Figure 74). Ergometrine plus
oxytocin and misoprostol plus oxytocin were also found to be
more effective thanmisoprostol and ergometrine when used alone.
There was no evidence of global inconsistency in this analysis (P
= 0.455). Figure 75 shows the cumulative probabilities for each
agent being at each possible rank for PPH ≥ 500 mL for trials
that used an objective method of measuring blood loss. The high-
est ranked agents were ergometrine plus oxytocin and misoprostol
plus oxytocin followed closely by carbetocin with almost 100%
probability of these three agents being ranked first, second or third.
Oxytocin was ranked fourth and its probability in being ranked
in the top three agents was less than 0%.
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Figure 74. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise analyses
for prevention of PPH ≥ 500 mL restricted to studies with an objective method of measuring blood loss.
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Figure 75. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 500
mL restricted to studies with an objective method of measuring blood loss.
PPH ≥ 1000 mL
The network diagram for PPH≥ 1000 mL for studies that used an
objectivemethod ofmeasuring blood loss is presented inAppendix
2. Pooled effect estimates from the network meta-analysis of 49
trials suggested that all agents except carbetocin and ergometrine
are effective for preventing PPH≥ 1000 mLwhen compared with
placebo or no treatment. Carbetocin demonstrated a similar trend
towards reduction of this outcome (Appendix 3). Ergometrine
plus oxytocin was found to be more effective when compared with
the standard agent oxytocin. Ergometrine plus oxytocin was also
found tobemore effective thanmisoprostol and ergometrinewhen
used alone. There was no evidence of global inconsistency in this
analysis (P = 0.606). Appendix 3 shows the cumulative probabil-
ities for each agent being at each possible rank for PPH ≥ 1000
mL for the studies that used an objective method of measuring
blood loss. The highest ranked agent was ergometrine plus oxy-
tocin. The ranking for carbetocin, oxytocin and misoprostol plus
oxytocin was very close without a clear hierarchy.
Large studies only (> 400 participants)
PPH ≥ 500 mL
The network diagram for PPH ≥ 500 mL restricted to large tri-
als with more than 400 participants is presented in Appendix 2.
Pooled effect estimates from the network meta-analysis of 46 tri-
als suggested that all agents except ergometrine are effective for
preventing PPH ≥ 500 mL when compared with placebo or no
treatment (Figure 76). Ergometrine plus oxytocin and misopros-
tol plus oxytocin were found to be more effective when compared
with the standard agent oxytocin with carbetocin not being in-
cluded in this analysis as there were no large studies comparing
carbetocin to any of the other agents (Figure 76). Ergometrine
plus oxytocin and misoprostol plus oxytocin were also found to be
more effective thanmisoprostol and ergometrine when used alone.
There was evidence of global inconsistency in this analysis (P =
0.011). However, we note that the CIs for both the network and
direct evidence were overlapping across all comparisons suggesting
locally-consistent results except for ergometrine versus placebo or
no treatment based on a single study. Figure 77 shows the cumu-
lative probabilities for each agent being at each possible rank for
PPH ≥ 500 mL for large trials. The highest ranked agents were
ergometrine plus oxytocin and misoprostol plus oxytocin. Oxy-
tocin was ranked third and its probability in being ranked in the
top two agents was close to 0%. Carbetocin could not be ranked
as there were no studies found comparing it with any other agents
in the network.
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Figure 76. Forest plot with relative risk ratios and 95% CIs from network meta-analysis and pairwise
analyses for prevention of PPH ≥ 500 mL restricted to large studies (> 400 participants).
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Figure 77. Cumulative rankograms comparing each of the uterotonic drugs for prevention of PPH ≥ 500
mL restricted to large studies (> 400 participants).
PPH ≥ 1000 mL
The network diagram for PPH ≥ 1000 mL restricted to large
trials with more than 400 participants is presented in Appendix
2. Pooled effect estimates from the network meta-analysis of 46
trials suggested that all agents except ergometrine are effective for
preventing PPH ≥ 500 mL when compared with placebo or no
treatment (Appendix 3). Ergometrine plus oxytocin was found to
bemore effective when comparedwith the standard agent oxytocin
with carbetocin not being included in this analysis as there were
no large studies comparing carbetocin to any of the other agents
(Appendix 3). Ergometrine plus oxytocin and oxytocin alone were
also found to be more effective than misoprostol when used alone.
There was no evidence of global inconsistency in this analysis (P
= 0.122). Appendix 3 shows the cumulative probabilities for each
agent being at each possible rank for PPH≥ 1000 mL for the large
trials. The highest ranked agents were ergometrine plus oxytocin
and misoprostol plus oxytocin. Oxytocin was ranked third and
its probability in being ranked in the top two agents was close to
10%. Carbetocin could not be ranked as there were no studies
found comparing it with any other agents in the network.
Further sensitivity analyses
Further sensitivity analyses for the primary outcomes were per-
formed by removing trials published earlier than 1990 (three tri-
als), a cluster trial (one trial), removing trials with high level of
missing data (10 trials) and removing trials where participants were
also randomised to co-agents such as uterine massage and/or early
controlled cord traction (three trials). Sensitivity analyses were also
performed according to the choice of relative effect measure (RR
versus OR) and the statistical model (fixed-effect versus random-
effects model). We found that the overall ranking did not vary and
the confidence intervals of the relative effects did not substantially
change. Of note is that the global inconsistency was substantially
reduced when the trials randomising to co-interventions were re-
moved (P = 0.218).
D I S C U S S I O N
Summary of main results
This network meta-analysis found that an ergometrine plus oxy-
tocin combination, carbetocin, and a misoprostol plus oxytocin
combination were more effective uterotonic drugs for preventing
postpartum haemorrhage (PPH) ≥ 500 mL than the standard
drug recommendation of oxytocin. An ergometrine plus oxytocin
combination was also more effective in preventing PPH ≥ 1000
mL while a trend was noted for carbetocin and a misoprostol plus
oxytocin combination. However, there was a higher risk of signif-
icant side-effects with the two combination regimens. Carbetocin
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had a favourable side-effect profile similar to oxytocin. However,
carbetocin trials were small and at high risk of bias, and when
we restricted the analysis including only trials at low risk of bias,
carbetocin lost its top ranking, although there was significant un-
certainty around the effect estimates.
Overall completeness and applicability of
evidence
This networkmeta-analysis provides the relative effectiveness of all
drugs used for the prevention of PPH in a coherent and method-
ologically robust way across important clinical outcomes by com-
bining both direct and indirect evidence, thus increasing the sta-
tistical power and confidence in the results. We found that most
of the included trials reported our primary outcomes and most
of the secondary outcomes. This increased the power across most
of our analyses and contributed to the consistency in the ranking
across all blood loss outcomes. We were thorough in our evalua-
tion of the important potential treatment effect modifiers (mode
of birth, prior risk of PPH, healthcare setting, dose, route and reg-
imen of the drugs). We did not encounter important differences
in the distribution of the effect modifiers between the different
comparisons. In addition, the ranking of the drugs in each of the
subgroups was comparable with the overall ranking. The results
of the network meta-analyses were mostly consistent and where
there was significant inconsistency this was likely due to unstable
estimates from single studies. Through our sensitivity analyses we
were able to identify that research underpinning the carbetocin
effectiveness is based on small studies at high risk of bias.
Many trials excluded women with significant comorbidities and
at very high risk for PPH. Women recruited to the included stud-
ies were predominantly delivered at more than 37 weeks of gesta-
tion. Most of the trials were carried out in hospital settings and
with women having a vaginal birth. For women having a vagi-
nal birth, uterotonic drug administration used to be a component
of the active management of the third stage of labour, alongside
controlled cord traction and early cord clamping. The most up-
to-date guidelines from the WHO (WHO 2012), place empha-
sis on the administration of a uterotonic drug as the main agent
within this package for prevention of PPH. These guidelines state
that early cord clamping is generally not advised, whilst controlled
cord traction is optional where skilled birth attendants are present
(WHO 2012). Rankings of the available agents were similar in
subgroups including only trials of women having a vaginal birth or
undergoing a caesarean section, but there were no trials that used
ergometrine plus oxytocin or ergometrine alone for prevention of
PPH at caesarean section births. For women undergoing caesarean
deliveries, the risk of PPH≥500 mL was reduced from 75% with
oxytocin down to almost 50% with more effective agents. Evi-
dently, uterine tone plays a major role in PPH at caesarean section,
with a relative reduction of PPH ≥500 mL similar to the one of
women undergoing vaginal births when more effective agents are
used. The ranking is relevant to women at either high or low risk
for PPH in hospital settings. There were not enough trials to be
able to recommend a ranking in community settings, even though
a similar ranking in terms of effectiveness can be expected.
The dosages, regimens and routes of drug administration for the
most effective drugs varied. Carbetocin in most of the studies was
administered as a single intravenous bolus of 100 mcg (15 stud-
ies) or intramuscularly (seven studies). The combination of er-
gometrine plus oxytocin was usually administered intramuscularly
combining 500mcg of ergometrine plus 5 IU (international units)
of oxytocin (21 studies). Misoprostol plus oxytocin combinations
varied greatly, with some studies administering an intravenous in-
fusion of 20 IU of oxytocin and 400 mcg of misoprostol sublin-
gually (three studies), or 200 mcg of misoprostol sublingually (two
studies), others administering an intravenous bolus of oxytocin of
10 IU plus 400 mcg misoprostol sublingually (two studies) while
others administered an intravenous infusion of 10 IU of oxytocin
and 400 mcg of misoprostol rectally (two studies). There were
another 12 ways of administering the oxytocin plus misoprostol
combination described and each was employed in only one in-
cluded study (see Characteristics of included studies).
Quality of the evidence
The majority of included trials were at uncertain risk of bias, with
more than half of the quality domains not reported. We did not
downgrade the estimates from the network meta-analysis involv-
ing combinations of either ergometrine or misoprostol plus oxy-
tocin due to risk of bias (See Summary of findings for the main
comparison). However, we regarded risk of bias from studies con-
tributing to carbetocin comparisons to warrant downgrading for
PPH ≥ 500 mL and PPH ≥ 1000 mL. We considered serious
imprecision to warrant downgrading the quality of evidence for
PPH ≥ 500 mL for carbetocin and for PPH ≥1000 mL for the
combination of misoprostol plus oxytocin, and for carbetocin. We
also downgraded the quality of the evidence for PPH ≥ 500 mL
for ergometrine plus oxytocin, carbetocin and misoprostol plus
oxytocin because of inconsistency in the comparisons with oxy-
tocin.
Potential biases in the review process
The earliest included trial was conducted in 1976 (Moodie 1976),
and in the decades since then, the clinical care and the clinical
response to PPH may have improved. These temporal changes
could have contributed to heterogeneity and increased the uncer-
tainty of findings. However, we carried out a sensitivity analysis by
removing trials published before 1990 and this did not vary the
ranking of the drugs. As objective methods of measuring blood
loss became increasingly available this could perhaps have also led
to apparent changes in reported blood loss. The trials included
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in the review recruited women with varied clinical characteristics,
and it is important to consider this when interpreting results. The
inclusion criteria were not always reported in detail and, when they
were, these varied across trials. Further heterogeneity may also be
present in the overall analysis related to the dose, route or regimen
of the drugs. Even though we did not observe subgroup effects
when we examined the dose of misoprostol or regimen of oxytocin
administration, we were not able to perform subgroup analyses for
every single increment in dosage or route of drug administration.
Lastly, not all trials reported data on side-effects hence these anal-
yses were often underpowered.
Agreements and disagreements with other
studies or reviews
Our results agree with existing Cochrane reviews (Begley 2015;
Liabsuetrakul 2007; McDonald 2004; Su 2012; Tuncalp 2012;
Westhoff 2013) that focus on the comparison of a uterotonic drug
versus another (direct comparisons). However, this network meta-
analysis has several more studies than included in the previous
reviews because of its nature of comparing all available uterotonic
drugs in one single analysis and because it is the most up-to-date
including recently published trials. Hence, some estimates differ
slightly, as expected.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The current WHO recommendation for preventing PPH is 10
IU of intramuscular or intravenous oxytocin (WHO 2012). Oxy-
tocin should be kept refrigerated (2 °C to 8 °C) or stored at room
temperature (25 °C or lower). Several studies have demonstrated
that oxytocin loses potency if stored at room temperature for too
long or at higher temperatures, making its use difficult in low-
resource countries (Hogerzeil 1993; WHO 1993). Since we have
shown that oxytocin is ranked fourth in effectiveness, and and er-
gometrine plus oxytocin combination, carbetocin, and misopros-
tol plus oxytocin combination are more effective, our results could
have important implications for clinical practice. Ergometrine plus
oxytocin combination is the only agent that significantly reduces
PPH≥ 500 mL and PPH≥ 1000 mL compared with oxytocin on
both network and pairwise estimates. Misoprostol plus oxytocin
combination evidence is less consistent and this may be related to
the different routes and doses of misoprostol used in the studies.
Carbetocin is more effective compared with oxytocin with a simi-
lar side-effect profile to oxytocin. However, when we restricted our
analysis to trials with low risk of bias, the ranking of carbetocin
changed and it did not appear to be more effective than oxytocin.
The manufacturer of carbetocin (Ferring Pharmaceuticals) has re-
cently developed a room temperature stable (RTS) formulation,
which makes it an attractive option for countries where maintain-
ing the cold chain is problematic. Therefore, we conclude that
there is an urgent need for a high-quality large trial comparing the
current standard of oxytocin with carbetocin, and especially RTS
carbetocin, to confirm or reject the findings of small and at high
risk of bias trials that have involved carbetocin to date.
Implications for research
There are two key studies that will inform a future update of this
review. The first one is a WHO-led multi-centre phase III clinical
study comparing the effectiveness of RTS carbetocin versus oxy-
tocin (administered intramuscularly) for the prevention of PPH
among women having a vaginal birth (Widmer 2016). This trial
is led by several of the study authors (MW, MG, JH and AC)
and includes approximately 30,000 women from 10 countries:
Argentina, Egypt, India, Kenya, Nigeria, Singapore, South Africa,
Thailand, Uganda, and the UK. Results are expected before the
end of 2018. If the results of the study support carbetocin, the aim
is to provide access to RTS carbetocin to public sector providers in
low-income countries with a high burden of maternal mortality,
at an affordable and sustainable price comparable to oxytocin. An-
other trial based in theUK is recruitingmore than 6000 women to
a three-arm trial comparing carbetocin, oxytocin and ergometrine
plus oxytocin combination (Draycott 2014). This trial is also ex-
pected to report in 2018. These trials will provide the high-quality
evidence needed to update our network meta-analysis.
Consultation with our consumer group has demonstrated a need
for more research into PPH outcomes identified as priorities for
women and their families, such as women’s views regarding the
drugs used, clinical signs of excessive blood loss, neonatal unit
admissions and breastfeeding at discharge. Trials to date have
rarely investigated these outcomes. Consumers also considered
the side-effects of uterotonic drugs to be important and these
were often not reported. The Postpartum Haemorrhage Core
Outcome Sets Project (http://www.comet-initiative.org/studies/
details/706) will elucidate outcomes to prioritise in trial reporting
and will inform futures updates of this review. We would urge all
trialists to consider reporting these outcomes for each drug in all
future randomised trials. Lastly, future evidence synthesis research
could compare the effects of different dosages and routes of ad-
ministration for the most effective drugs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abdel-Aleem 2010
Methods 3-arm controlled randomised trial.
Participants Between September 2006 and February 2009, 1964 parturients were randomised in
a hospital setting in Egypt and South Africa. The population comprised women of
unspecified parity, either singleton or multiple pregnancy, at both high and low risk for
PPH, who delivered by vaginal delivery. Exclusion criteria comprised parturients with
medical complications such as hypertension and diabetes, previous caesarean section, or
an abdominal wall that was not thin enough to allow easy palpation of the uterus after
delivery
Interventions 10 IU of oxytocin administered intramuscularly (n = 1302) versus placebo or control (n
= 662)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, manual removal of placenta. death
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were allocated to 1 of 3 groups by se-
lecting the next number in a computer-generated
random number sequence
Allocation concealment (selection bias) Low risk The allocated group was noted inside opaque
sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk In Assiut, investigators evaluated blood loss by
collection with a calibrated plastic drape placed
under the mother within 30 minutes of delivery.
At the East London Hospital Complex, investiga-
tors evaluated blood loss by collection with a low
profile plastic “fracture” bedpan placed under the
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Abdel-Aleem 2010 (Continued)
mother
Incomplete outcome data (attrition bias)
All outcomes
Low risk Investigators were unable to collect outcome data
from 14 randomised study participants
Selective reporting (reporting bias) Unclear risk The study protocol was registered retrospectively
(ACTRN: 12609000372280)
Intention to treat analysis Low risk All those who were enrolled and randomly allo-
cated to treatment were included in the analysis,
in the groups to which they were randomised
Funding source Low risk The study was supported by funding from the in-
stitution of the authors, or conducted without ex-
ternal funding
Acharya 2001
Methods 2-arm active-controlled randomised trial.
Participants Between dates unspecified, 60 parturients were randomised in a hospital setting in the
UK. The population comprised women of unspecified parity, unspecified whether sin-
gleton or multiple pregnancy, at high risk for PPH, who delivered by elective caesarean
section. Exclusion criteria were not specified
Interventions 10 IU of oxytocin administered by an intravenous bolus (n = 30) versus 400 mcg of
misoprostol administered orally (n = 30)
Outcomes The study recorded the following outcomes: PPH at 1000, additional uterotonics, trans-
fusion, blood loss (mL), change in Hb level, vomiting, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Low risk Randomisation was performed using sealed
opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
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Acharya 2001 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators
evaluated intra-operative blood loss by the
estimation of attending physicians, and by
measurement of preoperative and postoper-
ative Hb concentration and haematocrit
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Adanikin 2012
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between 1st July 2010 and 31st March 2011, 218 parturients were randomised in a
hospital setting in Nigeria. The population comprised women of unspecified parity,
unspecified whether singleton or multiple pregnancy, at high risk for PPH, who delivered
by elective caesarean section. Exclusion criteria comprised parturients with altered serum
electrolytes, peritonitis, sepsis, previous bowel surgery, thyroid disease, inflammatory
bowel disease, or chronic constipation
Interventions 25 IUof oxytocin administered by an intravenous bolus plus infusion (n=109) versus 600
mcg plus 5 IU of misoprostol plus oxytocin administered rectally plus by an intravenous
bolus (n = 109)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, blood loss (mL)
, nausea, vomiting, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Adanikin 2012 (Continued)
Random sequence generation (selection
bias)
Low risk The treatment allocation sequence was de-
veloped by 1 researcher (O.O.) using a
computer-generated table of random num-
bers with varied permutated blocks
Allocation concealment (selection bias) Low risk Investigators used sealed opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The same researcher administered the
drugs intra-operation and set up the infu-
sions in the operating room; hewas the only
person who was not blind to the drug allo-
cation and he did not take any further part
in the active running of the study.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Afolabi 2010
Methods 2-arm active-controlled randomised trial.
Participants Between dates unspecified, 200 parturients were randomised in a hospital setting inNige-
ria. The population comprised women of parity 4 or less, a singleton pregnancy, at low
risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised parturients
undergoing induction of labour or caesarean section, or those with haematocrit of less
than 30%, pre-eclampsia/eclampsia, grand multiparity (5 or more), multiple pregnancy,
coagulopathy, or medical disorders
Interventions 10 IU of oxytocin administered intramuscularly (n = 100) versus 400 mcg of misoprostol
administered orally (n = 100)
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Afolabi 2010 (Continued)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, manual removal of placenta, death, blood loss (mL)
, change in Hb, third-stage duration (min), nausea, vomiting, fever, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participantswere randomised into 2 groups,
A and B, by blocked (restrictive) double-
blind randomisation using random table
generated numbers
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss at deliv-
ery by collection with a large kidney dish,
for measurement in a graduated measuring
jar
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Ahmed 2014
Methods 2-arm active-controlled randomised trial.
Participants Between dates unspecified, 80 parturients were randomised in a hospital setting in Egypt.
The population comprised women of unspecified parity, a singleton pregnancy, at high
risk for PPH, who delivered by either elective or emergency caesarean. Exclusion criteria
comprised parturients with risk factors for excessive blood loss e.g. those with placenta
praevia or placental abruption
Interventions 100 mcg of carbetocin administered by an intravenous bolus (n = 40) versus 10 IU of
oxytocin administered by an intravenous bolus (n = 40)
Outcomes The study recorded the following outcomes: blood loss (mL).
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study was “single-blind” but the iden-
tity of those blinded and the method of
blinding were not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
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Ahmed 2014 (Continued)
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Al-Sawaf 2013
Methods 3-arm controlled randomised trial.
Participants Between October 2009 and February 2011, 120 parturients were randomised in a hos-
pital setting in Egypt. The population comprised women of parity 4 or less, a singleton
pregnancy, at both high and low risk for PPH, who delivered by vaginal delivery. Ex-
clusion criteria comprised parturients undergoing induction of labour or instrumental
delivery, or those with previous caesarean section, extensive perineal, vaginal or cervical
lacerations, bleeding disorders, Hb less than 100 g/L, uterine malformations, grand mul-
tiparity, multiple pregnancy, polyhydramnios, intrauterine fetal death, medical problems
such as pre-eclampsia, diabetes, cardiopulmonary problems, bowel disease, or allergy to
prostaglandins
Interventions Placebo or control (n = 40) versus 200 mcg of misoprostol administered sublingually (n
= 40) versus 5 IU of oxytocin administered intramuscularly (n = 40)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, blood loss (mL), change in Hb level
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Randomisation sequence generation was not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Investigators used closed envelopes.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
not reported
Objective assessment of blood loss Low risk Assessor blinding was not reported.
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Al-Sawaf 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Investigators evaluated blood loss by collection
with sterile packs weighed beforehand and after-
wards
Selective reporting (reporting bias) Unclear risk “Following randomisation, 16 study participants
were excluded from our analysis. Of these, 14 pa-
tients received intrapartum oxytocin, 1 patient ex-
perienced extensive vaginal laceration and another
experienced a cervical laceration.”
Intention to treat analysis High risk The protocol of the study was unavailable for ver-
ification.
Funding source Unclear risk Those who withdrew from the study after ran-
domisation were not included in the analysis
Amant 1999
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between 1st December 1997 and 20th April 1998, 213 parturients were randomised in
a hospital setting in Belgium. The population comprised women of unspecified parity,
either singleton or multiple pregnancy, at low risk for PPH, who delivered by vaginal
delivery. Exclusion criteria comprised parturients undergoing caesarean section, or those
with hypertensive disorders, gestational age less than 32 weeks, intrauterine fetal death,
uterine malformations, inflammatory bowel disease, obliterative vascular or coronary
disease, sepsis, allergy to prostaglandins or alkaloids
Interventions 600 mcg of misoprostol administered orally (n = 105) versus 200 mcg of ergometrine
administered by an intravenous bolus (n = 108)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonic, transfusion, manual removal of placenta, nausea, vomiting, headache, fever,
shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was allocated by a computer-
generated list and randomisation in blocks
Allocation concealment (selection bias) Low risk The study box contained either 2 capsules
of misoprostol and an ampoule containing
placebo, or 2 capsules with placebo and an
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Amant 1999 (Continued)
ampoule containing methylergometrine.
The study boxes and capsules were indis-
tinguishable in the 2 groups
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk “213 women were enrolled in the study,
but the data for 13 were excluded because a
caesarean section was performed after ran-
domisation (n = 3), or because no prede-
livery (n = 3) or postpartum (n = 7, short
hospital stay) blood sample was taken.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Amin 2014
Methods 2-arm active-controlled randomised trial.
Participants Between May 2011 and May 2012, 200 parturients were randomised in a hospital set-
ting in Pakistan. The population comprised women of unspecified parity, a singleton
pregnancy, at both high and low risk for PPH, who delivered by vaginal delivery. Ex-
clusion criteria comprised parturients undergoing caesarean section, or those with trau-
matic PPH, bleeding disorders, prolonged labour, placenta praevia, placental abruption,
multiple pregnancy, BMI more than 30, or previous PPH
Interventions 5 IU of oxytocin administered by an intravenous bolus (n = 100) versus 800 mcg of
misoprostol administered rectally (n = 100)
Outcomes The study recorded the following outcomes: PPH at 500, morbidity, manual removal of
placenta, death, blood loss (mL), third-stage duration (min), vomiting, fever, shivering
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Amin 2014 (Continued)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by col-
lection with special drapes placed under
the mother until 1-hour postpartum, and
weighed beforehand and afterwards. Blood
was also collected in graduated plastic bags
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Askar 2011
Methods 2-arm active-controlled double-blinded randomised trial.
Participants BetweenMay 2009 and December 2009, 240 parturients were randomised in a hospital
setting in Kuwait. The population comprised women of parity 5 or less, a singleton
pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients less than 18 years old and those with known or suspected co-
agulopathy, grand multiparity (5 or more), uterine fibroids, polyhydramnios, multiple
pregnancy, fetal macrosomia, severe anaemia, cervical tears or who required prophylactic
oxytocin infusion. The presence of contraindications for the use of either Syntometrine
or carbetocin that include pre-existing hypertension, pre-eclampsia, asthma, cardiac, re-
nal or liver diseases, epilepsy, or history of hypersensitivity to Syntometrine or carbetocin
Interventions 100 mcg of carbetocin administered intramuscularly (n = 120) versus 5 IU and 500 mcg
of ergometrine plus oxytocin administered intramuscularly (n = 120)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta, blood loss (mL), change in Hb
level, nausea, vomiting, hypertension, headache, abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was allocated by a computer-
generated code prepared before the recruit-
ment
Allocation concealment (selection bias) Low risk Investigators used sealed, consecutively-
numbered, opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by col-
lection with a new plastic sheet placed un-
der the mother following delivery of the
placenta, and weighed (together with any
gauzes, tampons and pads applied during
the delivery) beforehand and 2 hours after-
wards. A digital scale was used for weight
measurement
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Attilakos 2010
Methods 2-arm active-controlled double-blinded randomised trial.
Participants Between November 2006 and July 2007, 377 parturients were randomised in a hospi-
tal setting in the UK. The population comprised women of unspecified parity, a sin-
gleton pregnancy, at high risk for PPH, who delivered by either elective or emergency
caesarean. Exclusion criteria comprised parturients undergoing caesarean section with
general anaesthesia, gestational age less than 37 weeks performed for fetal or maternal
distress where, due to time constraints, it was not possible to recruit or randomise, or
those with multiple pregnancy, placenta praevia or placental abruption
Interventions 100 mcg of carbetocin administered by an intravenous bolus (n = 188) versus 5 IU of
oxytocin administered by an intravenous bolus (n = 189)
Outcomes The study recorded the following outcomes: PPH at 1000, morbidity,. additional utero-
tonics, transfusion, death, blood loss (mL), change in Hb level, nausea, vomiting,
headache, tachycardia, hypotension, shivering, abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation sequence (1:1 ratio-
blocks of 10, no stratification) was gener-
ated by computer
Allocation concealment (selection bias) Low risk The preparation of the ampoules was un-
dertaken by DHP Ltd. (Powys, UK) which
provided sequentially numbered and la-
belled boxes each containing a 1 mL am-
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poule of the study drug. All boxes and am-
poules were identically labelled, with the
study number being the only differentiat-
ing feature between different drug packs.
The random allocation sequence was not
known to the investigators until the study
had finished and the analysis was started
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Blood loss was estimated by the attending
surgeon “in the usual way (visual estima-
tion, number of used swabs and amount of
aspirated blood).”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk The study report matches the study proto-
col that was registered prospectively (Eu-
draCT 2005-002812-94)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk Ferring Pharmaceuticals funded the cost
of preparation of blinded medication am-
poules. No other external funding was re-
quired for the study
Atukunda 2014
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between 23rd September 2012 and 9th September 2013, 1140 parturients were ran-
domised in a hospital setting in Uganda. The population comprised women of unspec-
ified parity, a singleton pregnancy, at both high and low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised parturients undergoing induction or aug-
mentation of labour or elective caesarean section, or those with intrauterine fetal death,
heart disease, severe malaria or acute bacterial infection, multiple pregnancy, antepartum
haemorrhage, altered cognitive status or reported hypersensitivity to prostaglandins
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Interventions 10 IU of oxytocin administered intramuscularly (n = 570) versus 600 mcg of misoprostol
administered sublingually (n = 570)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, manual removal of placenta, death, blood loss (mL)
, change in Hb level.. third-stage duration (min), nausea, vomiting, headache, fever,
shivering, abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A study biostatistician generated a ran-
domisation list with a block size of 10
Allocation concealment (selection bias) Low risk The study clinical pharmacist prepared the
study drugs and placebos. The midwife re-
search assistants received opaque envelopes
with affixed study codes, containing both
an injection (1 mL of oxytocin 10 IU or its
placebo) and 3 pills (misoprostol 600 mg
or its placebo)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “To achieve blinding of the participants
and assessors, both inactive agents were
manufactured and packaged to resemble
actual study medicines in terms of shape,
size, and colour.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by collec-
tion with a clean plastic sheet placed under
the mother during and after the third stage
of labour. The sheet was specifically de-
signed and piloted for the purpose. Blood
was thendrained into a calibrated container
to improve accuracy in blood loss measure-
ment. Furthermore, “mothers were given
pre-weighed standard sanitary pads to place
in the perineum at all times. These pads
were changed and weighed hourly for the
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first 6 hours, and then every 6 hours until
24 hours postpartum. Blood loss was esti-
mated as 1 mL per g of weight of the pad
after subtracting the dry pad weight.” In-
vestigators added the estimated blood loss
in pads, to the volume of blood already col-
lected with the plastic sheet. To improve
consistency in the estimation of blood loss,
standardised electronic scales were used to
weigh soiled sanitary pads
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered (ClinicalTrials.gov
NCT01866241)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by scholarship
funding from the Father Bash Foundation
(public funding)
Badejoko 2012
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between 1st April 2009 and 31st December 2009, 264 parturients were randomised in
a hospital setting in Nigeria. The population comprised women of unspecified parity,
unspecified whether singleton or multiple pregnancy, at high risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised parturients in the second or third stage
of labour, or those with cervical lacerations or coagulopathy
Interventions 30 IU of oxytocin administered by an intravenous bolus plus infusion (n = 132) versus
20 IU plus 600 mcg of misoprostol plus oxytocin administered rectally plus by an
intravenous infusion (n = 132)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, death, blood loss (mL), vomiting, fever, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation code produced by an
independent statistician using a computer-
generated random number sequence
Allocation concealment (selection bias) Low risk Investigators used sequentially numbered
sealed packets made of identical opaque
brown-paper envelopes prepared by the
hospital pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by col-
lection with a BRASS-V calibrated drape
“which is a sterile intrapartum blood col-
lection mat with a calibrated receptacle”
placed under the mother after the delivery
of the baby and immediate clamping of the
umbilical cord.The drape included ribbons
tied around the abdomen of the mother to
optimise blood collection
Incomplete outcome data (attrition bias)
All outcomes
Low risk “6 women from the misoprostol group and
3 from the oxytocin group were excluded
from statistical analysis. 5 of these women
in the misoprostol group and all 3 in the
oxytocin group were excluded because of
the occurrence of cervical lacerations in
them. The sixth woman excluded in the
misoprostol group had developed features
of disseminated intravascular coagulopathy
(DIC). Analysis was thus based on 255 par-
turients (126 in the misoprostol group and
129 in the oxytocin group).”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
141Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Badejoko 2012 (Continued)
Funding source Low risk The study was conducted without external
funding.
Balki 2008
Methods 2-arm active-controlled double-blinded randomised trial.
Participants Between 12th June 2005 and 18th December 2006, 48 parturients were randomised in
a hospital setting in Canada. The population comprised women of unspecified parity, a
singleton pregnancy, at high risk for PPH, who delivered by emergency caesarean section.
Exclusion criteria comprised parturients requiring general anaesthesia, or those with car-
diac disease, hypertension or any condition predisposing to uterine atony and PPH, such
as placenta praevia, multiple pregnancy, pre-eclampsia, macrosomia, polyhydramnios,
uterine fibroids, bleeding disorders, chorioamnionitis, previous uterine atony, previous
PPH or allergy/hypersensitivity to oxytocin or ergot derivatives
Interventions 250 mcg plus 20 IU of ergometrine plus oxytocin administered by an intravenous bolus
(n = 24) versus 20 IU of oxytocin administered by an intravenous bolus plus infusion (n
= 24)
Outcomes The study recorded the following outcomes: additional uterotonics, transfusion, blood
loss (mL), nausea, vomiting, hypertension, tachycardia. hypotension
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using a com-
puter-generated list of numbers
Allocation concealment (selection bias) Low risk Investigators used consecutively-numbered
opaque sealed packets or envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss by mea-
surement of haematocrit preoperatively
and 48 hours postoperatively
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the institution of the authors
Bamigboye 1998a
Methods 2-arm placebo-controlled randomised trial.
Participants Betweendates unspecified, 550parturientswere randomised in a hospital setting in South
Africa. The population comprised women of unspecified parity, unspecified whether
singleton or multiple pregnancy, at low risk for PPH, who delivered by vaginal delivery.
Exclusion criteria were not specified
Interventions 400 mcg of misoprostol administered rectally (n = 275) versus placebo or control (n =
275)
Outcomes The study recorded the following outcomes: PPH at 1000, additional uterotonics, man-
ual removal of placenta, third-stage duration (min), vomiting, shivering, abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using a com-
puter-generated random sequence
Allocation concealment (selection bias) Low risk Allocation concealment was by means of
sealed, opaque containers containing 400
mg misoprostol or placebo tablets
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The placebo tablets were similar in size
and colour but were not identical in shape
to the misoprostol tablets. Blinding of
the midwife administering the tablets was
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therefore not possible.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by collec-
tion with an absorbent plastic-backed linen
saver and a low-profile plastic “fracture”
bedpan placed under the mother. Blood
collection in the plastic bedpan continued
until 1 hour after delivery of the baby. At
1 hour after delivery, all the blood on the
linen saver was scooped into the bedpan
with the blood already collected there, and
“the total blood was carefully measured.”
All the used linen savers and vaginal pads
were weighed, and the known dry weights
of these materials were subtracted from the
measured total weight
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Records of 4 of the 550 allocations (all
from the placebo group) could not be
traced.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Bamigboye 1998b
Methods 2-arm active-controlled randomised trial.
Participants Betweendates unspecified, 491parturientswere randomised in a hospital setting in South
Africa. The population comprised women of unspecified parity, unspecified whether
singleton or multiple pregnancy, at low risk for PPH, who delivered by vaginal delivery.
Exclusion criteria were not specified
Interventions 400 mcg of misoprostol administered rectally (n = 241) versus 500 mcg and 5 IU
respectively of ergometrine plus oxytocin administered intramuscularly (n = 250)
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Outcomes The study recorded the following outcomes: PPH at 500, additional uterotonics, trans-
fusion, manual removal of placenta, blood loss (mL), change in Hb level third-stage
duration (min)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using a com-
puter-generated random sequence
Allocation concealment (selection bias) Low risk Allocation concealment was by means of
sealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the es-
timation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “About halfway through enrolment it was
discovered that a small number of women
had been excluded from the Syntometrine
[ergometrine plus oxytocin] group because
of hypertension detected after enrolment
(thus contraindicating the use of Syn-
tometrine [ergometrine plus oxytocin]. The
Syntometrine envelopes had been reallo-
cated to subsequent participants, and it was
not possible to trace the women originally
allocated.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
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Funding source Low risk The study was supported by funding from
the South African Medical Research Coun-
cil (public funding)
Barton 1996
Methods 2-arm placebo-controlled randomised trial.
Participants Between dates unspecified, 119 parturients were randomised in a hospital setting in
the USA. The population comprised women of unspecified parity, unspecified whether
singleton ormultiple pregnancy, at high risk for PPH, who delivered by elective caesarean
section. Exclusion criteria were not specified
Interventions 100 mcg of carbetocin administered by an intravenous bolus (n = 62) versus placebo or
control (n = 57)
Outcomes The study recorded the following outcome: additional uterotonics
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Baskett 2007
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between October 2000 and February 2004, 622 parturients were randomised in a hos-
pital setting in Canada. The population comprised women of unspecified parity, a sin-
gleton pregnancy, at both high and low risk for PPH, who delivered by vaginal delivery.
Exclusion criteria comprised parturients undergoing caesarean section, or those with
placenta praevia, placental abruption, coagulopathy or unstable asthma
Interventions 5 IU of oxytocin administered by an intravenous bolus (n = 311) versus 400 mcg of
misoprostol administered orally (n = 311)
Outcomes The study recorded the following outcomes: PPH at 1000, additional uterotonics, trans-
fusion, manual removal of placenta, death, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation cards
were produced.
Allocation concealment (selection bias) Low risk Investigators used sealed, opaque, sequen-
tially numbered envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The packages were prepared by the hos-
pital pharmacy and their active drug un-
known to the physicians and nurses.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
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Objective assessment of blood loss High risk Investigators evaluated blood loss by a com-
bination of the visual estimation of attend-
ing physicians and measurement of blood
volume in a kidney dish placed under the
mother during the third stage of labour
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the Nova Scotia Health Research Founda-
tion (public funding)
Begley 1990
Methods 2-arm controlled randomised trial.
Participants Between 1st October 1987 and 31st October 1988, 1429 parturients were randomised
in a hospital setting in Ireland. The population comprised women of parity 5 or less, a
singleton pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion
criteria comprised parturients undergoing caesarean section, vaginal breech or instru-
mental delivery, or those with hypertension, epidural anaesthesia, antepartum haemor-
rhage, placenta praevia, placental abruption, first stage of labour more than 15 hours,
“quick” delivery or needing resuscitation
Interventions 500 mcg of ergometrine administered by an intravenous bolus (n = 705) versus placebo
or control (n = 724)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta, blood loss (mL), change in Hb
level. third-stage duration (min), nausea, vomiting, hypertension, headache, aAbdominal
pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Random number tables were used. The first num-
ber was selected from the table and the numbers
were then allocated in blocks of 100, following in
sequence
Allocation concealment (selection bias) Low risk Investigators used numbered, sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not blinded
to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss “as accurately
as possible, with full realisation of the well-docu-
mented problems of clinical measuring and esti-
mation.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses but dropouts for change in Hb
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Unclear risk The authors did not specify whether all those who
were enrolled and randomly allocated to treatment
were included in the analysis, in the groups to
which they were randomised
Funding source Low risk The study was supported by public funding, or
conducted without external funding
Bellad 2012
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between dates unspecified, 652 parturients were randomised in a hospital setting in
India. The population comprised women of unspecified parity, a singleton pregnancy,
at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised
parturients undergoing caesarean section or instrumental delivery, or those with medical
disorders, in active labour with more than 4 cm dilatation or stillbirths
Interventions 400 mcg of misoprostol administered sublingually (n = 321) versus 10 IU of oxytocin
administered intramuscularly (n = 331)
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Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, manual removal of placenta, death, blood loss (mL)
, third-stage duration (min), nausea, vomiting, fever, shivering, abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were assigned to treatment
with a 1:1 ratio using computer-generated
simple randomisation
Allocation concealment (selection bias) Low risk The study medications and placebos were
packaged in appropriately coded envelopes
by administrative staff from the depart-
ment of clinical pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by col-
lection with a BRASS-V calibrated drape
placed under the mother before delivery of
the baby. “The calibrated blood collection
receptacle was opened after delivery and
drainage of amniotic fluid. The blood col-
lected in the drape was transferred to amea-
suring jar with 10mL calibrations for accu-
racy. Blood-soaked swabs were weighed in
g, and the known dry weight of the swabs
was subtracted; this volume was added to
themeasured blood volume from the drape
(assuming an equivalence of 1 g and 1mL).
” Blood loss was measured at 1 and 2 hours
after delivery of the baby
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
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Selective reporting (reporting bias) Unclear risk The study protocol
was registered retrospectively (ClinicalTri-
als.gov NCT01373359)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
Jawaharlal Nehru Medical College (the in-
stitution of the authors). Study medica-
tions were donated by Cipla (misoprostol)
and AstraZeneca (oxytocin)
Benchimol 2001
Methods 3-arm controlled randomised trial.
Participants Between November 1999 and June 2000, 602 parturients were randomised in a hospital
setting in France. The population comprised women of unspecified parity, a singleton
pregnancy, at both high and low risk for PPH, who delivered by vaginal delivery. Ex-
clusion criteria comprised parturients undergoing caesarean section, or those with ges-
tational age less than 32 weeks, previous PPH, intrauterine fetal death, previous uterine
scar, multiple pregnancy or pre-eclampsia
Interventions Placebo or control (n = 220) versus 2.5 IU of oxytocin (n = 196) administered intra-
muscularly versus 600 mcg of misoprostol administered orally (n = 186)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, blood loss (mL)
, change in Hb level, vomiting, fever, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Slips with the words “control,” “Syntocinon,” and
“Cytotec” were placed into envelopes which were
then drawn at random upon admission into the
delivery room to determine to which group the
woman would belong
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
151Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Benchimol 2001 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by weighing
(methods of collecting blood were not reported)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All those who were enrolled and randomly allo-
cated to treatment were included in the analysis,
in the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not re-
ported.
Bhullar 2004
Methods 2-arm placebo-controlled randomised trial.
Participants Between October 2000 and December 2002, 756 parturients were randomised in a hos-
pital setting in the USA. The population comprised women of unspecified parity, either
singleton or multiple pregnancy, at both high and low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised parturients undergoing caesarean section,
or those with a bleeding disorder
Interventions 200 mcg plus 20 IU of misoprostol plus oxytocin administered sublingually plus by an
intravenous infusion (n = 377) versus 20 IU of oxytocin administered by an intravenous
infusion (n = 379)
Outcomes The study recorded the following outcomes: PPH at 500, additional uterotonics, trans-
fusion, manual removal of placenta, death, blood loss (mL), change in Hb level, third-
stage duration (min), vomiting, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
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Bhullar 2004 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Agent vials were coded with a number,
which had been assigned using a random
number table
Allocation concealment (selection bias) Low risk Investigators used opaque vials contain-
ing either a 200 mcg misoprostol tablet or
placebo
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The placebo tablets were similar in size
and colour, but not identical in shape to
the misoprostol tablet.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “The placebo tablets were similar in size
and colour, but not identical in shape to
the misoprostol tablet.”
Objective assessment of blood loss High risk Investigators evaluated blood loss by the es-
timation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Borruto 2009
Methods 2-arm active-controlled randomised trial.
Participants Between 1st September 2007 and 5th January 2008, 104 parturients were randomised
in hospital settings in France and Italy. The population comprised women of unspecified
parity, a singleton pregnancy, at high risk for PPH, who delivered by either elective or
emergency caesarean. Exclusion criteria comprised parturients with toxaemia, eclampsia
or epilepsy
Interventions 100 mcg of carbetocin administered by an intravenous bolus (n = 52) versus 10 IU of
oxytocin administered by an intravenous infusion (n = 52)
153Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Borruto 2009 (Continued)
Outcomes The study recorded the following outcomes: PPH at 500, additional uterotonics, blood
loss (mL), vomiting, headache, hypotension, shivering, abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The patients were divided in 2 groups with
blinding to the studymedication.” Blinding
of caregivers was unconfirmed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by “a sen-
sitive colorimetric method.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source High risk The authors “do not have a financial rela-
tionship with the organisation that spon-
sored the research.” No other source(s) of
funding for the study were reported
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Boucher 1998
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between dates unspecified, 60 parturients were randomised in a hospital setting in
Canada. The population comprised women of unspecified parity, a singleton pregnancy,
at high risk for PPH, who delivered by elective caesarean section. Exclusion criteria com-
prised parturients with heart disease or cardiac arrhythmia, hypertension or liver/renal/
endocrine disease
Interventions 100 mcg of carbetocin administered by an intravenous bolus (n = 29) versus 32.5 IU of
oxytocin administered by an intravenous bolus plus infusion (n = 28)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional utero-
tonics, transfusion, death, blood loss (mL), nausea, vomiting, headache, fever, shivering,
abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by a sen-
sitive colorimetric measurement of the Hb
concentration of blood loss collected “by
means of aspiration from the operative field
[that] began immediately after administra-
tion of the study drug and ceased at the
time of skin closure. All gauzes used dur-
ing this timeframe were placed in 15% Lyse
solution. All aspirated blood, gauzes, and
the reference blood sample were sent to the
laboratory for quantification of total blood
volume. Blood on gauzes was extracted
with Lyse solution, and Hb content was
determined with a sensitive colorimetric
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method adapted to the Cobas FARA anal-
yser. Haemoglobin concentration is pro-
portional to the absorbance of a hydro-
gen peroxide-activated aminophenazone-
phenol mixture measured at a wavelength
of 500 nm. The inter-assay coefficient of
variation averaged 3.3%, and the limit
of detection of the assay was 14 mg/dL.
The amount of blood collected in gauzes
was calculated with the following formula:
blood loss in dL = amount of Hb in surgical
gauzes in mg /Hb concentration in mg/dL
before caesarean section. Total blood loss
was calculated by means of summing the
volumes of blood aspirated and collected
with gauzes.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “3 patients who received general instead of
epidural anesthesia were excluded from the
study and did not receive the study medi-
cation” but the study report did not specify
whether these exclusions occurred before or
after randomisation
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source High risk The study was supported by funding from
Ferring Pharmaceuticals
Boucher 2004
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between dates unspecified, 164 parturients were randomised in a hospital setting in
Canada. The population comprised women of unspecified parity, either singleton or
multiple pregnancy, at high risk for PPH, who delivered by vaginal delivery. Exclusion
criteria comprised parturients younger than 18 years old, or those without known PPH
risk, known or suspected coagulopathy, heart disease or cardiac arrhythmia, chronic liver/
renal/endocrine disease or hypersensitivity to study drugs
Interventions 100 mcg of carbetocin administered intramuscularly (n = 84) versus 10 IU of oxytocin
administered by an intravenous infusion (n = 80)
156Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Boucher 2004 (Continued)
Outcomes The study recorded the following outcomes: PPH at 500, additional uterotonics, blood
loss (mL), change in Hb level, nausea, vomiting, headache, shivering, abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Investigators used computer-generated
randomisation codes with a block size of 4
Allocation concealment (selection bias) Unclear risk Investigators used consecutively-numbered
sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was “double-blind”: “for each
study subject, kits containing both the
study medication and a placebo were pre-
pared in the hospital pharmacy according
to the randomisation schedule, to assure
blinding of the clinical staff.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk “4 women did not receive study medica-
tion and were therefore not included in the
analysis (3 were excluded as a result of cae-
sarean births). Had these 4 women com-
pleted the study and received the medica-
tion, 1 would have received carbetocin and
3would have received oxytocin. This factor
contributed to the lower reported number
of women receiving oxytocin.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
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Funding source High risk The study was supported by funding from
Ferring Pharmaceuticals
Bugalho 2001
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between dates unspecified, 700 parturients were randomised in a hospital setting in
Mozambique. The population comprised women of unspecified parity, either singleton
or multiple pregnancy, at both high and low risk for PPH, who delivered by vaginal
delivery. Exclusion criteria comprised parturients undergoing induction or augmentation
of labour
Interventions 400 mcg of misoprostol administered rectally (n = 350) versus 10 IU of oxytocin ad-
ministered intramuscularly (n = 350)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, blood loss (mL), third-stage duration (min), vomiting, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Neither the investigators nor the nurses
participating in the study had access to the
codes until the completion of the study.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss with a
metallic collector placed under the mother,
from immediately after delivery of the baby
until the mother was removed from the de-
livery room
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Incomplete outcome data (attrition bias)
All outcomes
Low risk “A few subjects were excluded after ran-
domisation for emergency caesarean sec-
tion or incomplete data collection.”
Selective reporting (reporting bias) High risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study report
(cases of retained placenta were omitted)
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Low risk This study was financed by the Maputo
Central Hospital (the institution of the au-
thors) and the Special ProgramonResearch
and Research Training in Human Repro-
duction of the WHO (public funding)
Butwick 2010
Methods 5-arm placebo-controlled randomised trial.
Participants Between July 2008 and April 2009, 75 parturients were randomised in a hospital set-
ting in the USA. The population comprised women of unspecified parity, a singleton
pregnancy, at high risk for PPH, who delivered by elective caesarean section. Exclusion
criteria comprised parturients with active labour, ruptured membranes, drug allergy,
multiple pregnancy, significant obstetric disease, risk factors for PPH (abnormal pla-
centation, fibroids, previous PPH, previous classical uterine incision), coagulopathy or
thrombocytopenia
Interventions Placebo or control (n = 15) versus 5, 3, 1, or 0.5 IU of oxytocin administered by an
intravenous bolus (n = 60)
Outcomes The study recorded the following outcomes: additional uterotonics, transfusion, blood
loss (mL), nausea, vomiting, tachycardia, hypotension
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised using Mi-
crosoft Excel-generated random number
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allocations
Allocation concealment (selection bias) Unclear risk Investigators used opaque envelopes con-
taining group assignments
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The obstetrician and anaesthetist involved
in each case were blinded to the oxytocin
dose assignments.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators evaluated blood loss “by esti-
mating blood collected by suction and by
calculating the weight of blood on surgical
swabs.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “75 patients were enrolled, and 74 patients
completed the study; 1 patient was ex-
cluded due to protocol violation (obstetri-
cian request for supplemental oxytocin de-
spite adequate uterine tone).”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Low risk The study was supported by funding from
theDepartment of Anaesthesia of the Stan-
fordUniversity School ofMedicine (the in-
stitution of the authors)
Caliskan 2002
Methods 4-arm active-controlled double-dummy randomised trial.
Participants Between 1st January 2000 and 1st October 2000,1633 parturients were randomised in a
hospital setting in Turkey. The population comprised women of unspecified parity, either
singleton or multiple pregnancy, at both high and low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised parturients undergoing caesarean section,
or those with gestational age less than 32 weeks or hypersensitivity to prostaglandins
Interventions 400 mcg plus 10 IU of misoprostol plus oxytocin administered rectally plus by an
intravenous infusion (n = 407) versus 400 mcg of misoprostol administered rectally (n =
405) versus 10 IU of oxytocin administered by an intravenous infusion (n = 412) versus
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200 mcg plus 10 IU of ergometrine plus oxytocin administered intramuscularly plus by
an intravenous infusion (n = 409)
Outcomes The study recorded the following outcomes: PPH at 500. PPH at 1000, additional
uterotonics, transfusion, change in Hb level, third-stage duration (min), vomiting, fever,
shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was based on a table
of computer-generated blocks of random
numbers
Allocation concealment (selection bias) Low risk Investigators used sealed consecutively-
numbered opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Allmedicationswere applied bymidwives,
but residents who treat[ed] the birth and
the third stage of labour were blinded to
the identity of medication. Only the mid-
wife who applied the medication opened
the envelope once to read the code and
then transferred the randomisation code
into another identical envelope. The iden-
tities of the placebo and active medication
were also concealed fromcaregivers and res-
idents who followed the patient for the next
24 hours. The randomisation code was not
broken until study completion.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Allmedicationswere applied bymidwives,
but residents who treat[ed] the birth and
the third stage of labour were blinded to
the identity of medication. Only the mid-
wife who applied the medication opened
the envelope once to read the code and
then transferred the randomisation code
into another identical envelope. The iden-
tities of the placebo and active medication
were also concealed fromcaregivers and res-
idents who followed the patient for the next
24 hours. The randomisation code was not
broken until study completion.”
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Objective assessment of blood loss Low risk Investigators evaluated blood loss by collec-
tion with a sterile steel bedpan and plastic
bed linen. Gauzes and pads were also col-
lected and weighed until 1 hour after de-
livery of the placenta
Incomplete outcome data (attrition bias)
All outcomes
Low risk “The study enrolled 1633 women, but the
data for 27 women were excluded because
of lack of predelivery (n = 13) or postpar-
tum (n = 14, short hospital stay) haemo-
globin concentrations.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Caliskan 2003
Methods 4-arm active-controlled double-dummy randomised trial.
Participants Between January 2000 and October 2000, 1800 parturients were randomised in a hos-
pital setting in Turkey. The population comprised women of unspecified parity, either
singleton or multiple pregnancy, at both high and low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised parturients undergoing caesarean section,
or those with gestational age less than 32 weeks or hypersensitivity to prostaglandins
Interventions 400 mcg plus 10 IU of misoprostol plus oxytocin administered orally plus by an intra-
venous infusion (n = 450) versus 400 mcg of misoprostol administered orally (n = 450)
versus 10 IU of oxytocin administered by an intravenous infusion (n = 450) versus 200
mcg plus 10 IU of ergometrine plus oxytocin administered intramuscularly plus by an
intravenous infusion (n = 450)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta, blood loss (mL), change in Hb
level, third-stage duration (min), vomiting, fever, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was computer-gener-
ated without any blocking or stratification
Allocation concealment (selection bias) Low risk Investigators used sealed, consecutively-
numbered opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The placebo tablets were similar in size
and colour but were not identical in shape
to themisoprostol tablets. Tominimise this
limitation, the preparation and administra-
tion of themedication were carried out by a
midwife who had not been involved in the
management of the patient except for drug
administration. The identity of medication
was concealed from the resident physicians
who managed the delivery and the third
stage of labor. The caregivers and residents
who followed up on the patient for the next
24 hours were also blind as to which pa-
tients received placebo and which received
activemedication.The randomisation code
was not broken until the completion of the
study.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The placebo tablets were similar in size
and colour but were not identical in shape
to themisoprostol tablets. Tominimise this
limitation, the preparation and administra-
tion of themedication were carried out by a
midwife who had not been involved in the
management of the patient except for drug
administration. The identity of medication
was concealed from the resident physicians
who managed the delivery and the third
stage of labor. The caregivers and residents
who followed up on the patient for the next
24 hours were also blind as to which pa-
tients received placebo and which received
activemedication.The randomisation code
was not broken until the completion of the
study.”
Objective assessment of blood loss Low risk Investigators evaluated blood loss by collec-
tion with a sterile steel bedpan and plastic
bed linen from immediately after delivery.
Gauzes and pads were also collected 1 hour
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after delivery of the placenta and weighed
Incomplete outcome data (attrition bias)
All outcomes
High risk “The data for 226 patients were excluded
because of caesarean deliveries performed
after randomisation (n = 206) and the lack
of predelivery (n = 6) or postpartum (n =
14, short hospital stay) haemoglobin con-
centrations.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Carbonell 2009
Methods 2-arm active-controlled randomised trial.
Participants Between April 2007 and October 2008, 1410 parturients were randomised in a hospi-
tal setting in Spain. The population comprised women of parity 4 or less, unspecified
whether singleton or multiple pregnancy, at both high and low risk for PPH, who deliv-
ered by vaginal delivery. Exclusion criteria comprised parturients undergoing caesarean
section or instrumental delivery, or those with gestational age less than 32 weeks, coag-
ulopathy, Hb less than 80 g/L, liver or kidney disorder, grand multiparity (5 or more),
hypersensitivity or any contraindication for use of prostaglandins
Interventions 400 mcg and 200 mcg plus 10 IU of misoprostol plus oxytocin administered sublin-
gually and rectally plus intramuscularly (n = 702) versus 10 IU of oxytocin administered
intramuscularly (n = 698)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, manual removal of placenta, death, blood loss (mL)
, change in Hb level, third-stage duration (min), NNU admissions, nausea, vomiting,
fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Random assignments were generated by
computer.
Allocation concealment (selection bias) Low risk Investigators used sequentially-numbered,
opaque, sealed envelopes prepared by peo-
ple not related to the study. This process was
supervised by an analyst. Every morning a
secretary received the sealed envelopes for
distribution and this process wasmonitored
by someone working on the study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk After delivery of the baby, investigators eval-
uated blood loss by collection with a sterile
waterproof cloth placed under the mother,
to channel blood into a bottle with capac-
ity of 2 L: the volume reading was collected
once beyond the third stage of labour
Incomplete outcome data (attrition bias)
All outcomes
Low risk “3 y 7 de las mujeres aleatorizadas a los
grupos I y II, respectivamente, no reci-
bieron ningún tratamiento por incumplim-
iento del protocolo y, como la información
correspondiente a ellas no fue registrada en
ningún momento, no forman parte de este
informe”: 3 women in the misoprostol plus
active management group, and 7 women
in the active management group, were ex-
cluded from the analysis due to protocol de-
viations and non-availability of the infor-
mation
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Low risk The studywas supported by the Science and
Ethics Committee of the Hospital Eusebio
Hernandez in Habana, Cuba in conjunc-
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tion with the Clinica Mediterranea Medica
in Valencia, Spain (the institutions of the
authors)
Cayan 2010
Methods 4-arm controlled randomised trial.
Participants Between January 2005 and November 2008, 160 parturients were randomised in a
hospital setting in Turkey. The population comprised women of unspecified parity,
unspecified whether singleton or multiple pregnancy, at high risk for PPH, who delivered
by either elective or emergency caesarean. Exclusion criteria comprised parturients with
thyroid disorder, inflammatory bowel disease or other bowel diseases, previous bariatric
surgery or hypersensitivity to prostaglandins
Interventions 200 mcg, 400 mcg, or 600 mcg plus 10 IU of misoprostol plus oxytocin administered
rectally plus by an intravenous infusion (n = 120) versus 10 IU of oxytocin administered
by an intravenous infusion (n = 40)
Outcomes The study recorded the following outcomes: fever, shivering.
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was not re-
ported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
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Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All those who were enrolled and randomly allo-
cated to treatment were included in the analysis,
in the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not re-
ported.
Chaudhuri 2010
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between 1st December 2007 and 31st May 2009, 200 parturients were randomised in
a hospital setting in India. The population comprised women of unspecified parity, a
singleton pregnancy, at high risk for PPH, who delivered by either elective or emergency
caesarean. Exclusion criteria comprised parturients undergoing caesarean section for cord
prolapse or bradycardia, or those with cardiovascular, respiratory, liver or haematological
disorders or known hypersensitivity to prostaglandins
Interventions 800 mcg of misoprostol administered rectally (n = 100) versus 40 IU of oxytocin ad-
ministered by an intravenous infusion (n = 100)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, death, blood loss (mL), change inHb level, vomiting,
fever, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised using com-
puter-generated random numbers in a 1:1
ratio
Allocation concealment (selection bias) Low risk The packets containing the 2 drugs were
sealed and opaque, and could not be iden-
tified by the surgeons and anaesthetists
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The packets containing the 2 types of drug
were sealed and opaque, and could not be
identified by the surgeons and anaesthetist.
”
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Inves-
tigators evaluated intraoperative blood loss
by collection with a suction bottle for volu-
metric measurement, combined with linen
savers and mops weighed before and after
delivery. They added the approximate vol-
ume of the contents of the suction bottle
(a) to the difference in weight between dry
(b) and soaked (c) linen savers and mops
(1 g equivalent to 1 mL). Amniotic fluid
volume (d) was calculated by multiplying
amniotic fluid index by 30 mL. Finally, in-
traoperative blood loss was determined by
subtracting amniotic fluid volume from ap-
proximate blood loss ((a plus (c - b)) - d).
Furthermore, investigators evaluated post-
operative bleeding over the next 8 hours by
weighing soaked pads and subtracting the
dry weight
Incomplete outcome data (attrition bias)
All outcomes
Low risk “4 women in group 1 [misoprostol] and
6 women in group 2 [oxytocin] were ex-
cluded from the analysis: 4women required
conversion to general anaesthesia, 5women
had traumatic intraoperative bleeding (ex-
tension of lower segment incision or liga-
ment hematoma), and 1 woman had pla-
centa accreta resulting in hysterectomy.”
Selective reporting (reporting bias) Low risk The study report matches the study proto-
col that was registered (CTRI 2009/091/
000075)
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Chaudhuri 2012
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between 1st September 2009 and 31st August 2010, 530 parturients were randomised
in a hospital setting in India. The population comprised women of parity 4 or less, a
singleton pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion
criteria comprised parturients undergoing augmentation of labour, caesarean section or
instrumental delivery, or those with risk factors for PPH, including BMI more than 30,
grand multiparity (5 or more), polyhydramnios, fetal macrosomia, antepartum haem-
orrhage, prolonged labour, previous PPH, Hb less than 80 g/L, severe pre-eclampsia,
asthma or coagulopathy
Interventions 400 mcg of misoprostol administered sublingually (n = 265) versus 10 IU of oxytocin
administered intramuscularly (n = 265)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, manual removal of placenta, death, blood loss (mL)
, change in Hb level, third-stage duration (min), nausea, vomiting, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using a com-
puter-generated random number sequence
Allocation concealment (selection bias) Low risk Investigators used pre-prepared sealed and
opaque packet.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The misoprostol and placebo tablets were
similar in size, shape, and colour. The
ampoules of oxytocin and placebo were
also similar. Selection, enrolment, and ran-
domisation were done by the resident doc-
tors, whereas preparation of packets and
confidential record maintenance was done
by the labour room nursing staff in charge.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by collec-
tion with specially designed, pre-weighed
absorbent thick cotton pads with plastic
lining, placed under the mother. Blood
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clots, if any, were expressed from the vagina
into a polythene bag. Any episiotomy
wound was repaired immediately, and the
swabs used for the purpose of episiotomy
were not included in blood loss assessment.
If necessary, pads were replaced during the
observational hour after delivery. Then the
soaked pad(s) and the blood clots were
weighed. “The specific gravity of blood be-
ing 1.08, the amount of blood lost in mL
was approximately equal to the weight in
g.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “2women in the study group and 1woman
in the control group refused sublingual ad-
ministration of the drug.”
Selective reporting (reporting bias) Low risk The study report matches the study proto-
col that was registered (CTRI 2009/091/
000672)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Chaudhuri 2015
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between 1st October 2012 and 31st December 2013, 396 parturients were randomised
in a hospital setting in India. The population comprised women of unspecified parity,
unspecified whether singleton or multiple pregnancy, at high risk for PPH, who delivered
by emergency caesarean section. Exclusion criteria comprised parturients requiring con-
version to general anaesthesia, or those with cardiovascular, hepatic, or haematological
disorders or any contraindication for the use of misoprostol or oxytocin
Interventions 400 mcg plus 20 IU of misoprostol plus oxytocin administered sublingually plus by an
intravenous bolus and infusion (n = 198) versus 20 IU of oxytocin administered by an
intravenous bolus plus infusion (n = 198)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, death, blood loss (mL), change in Hb level, nausea,
fever, shivering
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Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed using a
computer-generated random number se-
quence and blocks of size 8
Allocation concealment (selection bias) Low risk Assignments were contained in sealed,
opaque and sequentially-numbered pack-
ets
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Randomisation and confidential record
maintenance were performed by residents
who were not involved in the trial, and
the operation theatre midwife prepared the
sealed packets and allocated and adminis-
tered the drugs. Thus, clinicians, investi-
gators, data analysts, and participants were
masked to the treatment allocation.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Inves-
tigators evaluated intraoperative blood loss
from after delivery of the placenta. Blood
was collected with a suction bottle, linen
savers and mops: the dry weights of these
materials were subtracted from the soaked
weights, and the total volume of intraop-
erative blood loss calculated on the basis
that 1 g is equivalent to 1 mL. Investigators
also evaluated postoperative blood loss by
weighing soaked pads
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered (CTRI 2013/05/
003645)
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Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Chhabra 2008
Methods 3-arm active-controlled randomised trial.
Participants Between dates unspecified, 300 parturients were randomised in a hospital setting in
India. The population comprised women of parity 5 or less, a singleton pregnancy, at
low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised par-
turients undergoing augmentation of labour, caesarean section or instrumental delivery,
or those with grand multiparity (more than 5), multiple pregnancy, pregnancy-induced
hypertension, antepartum haemorrhage, previous caesarean, Hb less than 80 g/L, other
obstetric problems or known hypersensitivity to prostaglandins
Interventions 100 mcg or 200 mcg of misoprostol administered sublingually (n = 200) versus 200 mcg
of ergometrine administered by an intravenous bolus (n = 100)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, death, blood loss (mL), change in Hb level, third-
stage duration (min), nausea, vomiting, headache, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using random
number tables.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
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Objective assessment of blood loss Unclear risk Investigators evaluated blood loss by “mea-
suring blood and blood clots collected in
sponges.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Choy 2002
Methods 2-arm active-controlled randomised trial.
Participants Between dates unspecified, 991 parturients were randomised in a hospital setting inHong
Kong. The population comprised women of parity 3 or less, a singleton pregnancy, at low
risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised parturients
with medical conditions that precluded the use of ergometrine, such as pre-eclampsia,
cardiac disease or conditions that required prophylactic oxytocin infusion after delivery
such as grand multiparity (4 or more) or presence of uterine fibroids
Interventions 500 mcg plus 5 IU of ergometrine plus oxytocin administered intramuscularly (n = 500)
versus 10 IU of oxytocin administered by an intravenous bolus (n = 491)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta, blood loss (mL), change in Hb
level, nausea, vomiting, hypertension, headache
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using com-
puter-generated random numbers
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Allocation concealment (selection bias) Low risk Investigators used sealed consecutively-
numbered opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The preparation and administration of the
medicationwas carried out by a secondmid-
wife who was not involved in the manage-
ment of the patient except for the drug ad-
ministration. The medical attendant who
delivered the baby was not informed of the
type of oxytocics used.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators evaluated blood loss “by mea-
suring the amount of blood clots andweigh-
ing the towels and swabs used.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Low risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Cook 1999
Methods 3-arm active-controlled randomised trial.
Participants Between December 1997 and December 1998, 930 parturients were randomised in a
hospital setting in Australia, Papua and China. The population comprised women of
unspecified parity, unspecified whether singleton or multiple pregnancy, at both high
and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised
parturients undergoing elective caesarean section, or those with coagulopathy, asthma,
heart disease, severe renal disease, epilepsy or hypertension
Interventions 400 mcg of misoprostol administered orally (n = 455) versus 500 mcg plus 5 IU of
ergometrine plus oxytocin administered intramuscularly (n = 310) versus 10 IU of oxy-
tocin administered intramuscularly (n = 129)
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Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, blood loss (mL), change in Hb level, third-stage duration (min)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved by a random
number list in blocks of 20, with separate
randomisation for each centre
Allocation concealment (selection bias) Low risk Investigators used sequentially-numbered
sealed security (opaque) envelopes contain-
ing the appropriate drug label for each cen-
tre
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment al-
locations.
Objective assessment of blood loss Unclear risk Investigators evaluated blood loss by com-
bining “estimated” and “measured” values
according to the standard clinical practice
of each study centre. The “estimated” blood
loss was judged by the attending seniormid-
wives and/or clinicians. The “measured”
blood loss was calculated as the actual vol-
ume of blood collected in a calibrated mea-
suring jug, combined with the difference in
weight between dry and blood-stained un-
dersheets and sanitary pads
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were not collected completely from
67 study participants: “the main reasons for
exclusion prior to randomisation, and fol-
lowing randomisationbut before treatment,
were the need for caesarean section and de-
velopment of hypertension, either before
or during labour. Two women (1 in each
group) were not included in the analysis as
no recordwasmade of the primary outcome
of blood loss.”
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Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Dansereau 1999
Methods 2-arm active-controlled double-blinded randomised trial.
Participants Between February 1992 and December 1994, 694 parturients were randomised in a hos-
pital setting in Canada. The population comprised women of unspecified parity, either
singleton or multiple pregnancy, at high risk for PPH, who delivered by elective cae-
sarean section. Exclusion criteria comprised parturients undergoing general anaesthesia
or requiring a classical uterine incision, or those with heart disease, chronic hypertension
requiring treatment, liver, renal, or endocrine disorders, coagulopathy, placenta praevia
or placental abruption
Interventions 100 mcg of carbetocin administered by an intravenous bolus (n = 348) versus 25 IU of
oxytocin administered by an intravenous bolus plus infusion (n = 346)
Outcomes The study recorded the following outcomes: additional uterotonics, transfusion, change
in Hb level, nausea, vomiting, headache, shivering, abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was allocated by a computer-
generated randomisation code, stratified by
centre and with use of random blocks of 2
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All physicians and nurses involved, all in-
vestigators and their staff, and all spon-
sor representatives were kept blinded to the
treatment codes at all times.”
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Informed consent was obtained from 694
patients. 35 patients were withdrawn from
the study before they received study drug,
leaving a total of 659 patients who received
[the] study drug and were included in the
safety analysis.” Major protocol violations
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source High risk The study was supported by funding from
Ferring Pharmaceuticals
Dasuki 2002
Methods 2-arm active-controlled randomised trial.
Participants Between dates unspecified, 196 parturients were randomised in a hospital setting in In-
donesia. The population comprised women of unspecified parity, unspecified whether
singleton or multiple pregnancy, at unspecified for PPH, who delivered by vaginal de-
livery. Exclusion criteria were not specified
Interventions 600 mcg of misoprostol administered orally (n = 98) versus 10 IU of oxytocin adminis-
tered intramuscularly (n = 98)
Outcomes The study recorded the following outcomes: blood loss (mL), third-stage duration (min)
, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
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Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
de Groot 1996b
Methods 3-arm placebo-controlled randomised trial.
Participants Between July 1993 and July 1994, 371 parturients were randomised in a hospital and
community setting in the Netherlands. The population comprised women of unspeci-
fied parity, a singleton pregnancy, at low risk for PPH, who delivered by vaginal deliv-
ery. Exclusion criteria comprised parturients undergoing induction or augmentation of
labour or instrumental delivery, requiring tocolysis or those who refuse to take part or
with cardiac disease, multiple pregnancy, non-cephalic presentation, polyhydramnios,
coagulopathy, stillbirth, antepartum haemorrhage, Hb less than 4.8 mmol/L or previous
complication in third stage
Interventions Placebo or control (n = 143) versus 5 IU of oxytocin administered intramuscularly (n =
78). There were 4 exclusions post randomisation but it was unclear from which group.
The oral ergometrine group was merged with the control group for analysis
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta, death, blood loss (mL)
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Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using a com-
puter-generated random list
Allocation concealment (selection bias) Low risk Investigators used identical study boxes.
Care was taken that no difference could be
seen or heard between the packages of the
ergometrine/placebo tablets and the oxy-
tocin ampoules
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The studywas “double-blind”with placebo
tomatch ergometrine treatment, but “to al-
low comparisonwith a standard prophylac-
tic regimen a third group receiving the stan-
dard intramuscular oxytocin was added,
but for obvious reasons this could not be
conducted in a blind manner.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by col-
lection with a “fresh” perineal pad placed
under the mother from immediately after
birth until 1 hour after the delivery of the
placenta. The difference in the weight of
the pad before and after delivery was cal-
culated on the basis that 1 g is equiva-
lent to 1 mL of blood. “During delivery
some blood was usually spattered on the
drapes and gowns of the attendants, al-
though attempts were made to minimise
such losses. This gave a constant error of
approximately 10%. In addition, the pla-
cental interstices contain maternal blood
(about 9% of placental weight). As system-
atic overestimations (amniotic fluid) and
underestimations (blood loss) are likely to
be equally distributed among the groups,
no corrections have been made for them.”
179Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
de Groot 1996b (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “4 women with exclusion criteria were en-
tered erroneously (3 forcipal extractions,
1 augmentation). They are considered as
non-participants.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Derman 2006
Methods 2-arm placebo-controlled randomised trial.
Participants Between September 2002 and December 2005, 1620 parturients were randomised in a
community setting in India. The population comprised women of unspecified parity, a
singleton pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion
criteria comprised parturients at high risk and inappropriate for home or community
births according to India’s ministry of health guidelines including those undergoing
elective caesarean section or breech vaginal delivery, or those previous caesarean section,
Hb less than80g/L, antepartumhaemorrhage, hypertension,multiple pregnancy, history
of previous antepartum or PPH, retained placenta, uterine inversion, diabetes, heart
disease, seizures, placenta praevia, asthma or contraindications to misoprostol
Interventions 600 mcg of misoprostol administered orally (n = 812) versus placebo or control (n =
808)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, manual removal of placenta, death, blood loss (mL)
, nausea, vomiting, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using a ran-
domisation list with a random block size
generated by the data co-ordinating centre
and stratified by the midwife
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Allocation concealment (selection bias) Low risk The envelopeswere numbered and each en-
velope had a 5-digit code number assigned
to it. The first 2 digits were the auxiliary
nurse midwife number, followed by a se-
quence number beginning with 001 and
ending with 100, assigned to the individ-
ual participant. Non-distinguishable en-
velopes in batches of 100 were distributed
to each of the midwives affiliated with the
4 selected primary-health centres
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The identical placebo was specifically
manufactured for the study.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by collec-
tion with a polyurethane blood collection
drape placed under themother from imme-
diately after birth until 1 hour after deliv-
ery of the baby. The blood collection drape
included a calibrated receptacle specifically
developed for the study. In the event of per-
sistent bleeding beyond 1 hour, the drape
was removed at 1 hour, blood loss mea-
sured, and a new drape used with a second
measurement made at 2 hours
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered (ClinicalTrials.gov
NCT00097123)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the National Institute of Child Health
and Human Development (public fund-
ing) and the Bill and Melinda Gates Foun-
dation (public funding)
181Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dhananjaya 2014
Methods 2-arm active-controlled randomised trial.
Participants Between December 2011 and May 2013, 100 parturients were randomised in a hospi-
tal setting in India. The population comprised women of parity 4 or less, unspecified
whether singleton or multiple pregnancy, at both high and low risk for PPH, who deliv-
ered by vaginal delivery. Exclusion criteria comprised parturients with grand multiparity
(not defined), rhesus negative blood group, cardiac disease, diabetes, bleeding disorder,
precipitated labour, overdistended uterus, traumatic PPH, PROM/chorioamnionitis, in-
trauterine death, previous caesarean section/scar on uterus or inability to obtain the in-
formed consent
Interventions 10 IU of oxytocin administered intramuscularly (n = 50) versus 200 mcg of ergometrine
administered intramuscularly (n = 50)
Outcomes The study recorded the following outcomes: PPH at 500, additional uterotonics, trans-
fusion, blood loss (mL), change in Hb level, third-stage duration (min), nausea, vomit-
ing, headache
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Investigators used a systematic random
sampling method.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by collec-
tion with drapes that were weighed together
with mops and clots, and by measurement
of Hb concentration and haematocrit of a
sample of venous blood before delivery and
24 hours after birth. A sample of venous
blood before delivery and 24 hours after the
birth was also collected, for Hb and haema-
tocrit measurement “as an objective index
of blood loss.”
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Docherty 1981
Methods 2-arm active-controlled randomised trial.
Participants Between dates unspecified, 50 parturients were randomised in a hospital setting in the
UK. The population comprised women of unspecified parity, unspecified whether sin-
gleton or multiple pregnancy, at unspecified for PPH, who delivered by vaginal delivery.
Exclusion criteria were not specified
Interventions 10 IU of oxytocin administered intramuscularly (n = 25) versus 500 mcg plus 5 IU of
ergometrine plus oxytocin administered intramuscularly (n = 25)
Outcomes The study recorded the following outcome: Blood loss (mL).
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
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Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Eftekhari 2009
Methods 2-arm active-controlled randomised trial.
Participants Between the beginning of August 2007 and the end of December 2007, 100 parturients
were randomised in a hospital setting in Iran. The population comprised women of
unspecified parity, a singleton pregnancy, at high risk for PPH, who delivered by elective
caesarean section. Exclusion criteria comprised parturients with multiple pregnancy,
prolonged labour more than 12 h, 2 ormore previous caesarean sections, previous uterine
rupture, Hb less than 80 g/L, who had a history of heart, renal or liver disorders or had
a coagulopathy
Interventions 400 mcg of misoprostol administered sublingually (n = 50) versus 20 IU of oxytocin
administered by an intravenous infusion (n = 50)
Outcomes The study recorded the following outcomes: additional uterotonics, blood loss (mL),
change in Hb level
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk By a simple randomisation method, pa-
tients were allocated into 2 equal groups
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by collec-
tion in a suction bottle, and with drapes and
pads beneath the mother. Amniotic fluid
was suctioned and measured, and then sub-
tracted from the total volume of the suction
bottle. Meanwhile the known dry weight
(s) of drapes and pads were subtracted from
the soaked weights of these materials. Mea-
surements of blood collected in the suction
bottle and on drapes and pads were added
together
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) High risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study report
(cases of transfusion were omitted)
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
El Behery 2015
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between 1st January 2013 and 31st June 2014,180 parturients were randomised in a
hospital setting in Egypt. The population comprised nulliparous women with a singleton
pregnancy, at high risk for PPH,whodelivered by emergency caesarean section. Exclusion
criteria comprised parturients undergoing elective caesarean section, vaginal delivery
or general anaesthesia, or those who were multigravida, or with malpresentation, fetal
anomalies, placenta praevia, diabetes, hypertension, pre-eclampsia or cardiac disease
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Interventions 100 mcg of carbetocin administered by an intravenous bolus (n = 90) versus 20 IU of
oxytocin administered by an intravenous infusion (n = 90)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, death, blood loss (mL), change in Hb level, nausea,
headache, fever
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was computer-gener-
ated.
Allocation concealment (selection bias) Low risk Investigators used sealed, opaque en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was “double-blinded”: “a dou-
ble dummy system for administration was
used.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss “in the
usual way (visual estimation, number of
used swabs and amount of aspirated blood)
.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “100 cases were excluded (4 had congenital
fetal anomalies, 7 cases had placenta prae-
via, 5 cases were diabetic, 8 had hyperten-
sion, 9 had pre-eclampsia, 3 cases were car-
diac,
28 cases [required] general anaesthesia, 17
cases delivered vaginally and 19 delivered
by elective caesarean section).”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
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randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
El Tahan 2012
Methods 2-arm placebo-controlled randomised trial.
Participants Between dates unspecified, 382 parturients were randomised in a hospital setting in
Egypt. The population comprised women of parity 3 or less, a singleton pregnancy, at
high risk for PPH, who delivered by elective caesarean section. Exclusion criteria com-
prised parturients with asthma, anaemia, bleeding disorders, cardiac disease, inflamma-
tory disease, bowel disease, multiple pregnancy, pre-eclampsia, placenta praevia, placen-
tal abruption, previous APH, previous PPH, grand multiparity (not defined), fibroids,
growth restriction, fetal malformations or allergy to prostaglandins
Interventions 400 mcg plus 10 IU of misoprostol plus oxytocin administered sublingually plus by an
intravenous bolus (n = 191) versus 10 IU of oxytocin administered by an intravenous
infusion (n = 191)
Outcomes The study recorded the following outcomes: morbidity, additional uterotonics, transfu-
sion, death, blood loss (mL), vomiting, fever, shivering, abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation code was computer-
generated.
Allocation concealment (selection bias) Low risk Investigators used sequentially-numbered
sealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo and misoprostol tables “looked
identical in size, colour, and packing.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated intraoperative
blood loss by collection in a suction bottle
minus sonographically estimated amniotic
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fluid volume, together with visual estimates
of the volume of blood on the floor and the
weight differences between dry and used
towels, linens, and swabs. Visual estimates
were performed by obstetricians blinded
to treatment allocation. Towels, linen and
swabs were weighed with an electronic
scale. Weights were added to volumetric
values on the basis that 1 g is equivalent to
1mL. Investigators evaluated postoperative
blood loss by weighing bed linen, gowns
and perineal pads. Furthermore, blinded
investigators estimated blood loss bymulti-
plyingmaternal blood volume inmLby the
difference between preoperative and post-
operative haematocrit measurements, all
divided by preoperative haematocrit mea-
surements
Incomplete outcome data (attrition bias)
All outcomes
Low risk “4 patients in the placebo group and 12
patients in the misoprostol group were ex-
cluded from the study due to loss to follow-
up or missed preoperative hematocrit data.
”
Selective reporting (reporting bias) Unclear risk The study report matches the study pro-
tocol that was registered retrospectively
(ClinicalTrials.gov NCT01466530)
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Low risk The study was supported by funding from
Mansoura University (the institution of the
authors)
El-Refaey 2000
Methods 2-arm active-controlled randomised trial.
Participants Between April 1996 and March 1998, 1000 parturients were randomised in a hospital
setting in the UK. The population comprised women of unspecified parity, either single-
ton or multiple pregnancy, at both high and low risk for PPH, who delivered by vaginal
delivery. Exclusion criteria comprised parturients undergoing caesarean section or water
birth, or those with severe asthma
Interventions 500 mcg of misoprostol administered orally (n = 501) versus 500 mcg plus 5 IU of
ergometrine plus oxytocin administered intramuscularly (n = 499)
188Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
El-Refaey 2000 (Continued)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta. death, blood loss (mL), change
in Hb level, third-stage duration (min), nausea, vomiting, headache, fever, shivering,
abdominal pain
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Statistician using com-
puter-generated block randomisation with
varying block size
Allocation concealment (selection bias) Low risk Investigators used opaque, sequentially-
numbered sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment al-
locations.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the es-
timation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between February 2010 and October 2012, 380 parturients were randomised in a hos-
pital setting in Egypt. The population comprised women of unspecified parity, either
singleton or multiple pregnancy, at high risk for PPH, who delivered by elective cae-
sarean section. Exclusion criteria comprised parturients undergoing general anaesthesia,
or those with coagulopathy, coronary artery disease, hypertension, PPH due to causes
other than uterine atony or hypersensitivity to carbetocin
Interventions 400 mcg plus 20 IU of misoprostol plus oxytocin administered sublingually plus by
an intravenous infusion (n = 190) versus 100 mcg of carbetocin administered by an
intravenous bolus (n = 190)
Outcomes The study recorded the following outcomes: morbidity, additional uterotonics, transfu-
sion, death, blood loss (mL), change in Hb level, nausea, vomiting, headache, hypoten-
sion, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using a com-
puter-generated random number sequence
Allocation concealment (selection bias) Low risk Drugs were in pre-prepared sealed and
opaque packets.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Randomisation was done by the resident
doctors immediately before transfer to the-
atre, whereas preparation of packets and
confidential record maintenance was done
by the labour room nursing staff... Cae-
sarean delivery was performed by 4 senior
obstetricians who were blinded to the allo-
cation.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss “in the
usual way (visual estimation, number of
used swabs and amount of aspirated blood)
.”
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Elsedeek 2012
Methods 2-arm placebo-controlled randomised trial.
Participants Between 1st January 2008 and 1st January 2009, 400 parturients were randomised in
a hospital setting in Egypt. The population comprised women of parity 4 or less, a
singleton pregnancy, at high risk for PPH, who delivered by elective caesarean section.
Exclusion criteria comprised parturients undergoing their first elective caesarean section,
or those unsure of gestation or with hypertension, diabetes, oligohydramnios, abnormal
placenta or abnormal laboratory investigations
Interventions 400 mcg plus 10 IU of misoprostol plus oxytocin administered rectally plus by an
intravenous infusion (n = 200) versus 10 IU of oxytocin administered by an intravenous
infusion (n = 200)
Outcomes The study recorded the following outcomes: PPH at 1000, additional uterotonics, trans-
fusion, blood loss (mL), change in Hb level, NNU admissions, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using com-
puter-generated tables.
Allocation concealment (selection bias) Unclear risk Allocation was placed in sealed envelopes
until the time of operation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Attending obstetricians and other care-
givers were blinded to treatment allocations
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators evaluated blood loss from af-
ter uterine incision, by collection in 2 sep-
arate suction sets administered by a nurse,
and by weighing surgical towels before and
after each operation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The study protocol was registered retro-
spectively (ACTRN 12611000638932)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the institution of the authors, or conducted
without external funding
Enakpene 2007
Methods 2-arm active-controlled randomised trial.
Participants Between 4th January 2004 and 30th January 2005, 864 parturients were randomised in
a hospital setting in Nigeria. The population comprised women of unspecified parity, a
singleton pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion
criteria comprised parturients with pre-eclampsia, hypertension, cardiac disease, severe
anaemia, asthma, renal/hepatic disorders, grandmultiparity (not defined),multiple preg-
nancy, polyhydramnios, previous PPH, fibroids or contraindications to misoprostol or
ergometrine
Interventions 400 mcg of misoprostol administered orally (n = 432) versus 500 mcg of ergometrine
administered intramuscularly (n = 432)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, manual removal of placenta, death, blood loss (mL), change in
Hb level, third-stage duration (min), nausea, vomiting, headache, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was by simple random se-
lection. An independent statistician gener-
ated sets of 4 random letters, which were
in boxes, and each box contained 4 sepa-
rate random allocations which was equiva-
lent to an opaque sealed envelope stratified
in a block of 4
Allocation concealment (selection bias) Low risk Investigators used opaque sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study was “single-blinded.” The iden-
tity of those blinded was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators evaluated blood loss by a com-
bination of careful collection in a receptacle
after the delivery of the baby, by visual esti-
mation of blood loss, and by extrapolation
of blood loss using the weight difference of
the total perineal pad used up to 24 hours
postpartum
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study report
(cases of transfusion, chest pain and abdom-
inal pain were omitted)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the National Postgraduate Medical College
and Faculty of Obstetrics and Gynaecol-
ogy of the University College Hospital in
193Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Enakpene 2007 (Continued)
Ibadan, Nigeria (the institution of the au-
thors)
Ezeama 2014
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between 1st September 2011 and 31st May 2012, 300 parturients were randomised in
a hospital setting in Nigeria. The population comprised women of unspecified parity, a
singleton pregnancy, at both high and low risk for PPH,who delivered by vaginal delivery.
Exclusion criteria comprised parturients undergoing caesarean section, or those with
premature labour (less than 28 weeks), multiple pregnancy, antepartum haemorrhage,
hypertension in pregnancy, severe anaemia or haemoglobinopathy
Interventions 10 IU of oxytocin administered intramuscularly (n = 151) versus 500mcg of ergometrine
administered intramuscularly (n = 149)
Outcomes The study recorded the following outcomes: PPH at 500, additional uterotonics, trans-
fusion, manual removal of placenta, blood loss (mL), third-stage duration (min), nausea,
vomiting, hypertension, headache
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using com-
puter-generated random tables
Allocation concealment (selection bias) Low risk A person uninvolved with the study pre-
pared the study drugs. The labels on the
ampoules (which were similar in size and
colour) were removed and the ampoules
were placed in opaque sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “A person uninvolved with the study pre-
pared the study drugs… The labels on the
ampoules (which were similar in size and
colour) were removed and the ampoules
were placed in opaque sealed envelopes,
such that only the computer-generated ran-
domisation numbers on the envelopes were
available to identify the study drug during
unblinding.”
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by col-
lection with “a fresh large perineal pad with
plastic backing.” They placed all the gauzes
and perineal pads used to absorb the blood
into a polythene bag, and subtracted the
dry weight from the wet weight. Volume of
blood loss was calculated on the basis that
1 g is equivalent to 1 mL
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk The study protocol was registered (PACTR
201105000292708).
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the institution of the authors
Fararjeh 2003
Methods 2-arm active-controlled randomised trial.
Participants Between 1st January 2002 and 30th June 2002, 97 parturients were randomised in a
hospital setting in Turkey. The population comprised women of parity 4 or less, a single-
ton pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients undergoing elective caesarean section or instrumental delivery, or
those with premature labour (less than 37 weeks), postmaturity (more than 43 weeks),
grand multiparity (more than 4), twin pregnancy, growth restriction, macrosomia, Hb
less than 100 g/L, systemic disorder, prolonged third stage, manual removal of placenta
or additional lacerations due to episiotomy or where it took longer than 30 min to repair
lacerations after episiotomy
Interventions 400 mcg of misoprostol administered rectally (n = 49) versus 200 mcg plus 10 IU of
ergometrine plus oxytocin administered intramuscularly (n = 48)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, blood loss (mL)
, change in Hb level
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Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was achieved using block
randomisation.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by collec-
tion with scale vessels, and by subtraction
of the dry weight(s) of cloths and pads from
the soaked weight(s) of these items
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Fawole 2011
Methods 2-arm placebo-controlled randomised trial
Participants 1345 parturients were randomised in a hospital setting in Nigeria. The population
comprised multiparous women, unspecified whether singleton or multiple pregnancy, at
both high and low risk for PPH, who delivered vaginally. Exclusion criteria comprised
severe allergic conditions or asthma, age below 18 years, pyrexia above 38°C, or abortion
of the pregnancy
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Interventions 400 mcg of misoprostol administered sublingually plus 10 IU of oxytocin or 250 mcg
to 500 mcg of ergometrine administered intramuscularly or by an intravenous bolus
(n = 658) or intravenous bolus versus 10 IU of Oxytocin or 250 mcg to 500 mcg of
ergometrine administered intramuscularly or intravenously (n = 660)
Outcomes Could not include in the analysis as could not separate out the patients that received
oxytocin from those who received ergometrine
Notes Contact with study authors for additional information: Yes. Additional data from au-
thors: Yes, but data not provided separate for each drug used and could not be included
in the meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was allocated in blocks of 6-8
women by the research nurse, who used
a computer-generated randomisation se-
quence
Allocation concealment (selection bias) Low risk The trial drugs were concealed in sealed,
sequentially numbered opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo was identical in shape, colour, size,
and design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded.
Objective assessment of blood loss Low risk Blood collection was initiated as soon as
possible after administration of the trial
medication. A low-profile plastic fracture
bedpan was placed below the woman’s per-
ineum to collect all subsequent blood loss
for a period of 1hour. Blood collected in the
bedpan and all blood soaked small gauze
swabs were emptied into a plastic measur-
ing jar and the volume was measured
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses stated by authors but 27 women
randomised were not included in the anal-
ysis for the primary outcome
Selective reporting (reporting bias) Unclear risk No available protocol.
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Intention to treat analysis Unclear risk 27 women randomised were not included
in the analysis for the primary outcome
Funding source Low risk The trial was funded by theMedical Re-
search Council of South Africa
Fazel 2013
Methods 2-arm active-controlled randomised trial.
Participants Between dates unspecified in 2009, 100 parturients were randomised in a hospital setting
in Iran. The population comprised women of parity 3 or less, a singleton pregnancy,
at high risk for PPH, who delivered by elective caesarean section. Exclusion criteria
comprised parturients with twin pregnancy, fetal distress, pregnancy-induced hyperten-
sion, oligohydramnios, polyhydramnios, macrosomia, grand multiparity (4 or more),
HELLP syndrome, coagulopathy, asthma, heart/lung/liver disease, previous more than 1
caesarean section, previous myomectomy, previous other abdominal operations, febrile
diseases or sensitivity to prostaglandins
Interventions 400 mcg of misoprostol administered rectally (n = 50) versus 10 IU of oxytocin admin-
istered by an intravenous infusion (n = 50)
Outcomes The study recorded the following outcomes: transfusion, blood loss (mL), nausea, vom-
iting, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Investigators used a table of random num-
bers.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators evaluated intraoperative blood
loss by collection with an isolated suction.
The volume of blood collected in suction
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was combined with the volume of blood
collected in gauzes and gowns: every small
gauze soaked with blood was considered to
contain 20mL, and every large gauze soaked
with blood 50 mL, and every g increase
in the weight of a gown was considered as
equivalent to 1 mL of blood
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the Kashan University of Medical Sciences
(the institution of the authors)
Fekih 2009
Methods 2-arm active-controlled randomised trial.
Participants Between 1st March 2007 and 1st June 2007, 250 parturients were randomised in a
hospital setting in Tunisia. The population comprised women of unspecified parity, a
singleton pregnancy, at high risk for PPH, who delivered by either elective or emergency
caesarean. Exclusion criteria comprised parturients undergoing caesarean section with
general anaesthesia, or those with placenta praevia, retroplacental clot, multiple preg-
nancy, premature labour (less than 32 weeks), intra-uterine death, Hb less than 80 g/L,
coagulopathy, HELLP syndrome, antepartum haemorrhage, ruptured uterus, previous
more than 2 caesareans or other uterine scar, prolonged labour (more than 12 hours) or
pyrexia
Interventions 200 mcg plus 20 IU of misoprostol plus oxytocin administered sublingually plus by an
intravenous bolus and infusion (n = 125) versus 20 IU of oxytocin administered by an
intravenous bolus plus infusion (n = 125)
Outcomes The study recorded the following outcomes: PPH at 1000, transfusion, blood loss (mL)
, change in Hb level, nausea, vomiting, headache, fever, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was computer-gener-
ated.
Allocation concealment (selection bias) Low risk A slip of paper was placed inside an opaque,
sealed envelope
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators evaluated perioperative blood
loss as a combinationof the volume of liquid
in the suction collection jar, and the weight
of swabs and pads
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Fenix 2012
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between May 2011 and August 2011, 75 parturients were randomised in a hospital set-
ting in the Philippines. The population comprised women of unspecified parity, either
singleton or multiple pregnancy, at high risk for PPH, who delivered by vaginal delivery.
Exclusion criteria comprised parturients with pre-existing hypertension, pre-eclampsia,
diabetes, asthma, cardiac/renal diseases, coagulopathy, abnormal laboratory tests or al-
lergy to the study medication
Interventions 100 mcg of carbetocin administered by an intravenous bolus (n = 39) versus 10 IU of
oxytocin administered by an intravenous infusion (n = 36)
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Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional utero-
tonics. transfusion, blood loss (mL,. change in Hb level, nausea, vomiting, headache,
tachycardia, abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was computer-gener-
ated.
Allocation concealment (selection bias) Unclear risk Investigators used sealed, consecutively-
numbered envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The patient and the principal investiga-
tor attending the delivery were blinded to
the type of medication administered” [ad-
ditional information from the authors]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “In addition to these, the following were
recorded by assigned personnel not blinded
in this study: any adverse events or experi-
ences from the 2 groups (carbetocin versus
oxytocin); vital signs before and after drug
infusion, the need for an additional utero-
tonic in each group, the need for a uter-
ine massage and the intensity of the uterine
contraction after infusion of the assigned
drug.”
Objective assessment of blood loss High risk Investigators evaluated blood loss by visual
estimation, not including blood loss con-
sidered to result from repair of lacerations
Incomplete outcome data (attrition bias)
All outcomes
High risk “9 women in the carbetocin group and
6 women in the oxytocin group failed to
have a paired haemoglobin test to mea-
sure the change in haemoglobin 24 hours
after delivery because they refused further
blood extraction.These 15womenwere ex-
cluded.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Fu 2003
Methods 2-arm controlled randomised trial.
Participants Between October 2002 and April 2003, 156 parturients were randomised in a hospital
setting in China. The population comprised women of unspecified parity, unspecified
whether singleton or multiple pregnancy, at both high and low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria were not specified
Interventions 400 mcg of misoprostol administered orally (n = 80) versus placebo or control (n = 76)
Outcomes The study recorded the following outcomes: PPH at 500, blood loss (mL)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was not re-
ported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators evaluated blood loss in the 2 hours
after delivery and after all amniotic fluids had been
drained, by collection in a small tray and absorp-
tion into disposable, sterile, water-resistant gauze.
The contents were weighed and volume was de-
termined on the basis that 1.05 g is equivalent to
1 mL of blood. A measuring cup was used to esti-
mate the blood in the tray; blood that soaked into
the gauze was measured on the basis that material
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measuring 10 cm by 10 cm holds 10 mL of blood.
These 3 measurements were combined to ascer-
tain total blood loss
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any incom-
plete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Unclear risk The authors did not specify whether all those who
were enrolled and randomly allocated to treatment
were included in the analysis, in the groups to
which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not re-
ported.
Garg 2005
Methods 2-arm active-controlled randomised trial.
Participants Between 2002 and 2003, 200 parturients were randomised in a hospital setting in India.
The population comprised women of primigravidas, a singleton pregnancy, at both high
and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria were not
specified
Interventions 600 mcg of misoprostol administered orally (n = 100) versus 200 mcg of ergometrine
administered by an intravenous bolus (n = 100)
Outcomes The study recorded the following outcomes: PPH at 500, additional uterotonics, man-
ual removal of placenta, third-stage duration (min), nausea, vomiting, headache, fever,
shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised in 1:1 ratio
by random number sequence
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Gavilanes 2016
Methods 2-arm active-controlled randomised trial.
Participants Between dates unspecified, 100 parturients were randomised in a hospital setting in
Ecuador. The population comprised women of unspecified parity, a singleton pregnancy,
at high risk for PPH, who delivered by elective caesarean section. Exclusion criteria
comprised parturients with Hb less than 80 g/L, multiple pregnancy, polyhydramnios,
previous uterine rupture, bleeding disorders, intrauterine death or hyperthermia (more
than 38.5°C)
Interventions 400 mcg of misoprostol administered sublingually (n = 50) versus 10 IU of oxytocin
administered by an intravenous infusion (n = 50)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, blood loss (mL), nausea, vomiting, headache, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
204Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gavilanes 2016 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was computer-gener-
ated.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated postoperative blood
loss by collection with “suction appara-
tus and sterile drapes before irrigation”
and by weighing the blood collected in
abdominal swabs and gauzes with a cali-
brated scale (Zhongshan Camry Electronic
Co Ltd, model EK 4052-E, Guangdong,
China). Investigators estimated the volume
of blood loss “by subtraction of amniotic
fluid at 30 cc per each centimetre reported
by amniotic fluid index.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Gerstenfeld 2001
Methods 2-arm placebo-controlled randomised trial.
Participants Between dates unspecified, 400 parturients were randomised in a hospital setting in the
USA. The population comprised women of unspecified parity, a singleton pregnancy,
at both high and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients with multiple pregnancy, coagulopathy, Hb less than 70 g/L,
indication for caesarean section or contraindication to prostaglandin or oxytocin use
Interventions 400 mcg of misoprostol administered rectally (n = 201) versus 20 IU of oxytocin ad-
ministered by an intravenous infusion (n = 199)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, nausea, vomiting, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by an unin-
volved party and determined by a random
number sequence
Allocation concealment (selection bias) Low risk The random number sequence was pre-
pared by a third party and was concealed
until the patient was enrolled. Packets were
prepared in advance of randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The random number sequence was “con-
cealed until the patient was enrolled” and
“packets were prepared in advance of ran-
domisation.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators evaluated blood loss (a) by
collection with drapes placed under the
mother. Each drape included a plastic
pouch andmeasured volume inmL.Mean-
while the dry weights of delivery linen
and sponges were subtracted frombloodied
weights to determine the volume of blood
collected with these materials, on the basis
that 1 g is equivalent to 1 mL. The vol-
umes of blood in drapes and linen were
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added together. Furthermore “if amniotic
fluid loss [after placement of the drape]
was significant... the approximate percent-
age was recorded on the data sheet and
blood loss was adjusted accordingly.” Inves-
tigators evaluated blood loss (b) by estima-
tion of the delivery attendant(s). Investiga-
tors evaluated blood loss (c) by measure-
ment of Hb and haematocrit values were
obtained on admission and on postpartum
day 1. The differences between these 2 val-
ues were recorded
Incomplete outcome data (attrition bias)
All outcomes
High risk “Of the 75womenwhowere excluded from
analysis, 73underwent caesareandeliveries,
1 woman was discharged to
home before delivery, and 1 had an initial
Hb
of 6.8 mg/dL.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Gulmezoglu 2001
Methods 2-arm active-controlled double-blinded randomised trial.
Participants Between April 1998 and November 1999, 18530 parturients were randomised in a hos-
pital setting in Argentina, China, Egypt, Ireland, Nigeria, South Africa, Switzerland,
Thailand, and Vietnam. The population comprised women of unspecified parity, un-
specified whether singleton or multiple pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised parturients undergoing
elective or emergency caesarean section after randomisation, or those with asthma, se-
vere chronic allergic conditions, abortion, pyrexia (more than 38°C) or inability to give
consent
Interventions 600 mcg of misoprostol administered orally (n = 9264) versus 10 IU of oxytocin admin-
istered intramuscularly or by an intravenous bolus (n = 9266)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, manual removal of placenta, death, blood loss (mL)
, third-stage duration (min, nausea, vomiting, fever, shivering
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Gulmezoglu 2001 (Continued)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The random allocation schedule was
generated centrally at WHO, Geneva,
Switzerland, by computer-generated ran-
dom numbers and was stratified by coun-
try.Within the strata, womenwere individ-
ually randomised into 1 of 2 intervention
groups with randomly varying block sizes
of 4-6 women
Allocation concealment (selection bias) Low risk The treatment packs were sealed, num-
bered sequentially, and could only be taken
from the dispenser consecutively
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The treatment packs and their contents
were identical in shape, colour, weight, and
feel… Double-blinding, including double
placebos, ensured that ascertainment bias
in themeasurement of blood loss and use of
additional uterotonics was unlikely. How-
ever, unblinding could have occurred be-
cause of the higher rate of shivering associ-
ated with misoprostol.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators evaluated blood loss from the
time of delivery of the baby until the third
stage of the labour was completed, when
themotherwas transferred to postnatal care
(usually up to 1 hour postpartum). Imme-
diately after the cord was clamped and cut,
they passed a flat bedpan or an unsoiled
receiver under the mother. The collected
blood was poured into a standard measur-
ing jar provided by WHO for volumetric
measurement. “To simplify the procedure..
. small gauze swabs soaked with blood were
put into the measuring jar and included in
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the measurement together with the blood
and clots.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Investigators excluded “37 and 34 women
with emergency caesarean section, and 13
and 4 women lost to follow-up in miso-
prostol and oxytocin groups, respectively,
for blood loss
at least 1000mL, and 2 and 4women with-
out information on the need for additional
uterotonics.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Low risk The study was supported by funding from
the UNDP/UNFPA/WHO/World Bank
Special Programme of Research, Devel-
opment and Research Training. Searle
(Skokie, IL, USA) and Novartis (Basel,
Switzerland) donated the active and
placebo medications used in the trial
Gupta 2006
Methods 2-arm active-controlled double-blinded randomised trial.
Participants Betweendates unspecified, 200parturientswere randomised in a hospital setting in India.
The population comprised women of unspecified parity, unspecified whether singleton
or multiple pregnancy, at both high and low risk for PPH, who delivered by vaginal
delivery. Exclusion criteria were not specified
Interventions 600 mcg of misoprostol administered rectally (n = 100) versus 10 IU of oxytocin ad-
ministered intramuscularly (n = 100)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta, blood loss (mL). change in Hb
level, third-stage duration (min), nausea, fever, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Randomisation was achieved using com-
puter-generated random tables
Allocation concealment (selection bias) Unclear risk A sealed envelope with a code number was
opened when vaginal delivery was immi-
nent. The code was not broken till the end
of the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was “double-blind.” “Each en-
velope contained either 3 tablets of 200
mcg misoprostol and an ampoule of nor-
mal saline or 3 identical looking placebo
tablets and an ampoule of 10 IU oxytocin.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by col-
lection with a BRASS-V calibrated drape
placed under the mother. Pre-weighed
gauzes were used to clean any perineal tears
or episiotomy. After 1 hour the dry weight
of the sponges was subtracted from the
soiled weight, and added to the volume of
blood collected in the drape on the basis
that 1 g is equivalent to 1 mL
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Hamm 2005
Methods 2-arm placebo-controlled randomised trial.
Participants Between August 2000 and May 2004, 352 parturients were randomised in a hospital
setting in the USA. The population comprised women of unspecified parity, unspecified
whether singleton or multiple pregnancy, at high risk for PPH, who delivered by either
elective or emergency caesarean. Exclusion criteria were not specified
Interventions 200 mcg plus 20 IU of misoprostol plus oxytocin administered sublingually plus by an
intravenous infusion (n = 173) versus 20 IU of oxytocin administered by an intravenous
infusion (n = 179)
Outcomes The study recorded the following outcomes: PPH at 1000, additional uterotonics, trans-
fusion, blood loss (mL), change in Hb level
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Low risk The group assignments were available only
to the pharmacy. The nurse selected an
opaque vial from the drug cabinet that con-
tained either a 200 mg misoprostol tablet
or placebo. The vial number (which had
been assigned in the pharmacy) and patient
identification were sent to the pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were un-
clear.
Harriott 2009
Methods 2-arm active-controlled randomised trial.
Participants Over 6 months between dates unspecified, 140 parturients were randomised in a hos-
pital setting in West Indies. The population comprised women of unspecified parity,
unspecified whether singleton or multiple pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised parturients with previous
PPH, hypertension, previous caesarean, intrauterine death, sepsis/pyrexia (more than
38°C), antepartum haemorrhage or Hb less than 80 g/L
Interventions 500 mcg plus 5 IU of ergometrine plus oxytocin administered intramuscularly (n = 70)
versus 400 mcg of misoprostol administered rectally (n = 70)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta, death, blood loss (mL), change in
Hb level, third-stage duration (min), nausea, vomiting, hypertension, fever, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomisation
was used to randomly assign participants
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Both the patient and themidwife conduct-
ing the delivery were aware of the drug ad-
ministered.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment al-
locations.
212Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Harriott 2009 (Continued)
Objective assessment of blood loss Low risk Investigators evaluated blood loss by collec-
tion with a modified plastic drape placed
under themother from the commencement
of the third stage of labour, until 1 hour af-
ter delivery. The collection drape measured
168 cm by 84 cm, and contained folded
over side-wings (to act as a chute) and a
34-cm collection pouch made by folding
the distal end of the drape. Standard sterile
drapes were placed above the blood collec-
tion drape. Every effort was made to avoid
soiling the sterile drapes before delivery of
the baby, because they were not weighed.
After delivery, overlying sterile drapes were
removed to facilitate the use of the collec-
tion drape
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the Mona Campus and Research Publica-
tion Committee of the University of the
West Indies (the institution of the authors)
Hofmeyr 1998
Methods 2-arm placebo-controlled randomised trial.
Participants Betweendates unspecified, 500parturientswere randomised in a hospital setting in South
Africa. The population comprised women of unspecified parity, unspecified whether
singleton or multiple pregnancy, at low risk for PPH, who delivered by vaginal delivery.
Exclusion criteria comprised parturients undergoing augmentation of labour, or those
with hypertension, diabetes or previous caesarean
Interventions 400 mcg of misoprostol administered orally (n = 250) versus placebo or control (n =
250)
Outcomes The study recorded the following outcomes: PPH at 1000, additional uterotonics, trans-
fusion, manual removal of placenta, shivering, abdominal pain
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Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using a com-
puter-generated random sequence, in bal-
anced blocks of 8
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The tablets were either misoprostol 2 x
200 mcg or 2 placebo tablets similar in size
and colour but not shape. Efforts to obtain
identical placebo tablets were unsuccessful.
Thismethod of blinding proved to be effec-
tive. In only 1 case did the attending mid-
wife inadvertently catch sight of the tablets.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Within a minute of delivery, investigators
removed any linen soiled with amniotic
fluid, and placed a fresh, disposable ab-
sorbent linen-saver sheet with plastic back-
ing, and a low wedge-shaped plastic “frac-
ture” bedpan under the mother. “This was
found to be a comfortable and efficient way
of collecting the great majority of blood
lost after delivery, and could be left in
place without discomfort even during per-
ineal suturing. When active bleeding had
stopped, any blood clots were expressed
from the uterus, the bedpan was removed
and a sanitary towel was applied. The [vol-
ume of ] blood in the bedpan was measured
in a measuring jug. An hour after deliv-
ery, any bloodstained linen-savers and san-
itary towels were placed in a plastic bag and
weighed in g.” After subtracting the known
dry weights of these materials, the blood-
stained weights were added to the volume
of blood collected in the bedpan to ascer-
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tain the total blood loss in the first hour
after delivery
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the South AfricanMedical Research Coun-
cil (public funding)
Hofmeyr 2001
Methods 2-arm placebo-controlled randomised trial.
Participants Betweendates unspecified, 600parturientswere randomised in a hospital setting in South
Africa. The population comprised women of unspecified parity, unspecified whether sin-
gleton or multiple pregnancy, at unspecified for PPH, who delivered by vaginal delivery.
Exclusion criteria were not specified
Interventions 600 mcg of misoprostol administered orally (n = 300) versus placebo or control (n =
300)
Outcomes The study recorded the following outcomes: PPH at 1000, additional uterotonics, trans-
fusion, manual removal of placenta, nausea, vomiting, fever, shivering, abdominal pain
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random assignments were generated by
computer in blocks of 18
Allocation concealment (selection bias) Low risk Investigators used sequentially-numbered,
opaque test tubes.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Misoprostol and placebo were similar in
size and colour but not shape
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Within a minute of delivery, investigators
removed any linen soiled with amniotic
fluid, and placed a fresh, disposable ab-
sorbent linen-saver sheet with plastic back-
ing, and a low wedge-shaped plastic ”frac-
ture“ bedpan under the mother. ”This was
found to be a comfortable and efficient way
of collecting the great majority of blood
lost after delivery, and could be left in
place without discomfort even during per-
ineal suturing. When active bleeding had
stopped, any blood clots were expressed
from the uterus, the bedpan was removed
and a sanitary towel was applied. The [vol-
ume of ] blood in the bedpan was measured
in a measuring jug. An hour after deliv-
ery, any bloodstained linen-savers and san-
itary towels were placed in a plastic bag and
weighed in g.“ After subtracting the known
dry weights of these materials, the blood-
stained weights were added to the volume
of blood collected in the bedpan to ascer-
tain the total blood loss in the first hour
after delivery”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “There were no withdrawals after randomi-
sation and all outcomes were analysed in
the allocated group.” However the primary
outcome data of 1 study participant in the
placebo group were unavailable
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
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Funding source Low risk The study was supported by funding from
the South AfricanMedical Research Coun-
cil (public funding) and University of the
Witwatersrand (the institution of the au-
thors)
Hofmeyr 2011
Methods 2-arm placebo-controlled randomised trial.
Participants Between 6thMarch 2006 and 13th August 2007, 1103 parturients were randomised in a
hospital setting in South Africa, Uganda, andNigeria. The population comprisedwomen
of unspecified parity, unspecified whether singleton or multiple pregnancy, at both high
and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised
parturients undergoing caesarean section or instrumental delivery, or those who declined
participation or were unable to consent, were too ill or distressed to participate or with
a not viable pregnancy
Interventions 400 mcg plus 10 IU of misoprostol plus oxytocin administered sublingually plus intra-
muscularly (n = 547) versus 10 IU of oxytocin administered intramuscularly (n = 556)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
manual removal of placenta, death, blood loss (mL), fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
were stratified by country in blocks of 6-8
Allocation concealment (selection bias) Low risk The trial medication was provided, and the
study drug packs were prepared, by Gynu-
ity Health Projects. When a participant en-
rolled, the researcher took the next study
drug pack from the dispenser and imme-
diately wrote the woman’s name both on
the pack and in the participant number
list, which was kept separate from the case
record forms. Enrolment took place when
the pack was removed from the pack dis-
penser. The pack could not be used for an-
other woman or returned to the dispenser
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Hofmeyr 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was ”double-blind.“ ”The packs
were identical in shape, colour, weight, and
feel, and contained either 2 tablets of 200
mcg of misoprostol (HRA Pharma, Paris,
France) or 2 matching placebo tablets.“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Similarly to the study team of Gulmezoglu
2001, investigators evaluated blood loss by
collection with a fresh non-absorbent sheet
and low plastic “fracture” bedpan placed
under the mother from as soon as possi-
ble after delivery until 1 hour postpartum.
Investigators considered that ”longer-term
blood loss measurement is more difficult
to standardise.“ They transferred the blood
collected in the sheet and the bedpan (to-
gether with any soaked small gauze swabs)
to a measuring jar to ascertain the volume.
Alternatively, they collected blood with a
plastic sheet placed under the mother im-
mediately after delivery. If bleeding contin-
ued beyond 1 hour, investigators restarted
collection and measurement until bleeding
subsided. Attempts were made tominimise
any losses on the drapes and gowns of de-
livery attendants. In addition, ”the placen-
tal interstices also contain maternal blood
(about 9% of placental weight). Because
overestimations (amniotic fluid) and un-
derestimations (blood loss) were likely to
be distributed equally between the 2 study
groups, and most would have occurred be-
fore the onset of measurement, the data
were not corrected
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Data for the primary outcome were not
available for 4 of the 1103 women.”
Selective reporting (reporting bias) High risk The prospectively registered protocol of the
study (ClinicalTrials.gov NCT 00124540)
lists some secondary outcomes different to
those included the study report (at least
1000 mL within the first hour only, trans-
fusion, Hb less than 8 g/dL 24 hours after
delivery)
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Hofmeyr 2011 (Continued)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
Gynuity Health Projects through a grant
from the Bill and Melinda Gates Founda-
tion (public funding)
Hoj 2005
Methods 2-arm placebo-controlled randomised trial.
Participants Between March 2003 and August 2004, 661 parturients were randomised in a commu-
nity setting in Guinea-Bissau. The population comprised women of unspecified parity,
unspecified whether singleton or multiple pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria were not specified
Interventions 600 mcg of misoprostol administered sublingually (n = 330) versus placebo or control
(n = 331)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, manual removal
of placenta, death, blood loss (mL), change in Hb level, third-stage duration (min),
nausea, vomiting, fever, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using a list of
random numbers.
Allocation concealment (selection bias) Low risk Investigators used opaque envelopes that
were consecutively-numbered and filled
with the study drugs
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Misoprostol and placebo tablets of iden-
tical form, size, colour, and packing were
produced.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
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Hoj 2005 (Continued)
Objective assessment of blood loss Low risk After delivery of the baby and drainage of
the amniotic fluid, investigators placed a
clean plastic-lined absorbent drape under
the mother. They changed the drape as
many times as needed. The mother stayed
on the drape or was asked to wear a pad
over the next 60 minutes. All drapes and
pads were weighed with an electronic scale
and the known dry weights were subtracted
in order to ascertain the volume of blood
loss on the basis that 1 g is equivalent to 1
mL
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding
from the Danish Society of Obstetrics
and Gynaecology, the Illum Foundation,
and the Danish International Develop-
ment Agency (public funding)
Hong 2007
Methods 2-arm placebo-controlled randomised trial.
Participants Between dates unspecified, 214 parturients were randomised in a hospital setting in Ko-
rea. The population comprised women of unspecified parity, unspecified whether single-
ton or multiple pregnancy, at high risk for PPH, who delivered by caesarean (unspecified
whether elective or emergency). Exclusion criteria were not specified
Interventions 20 IU of oxytocin administered by an intravenous infusion (n = 118) versus 400 mcg
plus 20 IU of misoprostol plus oxytocin administered rectally plus by an intravenous
infusion (n = 96)
Outcomes The study recorded the following outcomes: additional uterotonics, transfusion, change
in Hb level, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
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Hong 2007 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessor blinding was not reported, but the
use of placebo impeded knowledge of treat-
ment allocations
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Is 2012
Methods 2-arm active-controlled randomised trial.
Participants Betweendates unspecified, 200parturientswere randomised in a hospital setting in India.
The population comprised women of unspecified parity, unspecified whether singleton
or multiple pregnancy, at both high and low risk for PPH, who delivered by vaginal
delivery. Exclusion criteria were not specified
Interventions 400mcg of misoprostol administered rectally (n = 100) versus unspecified of ergometrine
administered intramuscularly (n = 100)
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Is 2012 (Continued)
Outcomes The study recorded the following outcomes: third-stage duration (min), nausea, vomit-
ing, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Jago 2007
Methods 2-arm active-controlled randomised trial.
Participants Between January 2001 and December 2002, 510 parturients were randomised in a hos-
pital setting inNigeria. The population comprised women of unspecified parity, a single-
ton pregnancy, at both high and low risk for PPH, who delivered by vaginal delivery. Ex-
clusion criteria comprised parturients undergoing induction or augmentation of labour
or instrumental delivery, or those requiring epidural analgesia or with hypertension in
pregnancy, existing hypertension, chronic renal disease, diabetes, vascular diseases, car-
diac disease, anticoagulation therapy or allergy to ergometrine or oxytocin
Interventions 500mcg of ergometrine administered intramuscularly (n = 254) versus 10 IU of oxytocin
administered by an intravenous bolus (n = 256)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, blood loss (mL)
, hypertension
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using a com-
puter-generated list of random numbers
Allocation concealment (selection bias) Unclear risk Investigators used numbers that were la-
belled on envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
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Jago 2007 (Continued)
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Jangsten 2011
Methods 2-arm controlled randomised trial.
Participants BetweenNovember 2006 andApril 2008, 1802parturientswere randomised in a hospital
setting in Sweden. The population comprised women of parity 4 or less, a singleton
pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients undergoing elective caesarean section, or those who were non-
Swedish speaking or with previous PPH, pre-eclampsia, grand multiparity (more than
4) or intrauterine death
Interventions 10 IU of oxytocin administered by an intravenous bolus (n = 903) versus of placebo or
control (n = 899)
Outcomes The study recorded the following outcomes: PPH at 1000, transfusion, manual removal
of placenta, blood loss (mL), change in Hb level, third-stage duration (min)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was computer-generated.
Allocation concealment (selection bias) Low risk Investigators used sealed envelopes containing the
randomisation group prepared in consecutive or-
der and kept in another unit. At randomisation,
midwives phoned the staff at the other unit who
opened the envelopes and disclosed the assigned
intervention and trial number
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Because of the nature of the study, blinding was
not possible for the midwives, but the parturients
were not informed of which management was to
be used for them.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment alloca-
tions.
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Jangsten 2011 (Continued)
Objective assessment of blood loss Low risk Investigators evaluated blood loss by removing
pads soaked with amniotic fluid and placing a dry
sanitary pad under the mother, immediately after
the birth of the baby. They weighed all sanitary
towels and pads before and after use. Blood loss
was recorded (a) between the birth of the baby and
the expulsion of the placenta, and (b) from expul-
sion of the placenta up to 2 hours postpartum
Incomplete outcome data (attrition bias)
All outcomes
Low risk 171 randomised women were not included in the
study analysis. Among those randomised to receive
oxytocin, 4 withdrew consent, 75 had caesareans,
and14were lost to follow-up. In the control group,
2 withdrew consent, 56 had caesareans, and 20
were lost to follow-up
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis High risk The authors excluded 131 randomised study par-
ticipants from the analysis because they experi-
enced caesarean deliveries
Funding source Low risk The study was supported by funding from the Re-
search and Development Board in Göteborg and
Bohuslän, Baby Bag and the SU Foundation in
Sweden (public funding)
Jerbi 2007
Methods 2-arm controlled randomised trial.
Participants Between February 2005 andMarch 2005, 130 parturients were randomised in a hospital
setting in Tunisia. The population comprised women of parity 5 or less, a singleton
pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients with placenta praevia, antepartum haemorrhage, non-cephalic
presentation, intrauterine death, grand multiparity, (more than 5), fibroids, anticoagu-
lation therapy, previous PPH or previous caesarean
Interventions 5 IU of oxytocin administered by an intravenous bolus (n = 65) versus placebo or control
(n = 65)
Outcomes The study recorded the following outcomes: PPH at 1000, transfusion, manual removal
of placenta, death, change in Hb level, third-stage duration (min)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was not re-
ported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All those who were enrolled and randomly allo-
cated to treatment were included in the analysis,
in the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were unclear.
Jirakulsawas 2000
Methods 2-arm active-controlled randomised trial.
Participants Between 1st June 1998 and 31st December 1998,140 parturients were randomised
in a hospital setting in Thailand. The population comprised women of unspecified
parity, unspecified whether singleton or multiple pregnancy, at unspecified for PPH,
who delivered by vaginal delivery. Exclusion criteria were not specified
Interventions 600 mcg of misoprostol administered orally (n = 70) versus 200 mcg of ergometrine
administered intramuscularly (n = 70)
Outcomes The study recorded the following outcomes: PPH at 500, blood loss (mL)
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Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Karkanis 2002
Methods 2-arm active-controlled randomised trial.
Participants Between dates unspecified, 238 parturients were randomised in a hospital setting in
Canada. The population comprised women of parity 5 or less, unspecified whether
singleton or multiple pregnancy, at low risk for PPH, who delivered by vaginal delivery.
Exclusion criteria comprised parturients with coagulopathy, anticoagulation therapy,
previous PPH or previous caesarean
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Interventions 400 mcg of misoprostol administered rectally (n = 100) versus 5 IU of oxytocin admin-
istered by an intravenous bolus or intramuscularly (n = 113). There were 15 exclusions
post randomisation but it was unclear from which group
Outcomes The study recorded the following outcomes: additional uterotonics, transfusion, manual
removal of placenta, change in Hb level. third-stage duration (min), nausea, vomiting,
headache, fever, shivering, abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A statistician developed blocked randomi-
sation tables for each centre
Allocation concealment (selection bias) Low risk Pharmacy assembled consecutively-num-
bered opaque, sealed packets that contained
the group allocation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment al-
locations.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “13 women randomised subsequently de-
livered by caesarean andwere excluded from
analysis. 2 women were lost to follow-up
early in the trial when their packets were
opened but the manoeuvre was not com-
pleted and no data were recorded.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Low risk The study was supported by funding from
the physicians of Ontario, through the
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Physician Services Incorporated Founda-
tion (public funding)
Kerekes 1979
Methods 3-arm controlled randomised trial.
Participants Between dates unspecified, 140 parturients were randomised in a hospital setting in
Hungary. The population comprised women of unspecified parity, unspecified whether
singleton or multiple pregnancy, at unspecified for PPH, who delivered by vaginal de-
livery. Exclusion criteria were not specified
Interventions 200 mcg of ergometrine administered by an intravenous bolus (n = 50) versus placebo
or control (n = 43) versus 1 mg dinoprost administered intramuscularly (n = 47). The
dinoprost arm was not included in the analysis
Outcomes The study recorded the following outcome: third-stage duration (min)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was not re-
ported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Investigators evaluated blood loss by collection in
a container placed under the mother during the
third stage of labour until 2 hours postpartum.
The contents of the container were transferred to a
measuring cylinder.However, blood loss data were
not reported in a format that could be extracted
for the purpose of this review
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
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Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All those who were enrolled and randomly allo-
cated to treatment were included in the analysis,
in the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not re-
ported.
Khan 1995
Methods 2-arm active-controlled double-blinded randomised trial.
Participants Between 1st January 1991 and 30th June 1991, 2040 parturients were randomised in a
hospital setting in United Arab Emirates. The population comprised women of unspec-
ified parity, a singleton pregnancy, at both high and low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised parturients undergoing induction or
augmentation of labour, caesarean section or instrumental delivery, or requiring gen-
eral anaesthesia, epidural or diazepam, or those with antenatal hypertension (160/100
mmHg or more), hypertension on antihypertensive drugs, multiple pregnancy, cardiac
disease or Hb of 90 g/L or less
Interventions 10 IU of oxytocin administered intramuscularly (n = 1017) versus 500 mcg plus 5 IU
of ergometrine plus oxytocin administered intramuscularly (n = 1023)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, transfusion,
manual removal of placenta, vomiting, headache
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Treatment was allocated as per a number
code generated by the hospital pharmacist
who alone was aware of the content of the
ampoules
Allocation concealment (selection bias) Low risk Participants were assigned an opaque sealed
envelope. Each envelope carried the in-
struction to use a numbered vial of the
study drug
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Khan 1995 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators evaluated blood loss “in the
standard way” by measurement of blood
and clots in a graduated jug, and by weigh-
ing swabs and linen
Incomplete outcome data (attrition bias)
All outcomes
Low risk “12 patients had to be excluded from
the trial (oxytocin 5; syntometrine [er-
gometrine plus oxytocin] 7) after randomi-
sation because they no longer fulfilled the
inclusion criteria... [including] 2 who re-
quired caesarean section (1 in each group)
and 10 who were
delivered by forceps or ventouse (oxytocin
4; syntometrine [ergometrine plus oxy-
tocin] 6).”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Kikutani 2006
Methods 4-arm active-controlled randomised trial.
Participants Betweendates unspecified, 136parturientswere randomised in a hospital setting in Japan.
The population comprised women of unspecified parity, either singleton or multiple
pregnancy, at high risk for PPH, who were scheduled for caesarean with ASA I or II.
Exclusion criteria comprised parturients that were affected by cardiovascular conditions,
were scheduled for autologous blood transfusion, who had tocolytics administered or
premature rupture of membranes
Interventions 10 IU up to 20 IU of oxytocin administered by an intravenous bolus (n = 102) versus
200 mcg ergometrine administered by an intravenous bolus (n = 34)
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Kikutani 2006 (Continued)
Outcomes The study recorded the following outcome: blood loss (mL).
Notes Contact with study authors for additional information: no. Additional data from authors:
no and data cannot be extracted for meta-analysis. Manuscript translated from Japanese
in full
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Methods of blinding were not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk Not reported.
Funding source Unclear risk Not reported.
Kumru 2005
Methods 2-arm active-controlled randomised trial.
Participants Between August 2003 and March 2004, 55 parturients were randomised in a hospital
setting in Turkey. The population comprised women of unspecified parity, a singleton
pregnancy, at high risk for PPH, who delivered by either elective or emergency caesarean.
Exclusion criteria comprised parturients with multiple pregnancy, hypertension or vas-
cular diseases
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Interventions 10 IU of oxytocin administered by an intravenous bolus plus infusion (n = 35) versus
200 mcg plus 10 IU of ergometrine plus oxytocin administered by an intravenous bolus
plus by intravenous bolus plus infusion (n = 20)
Outcomes The study recorded the following outcome: blood loss (mL).
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated intraoperative blood
loss byweighing compresses and rolls before
and after the birth of the baby, and calculat-
ing the difference between these measure-
ments. Pre-weighted pads were distributed
in advance to each mother, and collected at
intervals of 3-6 hours hour intervals after
the aspiration of amniotic fluid
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
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Funding source Unclear risk Source(s) of funding for the study were not
reported.
Kundodyiwa 2001
Methods 2-arm placebo-controlled randomised trial.
Participants Between October 1999 and February 2000, 500 parturients were randomised in a hos-
pital setting in Zimbabwe. The population comprised women of unspecified parity, a
singleton pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion
criteria comprised parturients undergoing instrumental delivery, or those with previous
PPH, antepartum haemorrhage, coagulopathy, multiple pregnancy, asthma or allergies
to prostaglandins or oxytocin
Interventions 400 mcg of misoprostol administered orally (n = 243) versus 10 IU of oxytocin admin-
istered intramuscularly (n = 256). There was 1 exclusion post randomisation but it was
unclear as to which group it was randomised to
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, manual removal of placenta, death, blood loss (mL)
, third-stage duration (min), nausea, vomiting, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using a com-
puter-generated random sequence
Allocation concealment (selection bias) Low risk The participantwas asked to randomly pick
a numbered sealed opaque envelope from
the study cooler-box
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Identical placebo tablets could not be ob-
tained from the manufacturers. The tablets
were similar in size and colour but not in
shape. However, most reviewed trials on
misoprostol had this similar problem al-
though this method of blinding proved to
be effective.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “The data sheet was completed by the mid-
wife supervising the delivery and collected
and checked by the research assistant.”
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Kundodyiwa 2001 (Continued)
Objective assessment of blood loss Low risk After delivery, investigators evaluated
blood loss by removing linen soiled with
amniotic fluid, and then placing a fresh
disposable incontinence pad with a plastic
backing under themother. Blood expressed
from the uterus was measured with a cali-
bratedmeasuring jug. The volume of blood
soiling linen savers and sanitary pads was
determined as the difference between dry
weights and soiled weights: these measure-
ments were added to the volume recorded
by the calibrated jug
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Data for 1 woman were excluded because
she delivered undiagnosed twins after ran-
domisation.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Lam 2004
Methods 2-arm active-controlled randomised trial.
Participants Between dates unspecified, 60 parturients were randomised in a hospital setting in China
(Hong Kong SAR). The population comprised women of unspecified parity, a singleton
pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients undergoing induction or augmentation of labour, or those with
antepartum haemorrhage, anaemia, 2 or more surgical terminations, previous manual
removal of placenta, previous PPH or previous third stage complications
Interventions 500 mcg plus 5 IU of ergometrine plus oxytocin administered by an intravenous bolus
(n = 30) versus 600 mcg of misoprostol administered sublingually (n = 30)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, manual removal of placenta, death, fever
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
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Lam 2004 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was allocated using a random
number-generated table
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss during
the third stage by visual estimation, and
by objective measurement on the basis of
a method previously described by Newton
et al. Whilst any blood clots were collected
and measured with a jug, white linen was
placed under the mother during delivery
and subsequently processed for 15 minutes
with sodium hydroxide solution in an au-
tomatic stomacher (laboratory blender), to
achieve the formation of alkaline hematin.
“The optical density at 550 nm of the alka-
line hematin was measured by spectropho-
tometry and comparedwith that of a known
volume of a sample of the patient’s venous
blood” to calculate the volume of blood loss
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk Itwas unclear from the study reportwhether
all those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Lapaire 2006
Methods 2-arm active-controlled double-blinded randomised trial.
Participants Between January 1999 and February 2002, 56 parturients were randomised in a hospital
setting in Switzerland. The population comprised women of unspecified parity, either
singleton ormultiple pregnancy, at high risk for PPH, who delivered by elective caesarean
section. Exclusion criteria comprised parturients undergoing emergency caesarean sec-
tion, or those with fetal distress, fetal malformations, pre-eclampsia, HELLP syndrome,
coagulopathy, severe systemic disorders, an American Society of Anaesthesiologists phys-
ical status of 3 or greater, severe asthma, previous myomectomy, pyrexia (more than 38.
5°C) or hypersensitivity to prostaglandins
Interventions 25 IU of oxytocin administered by an intravenous bolus plus infusion (n = 28) versus 800
mcg plus 5 IU of misoprostol plus oxytocin administered orally plus by an intravenous
bolus (n = 28)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, death, blood loss (mL), nausea, headache, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The hospital pharmacy performed the 1:
1 computer-generated randomisation that
assigned the participants to their group
Allocation concealment (selection bias) Low risk Investigators used identical study boxes
from pharmacy.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was “double-blind”: “the study
drugs and placebos [were provided by the
pharmacy] in unidentifiable form.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk When the membranes ruptured before de-
livery, investigators evaluated intraopera-
tive and postoperative blood loss by deter-
mining the difference in weight of cloths
and pads used to absorb blood during
surgery and in the intermediate care unit.
When membranes did not rupture preop-
eratively, investigators evaluated blood loss
by collection in suction bottles and sub-
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Lapaire 2006 (Continued)
tracting estimated amniotic fluid volume.
Investigators considered that 1 g is equiva-
lent to 1 mL of blood or amniotic fluid
Incomplete outcome data (attrition bias)
All outcomes
Low risk “3 patients in the oxytocin group were ex-
cluded from statistical analysis because of
errors in drug administration.” Moreover
calculated blood loss data were unavailable
in 13 cases and for these women the pri-
mary outcome was estimated clinically
Selective reporting (reporting bias) High risk The study protocol that was registered ret-
rospectively (ClinicalTrials.gov) lists PPH
as the primary outcome of the study, but
the study report lists the primary outcomes
as intraoperative and postoperative blood
loss and drug-related adverse effects (these
items are listed only as secondary outcomes
in the registration file). The study does not
report the incidence of PPH at 500 mL,
nor PPH at 1000 mL
Intention to treat analysis High risk The authors excluded 3 study participants
in the oxytocin group from the analysis be-
cause they incurred errors in drug admin-
istration
Funding source Low risk The study was supported by funding from
the Scientific Pool of Basel University Hos-
pital (the institution of the authors)
Leung 2006
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between July 2004 and March 2005, 329 parturients were randomised in a hospital
setting in Hong Kong. The population comprised women of parity 4 or less, a singleton
pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients requiring prophylactic oxytocin infusion, or those with pre-exist-
ing hypertension, pre-eclampsia, asthma, cardiac/renal/liver diseases, grand multiparity
or fibroids
Interventions 100 mcg of carbetocin administered intramuscularly (n = 165) versus 500 mcg plus 5
IU of ergometrine plus oxytocin administered intramuscularly (n = 164)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta, blood loss (mL), change in Hb
level, third-stage duration (min), nausea, vomiting, hypertension, headache, tachycardia,
shivering
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Leung 2006 (Continued)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using a com-
puter-generated code before recruitment
Allocation concealment (selection bias) Low risk This was performed by opening a sealed,
consecutively-numbered, opaque envelope
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss by visual
estimation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “15 women in the carbetocin group and 14
women in the syntometrine [ergometrine
plus oxytocin] group failed to have a paired
haemoglobin test to measure the change in
haemoglobin 48 hours after delivery either
because they had requested early home dis-
charge or refused.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study report
(cases of fever were omitted)
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source High risk The study was supported by funding from
Ferring Pharmaceuticals
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Lokugamage 2001
Methods 2-arm active-controlled randomised trial.
Participants Between dates unspecified, 40 parturients were randomised in a hospital setting in the
UK.The population comprisedwomen of unspecified parity, either singleton ormultiple
pregnancy, at high risk for PPH, who delivered by either elective or emergency caesarean.
Exclusion criteria comprised parturients with 2 or more previous caesarean sections or
previous uterine rupture
Interventions 10 IU of oxytocin administered by an intravenous bolus (n = 20) versus 500 mcg of
misoprostol administered orally (n = 20)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, blood loss (mL), change in Hb level, fever, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was undertaken by means
of computer-generated random numbers
Allocation concealment (selection bias) Low risk Investigators used sealed opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The obstetrician, surgical assistant, scrub
nurse and recovery midwife were blinded
to the treatment. The anaesthetist and the
anaesthetic assistant were not blinded as
it was important for patient safety that a
record was kept of all drugs administered.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators evaluated intraoperative and
postoperative (up to 1 hour) blood loss by
visual estimation “in a standard manner
(volume of blood in suction bottle plus soil-
ing of swabs and bed sheets).”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Lokugamage 2001 (Continued)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by “assistance”
from the Department of Anaesthesia at
University College London Hospitals NHS
Trust (the institution of the authors)
Lumbiganon 1999
Methods 3-arm active-controlled double-dummy randomised trial.
Participants Between dates unspecified, 597 parturients were randomised in a hospital setting in
South Africa and Thailand. The population comprised women of unspecified parity,
unspecified whether singleton or multiple pregnancy, at both high and low risk for PPH,
who delivered by vaginal delivery. Exclusion criteria comprised parturients undergoing
elective caesarean section or abortion, or those with asthma, other severe chronic allergic
conditions a contraindication to use of misoprostol or if they were not willing or able to
give informed consent
Interventions 600 mcg or 400 mcg of misoprostol administered orally (n = 397) versus 10 IU of
oxytocin administered intramuscularly (n = 200)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta, death, blood loss (mL), nausea,.
vomiting, fever, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random allocation sequence was gener-
ated centrally.
Allocation concealment (selection bias) Low risk The treatment packs were consecutively-
numbered and sealed.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”The packs were identical in shape, colour,
weight and feel. Each woman received an
injection and 3 tablets. Thus, the trial was
double-blinded using double placebos.“
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Lumbiganon 1999 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators evaluated blood loss from the
delivery of the baby until the mother was
transferred to postnatal care. The collected
blood was poured into a standard measur-
ing jar provided by WHO for the purpose
of volumetric measurement. Linen was not
weighed but clots and small gauze swabs
soaked with blood were included in the
measurement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusion after randomisation: “8 women
did not comply with treatment in the oxy-
tocin group (6 because of emergency cae-
sarean section, 1 was HIV positive (mis-
takenly excluded despite HIV sero-positiv-
ity not being an exclusion criterion), and
in another case the ampoule could not be
located in the treatment pack. There was 1
woman in the misoprostol 600 mcg group
whodidnot complywith the treatment, be-
cause the tablets could not be located after
the treatment pack was opened. Finally, in
the misoprostol 400 mcg group, 1 woman
had an emergency caesarean section after
the treatment pack was opened and could
not receive the allocated treatment.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the WHO (public funding). Active and
placebo medications, syringes and swabs
were donated by Searle, Novartis Pharma
AG and Becton Dickinson International
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Maged 2016
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between May 2013 and December 2014, 200 parturients were randomised in a hos-
pital setting in Egypt. The population comprised women of unspecified parity, either
singleton or multiple pregnancy, at high risk for PPH, who delivered by vaginal deliv-
ery. Exclusion criteria comprised parturients with placenta praevia, coagulopathy, pre-
eclampsia, cardiac/renal/liver disorders, epilepsy or known hypersensitivity to oxytocin
or carbetocin
Interventions 100 mcg of carbetocin administered intramuscularly (n = 100) versus 5 IU of oxytocin
administered intramuscularly (n = 100)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, blood loss (mL), change in Hb level, third-stage duration (min)
, nausea, vomiting, headache, tachycardia, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were equally randomised us-
ing an automated web-based randomisa-
tion system
Allocation concealment (selection bias) Unclear risk The study report states that investigators
ensured allocation concealment, but gives
no further details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss byweigh-
ing swabs and using pictorial charts
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Maged 2016 (Continued)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
McDonald 1993
Methods 2-arm active-controlled double-blinded randomised trial.
Participants Between 19th February 1990 and 20thOctober 1991, 3497 parturients were randomised
in a hospital setting in Australia. The population comprised women of unspecified
parity, unspecified whether singleton or multiple pregnancy, at both high and low risk
for PPH, who delivered by vaginal delivery. Exclusion criteria comprised parturients
undergoing emergency or elective caesarean section, or requiring general anaesthetic for
instrumental delivery, or those with hypertension in labour (more than 150/100 mmHg)
, antenatal hypertension, maternal distress, advanced stage in labour, language barrier,
fetal abnormality, intrauterine death or medical disorder
Interventions 500 mcg plus 5 IU of ergometrine plus oxytocin administered intramuscularly (n =
1730) versus 10 IU of oxytocin administered intramuscularly (n = 1753). There were
14 exclusions post randomisation but it was unclear from which group
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta, NNU admissions, breastfeeding,
nausea, vomiting
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The ampoules were numbered by Sandoz
using simple randomisation. There was no
blocking or prognostic stratification
Allocation concealment (selection bias) Low risk The ampoules were numbered by third
party (Sandoz).
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Delivery attendants were blinded to treat-
ment allocations.
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McDonald 1993 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the
estimation of attending obstetricians and
midwives
Incomplete outcome data (attrition bias)
All outcomes
Low risk “All women allocated to receive a drugwere
included in that group, excluding only the
14 women for whom drug allocation was
not recorded.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source High risk The study was supported by funding from
Sandoz.
Mitchell 1993
Methods 2-arm active-controlled double-blinded randomised trial.
Participants Between dates unspecified in 1984, 461 parturients were randomised in a hospital setting
in UK. The population comprised women of unspecified parity, either singleton or
multiple pregnancy, at both high and low risk for PPH, who delivered by vaginal delivery.
Exclusion criteria comprised parturients undergoing elective caesarean section, or those
with significant hypertension or cardiac disease
Interventions 500 mcg plus 5 IU of ergometrine plus oxytocin administered intramuscularly (n = 230)
versus 5 IU of oxytocin administered intramuscularly (n = 231)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, manual removal
of placenta, blood loss (mL), third-stage duration (min)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Mitchell 1993 (Continued)
Random sequence generation (selection
bias)
Unclear risk Unclear sequence: described as without any
blocking or stratification
Allocation concealment (selection bias) Low risk Investigators used identical study boxes
prepared by third party (Sandoz)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss “in the
standard way by graduated jug measure-
ment plus an allowance for spillage.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the Perinatal Trials Service (public funding)
, for theDepartment of Health for England
and Wales, and for Birthright (the charita-
ble arm of the RCOG). Coded medication
ampoules were provided by Sandoz
Mobeen 2011
Methods 2-arm placebo-controlled randomised trial.
Participants Between June 2006 and June 2008, 1119 parturients were randomised in a community
setting in Pakistan. The population comprised women of unspecified parity, a singleton
pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients with hypertension, non-cephalic presentation, polyhydramnios,
previous caesarean, multiple pregnancy, intrauterine death, antepartum haemorrhage or
Hb less than 80 g/L
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Mobeen 2011 (Continued)
Interventions 600 mcg of misoprostol administered orally (n = 534) versus placebo or control (n =
585)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
manual removal of placenta, death, blood loss (mL), change in Hb level, third-stage
duration (min), nausea, vomiting, headache, fever. shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated random code in
blocks of 6 was maintained by Gynuity
Health Projects in New York and not re-
vealed until data collection and cleaning
were completed
Allocation concealment (selection bias) Low risk Study medication was packed in numbered
colour-coded boxes by Gynuity Health
Projects in New York
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both women and TBAs were blinded to
study assignment.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk To evaluate postpartum blood loss, blood
was collectedwith a perineal sheet and bed-
pan placed under the mother for a min-
imum of 1 hour or until active bleeding
stopped (whichever occurred last). “Blood
collected in the bedpan was transferred to
a measuring jar, which was then closed,
and the perineal sheet and cotton roll were
placed in a sealed plastic bag. The closed
measuring jar and sealed plastic bag were
then placed inside a plastic cooler which
was tightly closed and stored in a secure
place in the woman’s home until the local
health visitor or community health nurse
arrived for weighing, 1-2 days after deliv-
ery.”
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Mobeen 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Invalid blood loss measures, whichmainly
occurred when monitoring visits were not
possible because of poor weather condi-
tions, were excluded from our analysis.”
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered (ClinicalTrials.gov
NCT00120237)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the Bill and Melinda Gates Foundation
(public funding)
Moertl 2011
Methods 2-arm active-controlled double-blinded randomised trial.
Participants Between January 2008 and July 2008, 84 parturients were randomised in a hospital set-
ting in Austria. The population comprised women of unspecified parity, a singleton preg-
nancy, at high risk for PPH, who delivered by elective caesarean section. Exclusion crite-
ria comprised parturients requiring general anaesthesia, or those with placenta praevia,
placental abruption, multiple pregnancy, pre-eclampsia, gestational diabetes, pre-exist-
ing insulin-dependent diabetes, cardiovascular/renal disorders, hypo-/hyperthyroidism
or women on cardiovascular system medications
Interventions 100 mcg of carbetocin administered by an intravenous bolus (n = 28) versus 5 IU of
oxytocin administered by an intravenous bolus (n = 28). There were 28 exclusions post
randomisation but it was unclear from which group
Outcomes The study recorded the following outcomes: additional uterotonics. change in Hb level,
nausea, headache
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by a com-
puter-generated randomisation sequence
in a 1:1 ratio with blocks of 10 and no strat-
ification
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Moertl 2011 (Continued)
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Study medication was double-blinded to
the clinical staff (obstetricians as well as
anaesthesiologists) and the technicians per-
forming the measurements.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Investigators did not evaluate blood loss.
Incomplete outcome data (attrition bias)
All outcomes
High risk After randomisation, investigators ex-
cluded 28 women from analysis for tech-
nical problems (n = 15), change to general
anaesthesia (n = 9), recording artefacts (n =
3) and patient withdrawal (n = 1)
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered (EudraCT 2007-
005498-78)
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Low risk CNSystems Medizintechnik AG in Graz,
Austria provided the Task Force®Monitor
3040i system used to measure haemody-
namic parameters. No other external fund-
ing was required for the study
Moir 1979
Methods 2-arm active-controlled randomised trial.
Participants Between dates unspecified, 88 parturients were randomised in a hospital setting in the
UK. The population comprised women of primigravidas, a singleton pregnancy, at low
risk for PPH, who delivered by vaginal delivery. Exclusion criteria were not specified
Interventions 500 mcg of ergometrine administered by an intravenous bolus (n = 44) versus 10 IU of
oxytocin administered by an intravenous bolus (n = 44)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, blood loss (mL)
, nausea
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
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Moir 1979 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by
“the haemoglobin extraction-dilution tech-
nique, which is acceptably accurate (Roe,
Gardiner and Dudley, 1962; Thornton et
al, 1963) and particularly suited to obstet-
ric use (Moir and Wallace, 1967; Wallace,
1967). The pedometer apparatus was used
and all blood and blood-stained linen were
collected.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Moodie 1976
Methods 2-arm active-controlled randomised trial.
Participants Between dates unspecified, 148 parturients were randomised in a hospital setting in the
UK. The population comprised women of unspecified parity, a singleton pregnancy, at
high risk for PPH, who delivered by vaginal delivery. Exclusion criteria were not specified
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Moodie 1976 (Continued)
Interventions 500 mcg of ergometrine administered by an intravenous bolus (n = 78) versus 5 IU of
oxytocin administered by an intravenous bolus (n = 70)
Outcomes The study recorded the following outcomes: PPH at 500, blood loss (mL), nausea
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by collec-
tion with the placenta bowl and soiled linen
and swabs. “The principles of the haemo-
globin extraction-dilution technique em-
ployed have been discussed by Roe, Gar-
diner and Dudley (1962) and Thornton
and colleagues (1963).”
Incomplete outcome data (attrition bias)
All outcomes
High risk There were 148 study participants but
blood loss data were available in only 80
cases
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Mukta 2013
Methods 2-arm active-controlled randomised trial.
Participants Between May 2010 and October 2011, 200 parturients were randomised in a hospital
setting in India. The population comprised women of unspecified parity, unspecified
whether singleton or multiple pregnancy, at both high and low risk for PPH, who deliv-
ered by vaginal delivery. Exclusion criteria comprised parturients undergoing emergency
or elective caesarean section, or those with eclampsia, asthma, epilepsy, cardiac/kidney
disorder or coagulopathy
Interventions 600 mcg of misoprostol administered orally (n = 100) versus 10 IU of oxytocin admin-
istered intramuscularly (n = 100)
Outcomes The study recorded the following outcomes: PPH at 500, additional uterotonics, nausea,
vomiting, fever, shivering, abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly divided into 2
equal groups.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Investigators evaluated blood loss in mL, by
collectionwith a calibrated plastic drape, af-
ter the drainage of amniotic fluid and de-
livery of the baby until the third stage of
labour was completed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
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analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Musa 2015
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between 1st January 2013 and 30th June 2013, 235 parturients were randomised in
a hospital setting in Nigeria. The population comprised women of parity 4 or less, a
singleton pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion
criteria comprised parturients undergoing planned instrumental, or those who received
oxytocin and/or misoprostol other than in the third stage of labour, or those with grand
multiparity (more than 4), multiple pregnancy, fibroids, polyhydramnios, pre-eclampsia,
eclampsia, hypertension, cardiac disorder, asthma, antepartum haemorrhage previous
PPH, prolonged rupture of membranes or Hb less than 100 g/L)
Interventions 600 mcg of misoprostol administered orally (n = 121) versus 10 IU of oxytocin admin-
istered intramuscularly (n = 114)
Outcomes The study recorded the following outcomes: PPH at 500, morbidity, additional utero-
tonics, manual removal of placenta, death, blood loss (mL), change in Hb level, third-
stage duration (min), nausea, vomiting, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation was blocked (restrictive), using
computer-generated random numbers pre-
pared by an independent statistician
Allocation concealment (selection bias) Unclear risk Investigators used opaque envelopes but no
other details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Participants, caregivers, and outcome as-
sessors (researchers or research assistants)
were masked to group allocation. Investi-
gators were not masked for data analysis.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Participants, caregivers, and outcome as-
sessors (researchers or research assistants)
were masked to group allocation. Investi-
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gators were not masked for data analysis.”
Objective assessment of blood loss Low risk Investigators evaluated blood loss by “the
gravimetric method” (Ambardekar 2009)
until 1 hour after delivery
Incomplete outcome data (attrition bias)
All outcomes
High risk 235 study participants were randomised
but only 200 were analysed due to protocol
deviations and missing data
Selective reporting (reporting bias) Unclear risk The study protocol was registered retro-
spectively (PACTR 201407000825227)
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Low risk The study was supported by funding from
the University of Ilorin Teaching Hospital
(the institution of the authors)
Nasr 2009
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between dates unspecified, 514 parturients were randomised in a hospital setting in
Egypt. The population comprised women of unspecified parity, a singleton pregnancy,
at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised
parturients undergoing caesarean section, or those with antepartum haemorrhage, coag-
ulopathy, hypertension in pregnancy or the need for anticoagulants
Interventions 800 mcg of misoprostol administered rectally (n = 257) versus 5 IU of oxytocin admin-
istered by an intravenous infusion (n = 257)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity, addi-
tional uterotonics, transfusion, manual removal of placenta, death, third-stage duration
(min), nausea, vomiting, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was allocated by a computer-
generated random allocation system cre-
ated at the Statistics Unit of Assiut Univer-
sity Hospital
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Allocation concealment (selection bias) Low risk Allocation codes were placed
in sealed, opaque, consecutively-numbered
envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was “double-blind”: active treat-
ments and placebo treatments were “iden-
tical-looking.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the es-
timation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were un-
clear.
Ng 2001
Methods 2-arm active-controlled randomised trial.
Participants Between June 1998 and February 1999, 2058 parturients were randomised in a hospital
setting in Hong Kong. The population comprised women of parity 3 or less, a single-
ton pregnancy, at both high and low risk for PPH, who delivered by vaginal delivery.
Exclusion criteria comprised parturients requiring oxytocin infusion in the third stage,
or those with pre-eclampsia, cardiac disorder, asthma, grand multiparity (more than 3),
fibroids or contraindications for the use of either misoprostol or syntometrine
Interventions 600 mcg of misoprostol administered orally (n = 1026) versus 500 mcg plus 5 IU of
ergometrine plus oxytocin administered intramuscularly (n = 1032)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, manual removal of placenta, death, blood loss (mL)
, change in Hb level, nausea, vomiting, hypertension, headache, fever, shivering
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Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwas based on a table of com-
puter-generated blocks of random numbers
Allocation concealment (selection bias) Low risk Allocation was placed in consecutively-
numbered opaque sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “This was not a double-blinded study.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment al-
locations.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the es-
timation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Ng 2007
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between April 2000 and January 2001, 360 parturients were randomised in a hospital
setting in Hong Kong. The population comprised women of parity 3 or less, a singleton
pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients requiring oxytocin infusion in the third stage, or those with pre-
eclampsia, cardiac disorder, asthma, grand multiparity (more than 3), fibroids or con-
traindications for the use of either misoprostol or syntometrine
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Interventions 400 mcg of misoprostol administered orally (n = 178) versus 500 mcg plus 5 IU of
ergometrine plus oxytocin administered intramuscularly (n = 177). There were 5 exclu-
sions post randomisation but it was unclear from which group
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, manual removal of placenta, death, blood loss (mL)
, change in Hb level, nausea, vomiting, hypertension, headache, fever, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was based on a table of
computer-generated random numbers
Allocation concealment (selection bias) Low risk Investigators used consecutively-numbered
and sealed opaque packages
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The placebo was identical in size and
colour but had a different shape to the
misoprostol tablet. All women were asked
to swallow the tablets directly from the
opaque cup without looking at them.
The identity of the active medication and
placebo were concealed from the caregivers
and the parturient.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the es-
timation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk “5 women were excluded from the analy-
sis because of missing post-delivery haemo-
globin level.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study report
(cases of tachycardia and dizziness were
omitted)
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Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Nirmala 2009
Methods 2-arm active-controlled randomised trial.
Participants Between dates unspecified, 120 parturients were randomised in a hospital setting in
Malaysia. The population comprised women of unspecified parity, either singleton or
multiple pregnancy, at high risk for PPH, who delivered by vaginal delivery. Exclusion
criteria comprised parturients younger than 18 years old, or those with cardiac disor-
der, hypertension requiring treatment, liver/renal/vascular/endocrine disorder (exclud-
ing gestational diabetes) or hypersensitivity to oxytocin or carbetocin
Interventions 100 mcg of carbetocin administered intramuscularly (n = 60) versus 500 mcg plus 5 IU
of ergometrine plus oxytocin administered intramuscularly (n = 60)
Outcomes The study recorded the following outcomes: PPH at 500, morbidity, additional utero-
tonics, transfusion, manual removal of placenta, death, blood loss (mL), change in Hb
level, nausea, vomiting, hypertension, headache, shivering, abdominal pain
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was computer-gener-
ated.
Allocation concealment (selection bias) Unclear risk Investigators used sealed, sequentially-
numbered envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The preparation and administration of the
medication was carried out by midwives
who were not involved in the management
of the patient except for the drug adminis-
tration.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
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Objective assessment of blood loss Low risk Investigators evaluated blood loss by “the
gravimetric method” from immediately af-
ter drug administration. They used a digi-
tal scale (Soehnle, Venezia) for weight mea-
surement. In order to minimise confound-
ing by fluid absorbed into drapes, they col-
lected blood with a new plastic sheet placed
under the mother after delivery of the baby.
They also weighed any gauzes, tampons and
pads used in the first hour after delivery of
the placenta, and subtracted the dry weights
of these materials to calculate blood loss on
the basis that 1 g is equivalent to 1 mL
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Nordstrom 1997
Methods 2-arm placebo-controlled randomised trial.
Participants Between16thDecember 1993 and6thOctober 1994, 1000 parturientswere randomised
in a hospital setting in Sweden. The population comprised women of unspecified parity,
a singleton pregnancy, at both high and low risk for PPH, who delivered by vaginal
delivery. Exclusion criteria were not specified
Interventions 10 IU of oxytocin administered by an intravenous bolus (n = 513) versus placebo or
control (n = 487)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional utero-
tonics, transfusion, manual removal of placenta, blood loss (mL), third-stage duration
(min)
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was computer-gener-
ated.
Allocation concealment (selection bias) Low risk Ampoules were prepared at the hospital
pharmacy and consecutively-numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The content of the ampullaswas unknown
tomothers, midwives and doctors until the
study was completed.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss “by mea-
suring collected blood and addingwhat was
estimated to have been absorbed by surgi-
cal cloths and tissues.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding
from the County Council and County
Health Authority Research and Devel-
opment Foundation in the County of
Jämtland, Sweden (public funding)
Oboro 2003
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between August 2000 and July 2001, 496 parturients were randomised in a hospital
setting in Nigeria. The population comprised women of parity 4 or less, a singleton
pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients undergoing induction or augmentation of labour, or those with
previous caesarean, Hb less than 80 g/L, previous PPH, grand multiparity (not defined)
, multiple pregnancy, polyhydramnios, fibroids or precipitate labour
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Interventions 10 IU of oxytocin administered intramuscularly (n = 249) versus 600 mcg of misoprostol
administered orally (n = 247)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta, death, blood loss (mL), change in
Hb level, third-stage duration (min), nausea, vomiting, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwas achievedusing random
tables.
Allocation concealment (selection bias) Low risk Pharmacy prepared opaque sealed sequen-
tially-numbered packets
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The identity of the active medication and
placebo were concealed from the caregivers
and parturients.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the es-
timation of attending obstetricians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Methods 3-arm active-controlled randomised trial.
Participants Between dates unspecified, 144 parturients were randomised in a hospital setting in
Nigeria. The population comprised women of unspecified parity, a singleton pregnancy,
at both high and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients undergoing instrumental delivery, or those with previous PPH,
multiple pregnancy, polyhydramnios or vaginal lacerations
Interventions 200 mcg or 500 mcg of ergometrine administered intramuscularly (n = 96) versus 500
mcg plus 5 IU of ergometrine plus oxytocin administered intramuscularly (n = 48)
Outcomes The study recorded the following outcomes: PPH at 500, manual removal of placenta,
blood loss (mL)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Investigators performed restricted random
allocation.
Allocation concealment (selection bias) Unclear risk Investigators used sealed sequentially-num-
bered envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The identity of the various drugs was not
known to the investigators until after com-
pletion of the trial.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators evaluated blood loss by collec-
tion in a dish pressed against the vulva for
3 minutes: the contents were carefully mea-
sured
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
262Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ogunbode 1979 (Continued)
randomised
Funding source High risk The study was supported by funding from
Sandoz.
Orji 2008
Methods 2-arm active-controlled randomised trial.
Participants Between January 2006 and September 2007, 600 parturients were randomised in a hos-
pital setting in Nigeria. The population comprised women of parity 6 or less, unspecified
whether singleton or multiple pregnancy, at both high and low risk for PPH, who deliv-
ered by vaginal delivery. Exclusion criteria comprised parturients undergoing caesarean
section, or those with hypertension in pregnancy, packed cell volume less than 30%,
previous PPH, haemoglobinopathy or cardiac disorder
Interventions 10 IU of oxytocin administered by an intravenous bolus (n = 297) versus 250 mcg of
ergometrine administered by an intravenous bolus (n = 303)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, manual removal of placenta, blood loss (mL), change in Hb level, third-
stage duration (min), nausea, vomiting, hypertension, headache
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation was done by sealed sequentially-
numbered envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Investigators evaluated blood loss by “using
a pre-weighed gauze that was weighed again
after delivery.”
263Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Orji 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study report
(cases of transfusion and PPH at least 1000
mL were omitted)
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Ortiz-Gomez 2013
Methods 3-arm active-controlled randomised trial.
Participants Between dates unspecified, 156 parturients were randomised in a hospital setting in
Spain. The population comprised women of unspecified parity, a singleton pregnancy,
at high risk for PPH, who delivered by elective caesarean section. Exclusion criteria com-
prised parturients with comorbidities, refractory hypotension due to neuraxial blockage,
vasoactive drugs needed to control haemodynamic issues or multiple pregnancy
Interventions 100 mcg of carbetocin administered by an intravenous bolus (n = 52) versus 61 IU of
oxytocin administered by an intravenous bolus plus infusion (n = 104)
Outcomes The study recorded the following outcomes: additional uterotonics, nausea, vomiting,
headache, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using a com-
puter-generated sequence
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Investigators evaluated blood loss by the es-
timation of delivery attendants, but blood
loss data were not reported in a format way
that could be extracted for the purpose of
this review
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Owonikoko 2011
Methods 2-arm active-controlled randomised trial.
Participants Between June 2006 and April 2007, 100 parturients were randomised in a hospital set-
ting in Nigeria. The population comprised women of unspecified parity, a singleton
pregnancy, at high risk for PPH, who delivered by either elective or emergency cae-
sarean. Exclusion criteria comprised parturients requiring general anaesthesia, or those
with multiple pregnancy, placenta praevia, antepartum haemorrhage, cardiac/renal/liver
disorders, coagulopathy, asthma, glaucoma, pre-eclampsia, eclampsia, prolonged labour
or contraindications to administration of prostaglandins
Interventions 20 IU of oxytocin administered by an intravenous infusion (n = 50) versus 400 mcg of
misoprostol administered sublingually (n = 50)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional utero-
tonics, transfusion, blood loss (mL), change in Hb level, nausea, vomiting, headache,
hypotension, shivering
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Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The treatment allocation sequence was de-
veloped by a statistician who was not oth-
erwise involved with the study using com-
puter-generated table of random numbers
and varied permutated blocks
Allocation concealment (selection bias) Low risk Investigators used sealed, opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The anaesthetist was blind to the alloca-
tion until he opened each participant’s en-
velope at surgery… The obstetricians were
unaware of what oxytocic was given as the
faces of the patients were screened off dur-
ing the surgery.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “The obstetricians were unaware of what
oxytocic was given as the faces of the pa-
tients were screened off during the surgery.
”
Objective assessment of blood loss Low risk Investigators evaluated blood loss by col-
lection in a suction bottle, and by weigh-
ing delivery drapes and gauzes on the ba-
sis that 1 g is equivalent to 1 mL of
blood. “Both the surgeon and anaesthetist
estimated blood loss independently... The
scrub nurse weighed the drapes and gauze
before and after the operation, noted the
amount of blood in the suction bottle,
and recorded these... The postoperative care
nurse also recorded the blood loss during the
first 4 hours after surgery.” Finally a research
assistant (not part of the medical team) cal-
culated the mean estimated blood loss from
all these values
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
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Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Parsons 2006
Methods 2-arm active-controlled randomised trial.
Participants Between April 2002 and October 2002, 450 parturients were randomised in a hospital
setting in Ghana. The population comprised women of unspecified parity, either single-
ton or multiple pregnancy, at both high and low risk for PPH, who delivered by vaginal
delivery. Exclusion criteria comprised parturients with asthma, epilepsy or contraindi-
cations to prostaglandins
Interventions 10 IU of oxytocin administered intramuscularly (n = 225) versus 800 mcg of misoprostol
administered orally (n = 225)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, manual removal of placenta, death, blood loss (mL)
, change in Hb level, third-stage duration (min), nausea, vomiting, hypertension, fever,
shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The treatment allocation was computer-
generated.
Allocation concealment (selection bias) Low risk Investigators used sequentially-numbered,
opaque, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “We acknowledge that unblinding for some
participants was possible because the en-
velopes for women who were initially ran-
domised but who subsequently underwent
caesarean section were returned and used
for the next women enrolled.”
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Parsons 2006 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the es-
timation of attending physicians and mid-
wives
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
Matercare International and the Society
of Obstetricians and Gynaecologists of
Canada (public funding)
Parsons 2007
Methods 2-arm active-controlled randomised trial.
Participants Between April 2002 and December 2002, 450 parturients were randomised in a hos-
pital setting in Ghana. The population comprised women of unspecified parity, either
singleton or multiple pregnancy, at both high and low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised parturients with asthma, epilepsy or con-
traindications to prostaglandins
Interventions 10 IU of oxytocin administered intramuscularly (n = 226) versus 800 mcg of misoprostol
administered rectally (n = 224)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, manual removal of placenta, death, blood loss (mL)
, change in Hb level, third-stage duration (min), nausea, vomiting, hypertension, fever,
shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Parsons 2007 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Low risk Investigators used sequentially-numbered,
opaque, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Unblinding for some participants was pos-
sible because the envelopes for women who
were initially randomised but who subse-
quently underwent caesarean section were
returned and used for the next women en-
rolled.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the es-
timation of attending physicians and mid-
wives
Incomplete outcome data (attrition bias)
All outcomes
Low risk Estimated blood loss data were unavailable
in 9 cases (misoprostol 7; oxytocin 2) and
Hb measurements (misoprostol 4; oxytocin
6) were unavailable in 10 cases
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
Matercare International and the Society
of Obstetricians and Gynaecologists of
Canada (public funding)
Penaranda 2002
Methods 3-arm active-controlled randomised trial.
Participants Between29thOctober 2000 and6thNovember 2000, 78 parturientswere randomised in
a hospital setting inColombia. The population comprisedwomen of unspecified parity, a
singleton pregnancy, at both high and low risk for PPH,who delivered by vaginal delivery.
Exclusion criteria comprised parturients with asthma, multiple pregnancy, intrauterine
death, coagulopathy, cervical tear or water in the blood collector
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Penaranda 2002 (Continued)
Interventions 50 mcg of misoprostol administered sublingually (n = 25) versus 16 mLU/min of oxy-
tocin administered by an intravenous infusion (n = 25) versus 200 mcg of ergometrine
administered intramuscularly (n = 25). There were 3 exclusions post randomisation but
it was unclear from which group
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, blood loss (mL)
, third-stage duration (min), vomiting, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Investigators evaluated blood loss from cord
clamping until 1 hour after delivery
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 women were excluded from the analysis
after entering the study: “se excluyeron 3
pacientes por obito fetal, desgarro de cervix
severo, vertimiento de agua en el recipiente
recolector de sangre.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Prendiville 1988
Methods 2-arm controlled randomised trial.
Participants Between 1st January 1986 and 31st January 1987, 1695 parturients were randomised in
a hospital setting in the UK. The population comprised women of unspecified parity, a
singleton pregnancy, at both high and low risk for PPH,who delivered by vaginal delivery.
Exclusion criteria comprised parturients with cardiac disorder, antepartum haemorrhage,
non-cephalic presentation, multiple pregnancy, intrauterine death but after change in
the protocol multiple other exclusion criteria were introduced
Interventions 500 mcg plus 5 IU of ergometrine plus oxytocin administered intramuscularly (n = 846)
versus of placebo or control (n = 849)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional utero-
tonics, transfusion, manual removal of placenta, change in Hb level, NNU admissions,
breastfeeding, vomiting, headache
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was not re-
ported.
Allocation concealment (selection bias) Low risk Investigators used sequentially-numbered,
opaque, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not blinded
to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the estima-
tion of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All those who were enrolled and randomly allo-
cated to treatment were included in the analysis,
in the groups to which they were randomised
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Prendiville 1988 (Continued)
Funding source Low risk The study was supported by funding from the
South Western Regional Health Authority of the
United Kingdom (public funding)
Rajaei 2014
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between dates unspecified, 400 parturients were randomised in a hospital setting in
Iran. The population comprised women of unspecified parity, a singleton pregnancy, at
both high and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients with placenta praevia, placental abruption, coagulopathy, previous
caesarean, macrosomia (more than 4 kg), polyhydramnios or uncontrolled asthma
Interventions 20 IU of oxytocin administered by an intravenous infusion (n = 200) versus 400 mcg of
misoprostol administered orally (n = 200)
Outcomes The study recorded the following outcomes: additional uterotonics, transfusion, blood
loss (mL), change in Hb level, hypotension, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was allocated using simple
randomisation with computer-generated
numbers in a 1:1 ratio
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was “double-blind”: “for blind-
ing the study, identical-appearing solutions
and tablets corresponding to the 2 pharma-
cological groupswere prepared by the phar-
macy and kept in the fridge until required.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Investigators evaluated blood loss during
the first hour after delivery, by collection
with pads weighed before and after ab-
sorbance of blood
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Rajaei 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Low risk The study protocol was registered (Clini-
calTrials.govNCT01863706) but not all of
the outcomes projected by methodological
descriptions were reported as results in the
study report (cases of diarrhoea, nausea and
vomiting were not completely reported)
. Moreover, the study publication reports
outcomes (hypotension, nausea, transfu-
sion) not listed in the registered protocol
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the Hormozgan University of Medical Sci-
ences (the institution of the authors)
Ramirez 2001
Methods 3-arm controlled randomised trial.
Participants Between dates unspecified, an unspecified number of parturients were randomised in an
unspecified setting and country. The population comprised primiparous women, with
singleton pregnancy, at both high and low risk for PPH,who delivered by vaginal delivery.
Exclusion criteria comprised parturients that were multiparous, severely anaemic, and
hypertensive conditions during pregnancy
Interventions 5 IU of oxytocin administered by an intravenous bolus versus 200 mcg ergometrine
administered by an intravenous bolus vs placebo or control
Outcomes The study recorded the following outcome: Change in Hb level
Notes Contact with study authors for additional information: no. Additional data from authors:
no. Abstract only available and data provided could not be used for meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was not re-
ported.
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Ramirez 2001 (Continued)
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Methods of blinding were not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Unclear risk Not reported.
Funding source Unclear risk Not reported.
Rashid 2009
Methods 2-arm active-controlled randomised trial.
Participants Between January 2003 and December 2003, 686 parturients were randomised in a hos-
pital setting in Saudi Arabia. The population comprised women of unspecified parity, a
singleton pregnancy, at both high and low risk for PPH, who delivered by vaginal deliv-
ery. Exclusion criteria comprised parturients undergoing caesarean section or requiring
oxytocin infusion in the third stage, or those with pre-eclampsia, cardiac disorder, hyper-
tension on treatment, antepartum haemorrhage, pre-term labour (less than 37 weeks),
post maturity (more than 42 weeks) or Hb less or equal to 90 g/L
Interventions 500 mcg plus 5 IU of ergometrine plus oxytocin administered intramuscularly (n = 340)
versus 10 IU of oxytocin administered by an intravenous infusion (n = 346)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional utero-
tonics, transfusion, manual removal of placenta, blood loss (mL), third-stage duration
(min), nausea, vomiting headache
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Rashid 2009 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using com-
puter-generated random numbers
Allocation concealment (selection bias) Unclear risk Investigators used sequentially-numbered,
sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment al-
locations.
Objective assessment of blood loss Low risk Investigators evaluated blood loss “clinically
in a standard way” by collection with a
plastic sheet that was subsequently drained
(with clots) into a graduated measuring jug,
and by weighing swabs and towels. “Any
delayed haemorrhage within 24 hours after
delivery was calculated.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data were collected completely
from all randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study report
(cases of requirement for additional syn-
tometrine [ergometrine plus oxytocin] were
omitted)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Ray 2001
Methods 2-arm active-controlled randomised trial.
Participants Betweendates unspecified, 200parturientswere randomised in a hospital setting in India.
The population comprised women of unspecified parity, a singleton pregnancy, at both
high and low risk for PPH,whodelivered by vaginal delivery. Exclusion criteria comprised
275Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ray 2001 (Continued)
parturients undergoing elective caesarean section, or those with pre-term labour (less
than 32 weeks), prolonged labour, antepartum haemorrhage, pre-eclampsia, intrauterine
death, multiple pregnancy, epilepsy, asthma, cardiac/kidney disorder, coagulopathy or
anaemia
Interventions 400 mcg of misoprostol administered orally (n = 100) versus an unspecified dose of
ergometrine administered by an unspecified injectable method (n = 100)
Outcomes The study recorded the following outcomes: additional uterotonics, transfusion, manual
removal of placenta, hypertension
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Investigators evaluated blood loss in the first
2 hours after delivery of the placenta, by
“clinical estimation.” However, blood loss
data were not reported in a format that
could be extracted for the purpose of this
review
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study report
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
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Ray 2001 (Continued)
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Reyes 2011a
Methods 2-arm active-controlled randomised trial.
Participants Between August 2008 and August 2009, 144 parturients were randomised in a hospital
setting in Panama. The population comprised women of parity 5 or more, a singleton
pregnancy, at high risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients undergoing emergency caesarean section, or those with coagu-
lopathy, unknown parity or known allergy to carbetocin
Interventions 100 mcg of carbetocin administered by an intravenous bolus (n = 45) versus 20 IU of
oxytocin administered by an intravenous infusion (n = 90). There were 9 exclusions post
randomisation but it was unclear from which group
Outcomes The study recorded the following outcomes: additional uterotonics, transfusion, manual
removal of placenta, breastfeeding, nausea, vomiting. Headache. Shivering. Abdominal
pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Low risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
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Reyes 2011a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk ”Se pudieron reclutar 144 pacientes, en
quienes se dio la aleatorización en dos
grupos (carbetocina:oxitocina) en una pro-
porción 1:2. Cualquier causal de falla en el
seguimiento del protocolo establecido obli-
gaba a la exclusión de la paciente del estudio
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study report
(cases of PPH were omitted)
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Unclear risk Ferring Pharmaceuticals donated carbe-
tocin. No other external funding was re-
quired for the study
Reyes 2011b
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between July 2010 and September 2010, 57 parturients were randomised in a hospital
setting in Panama. The population comprised women of unspecified parity, a singleton
pregnancy, at high risk for PPH, who delivered by both caesarean and vaginal delivery.
Exclusion criteria comprised parturients with HELLP syndrome, blood dyscrasia or
multiple pregnancy
Interventions 100 mcg of carbetocin administered by an intravenous bolus (n = 26) versus 10 IU of
oxytocin administered by an intravenous infusion (n = 29). There were 2 exclusions post
randomisation but it was unclear from which group
Outcomes The study recorded the following outcomes: additional uterotonics, transfusion, change
in Hb level, third-stage duration (min), breastfeeding. Vomiting. Headache. Fever
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The randomisation was computer-gener-
ated.
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Reyes 2011b (Continued)
Allocation concealment (selection bias) Unclear risk Investigators used opaque, sealed en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study was “double-blind”: “because
the 2 drugs are administered differently, a
double dummy system for administration
was used.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 women were excluded from the study
analysis after randomisation (“1 given drug
before expulsion of placenta; 1 ampoule of
the drug broken before use”)
Selective reporting (reporting bias) High risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Those who withdrew from the study af-
ter randomisation were not included in the
analysis
Funding source Low risk Source(s) of funding for the study were not
reported.
Rogers 1998
Methods 2-arm controlled randomised trial.
Participants Between June 1993 and December 1995, 1512 parturients were randomised in a hospi-
tal setting in the UK. The population comprised women of parity 5 or less, a singleton
pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients undergoing augmentation of labour or instrumental delivery or
requiring epidural analgesia, or those with placenta praevia, previous PPH, antepartum
haemorrhage, Hb less than 100 g/L or mean corpuscular volume less than 75 fL, non-
cephalic presentation, multiple pregnancy, intrauterine death, grand multiparity (more
than 5), fibroids, anticoagulation therapy, pre-term labour (less than 32 weeks) or con-
traindications to any of the drugs
Interventions An unspecified dose of ergometrine plus oxytocin administered by an unspecified route
(n = 748) versus placebo or control (n = 764)
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Rogers 1998 (Continued)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000.,Aaditional
uterotonics, transfusion, manual removal of placenta, blood loss (mL), change in Hb
level, third-stage duration (min), NNU admissions, breastfeeding, nausea, vomiting,
headache
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation schedule used variably sized
balanced blocks, and the randomisation envelopes
were prepared in advance in theNational Perinatal
Epidemiology Unit (NEPU)
Allocation concealment (selection bias) Low risk Investigators used sequentially-numbered,
opaque, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not blinded
to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the estima-
tion of attending midwives
Incomplete outcome data (attrition bias)
All outcomes
Low risk Blood loss data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All those who were enrolled and randomly allo-
cated to treatment were included in the analysis,
in the groups to which they were randomised
Funding source Low risk The study was supported by funding from the
PublicHealth andOperational ResearchCommit-
tee of the Anglia and Oxford Regional Health Au-
thority, UK (public funding)
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Rosseland 2013
Methods 3-arm placebo-controlled randomised trial.
Participants Between November 2009 and September 2011, 76 parturients were randomised in a
hospital setting in Norway. The population comprised women of unspecified parity, a
singleton pregnancy, at high risk for PPH, who delivered by elective caesarean section.
Exclusion criteria comprised parturients with pre-eclampsia, placenta praevia, placenta
accreta, vonWillebrand disease or other bleeding disorder or preoperative systolic arterial
pressure less than 90 mmHg
Interventions 5 IU of oxytocin administered by an intravenous bolus (n = 26) versus 100 mcg of
carbetocin administered by an intravenous bolus (n = 25) versus placebo or control (n =
25)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, blood loss (mL), change in Hb level, headache
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was allocated by a computer-
generated list of random numbers. The
block size varied between 6 and 9, with
stratification into 2 strata: BMI less than
30 and BMI of 30 or more
Allocation concealment (selection bias) Low risk Investigators used sequentially-numbered,
opaque, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was “double-blinded”: “tomain-
tain blinding of the participants and in-
vestigators, the test medicine was delivered
to the Department of Anaesthesiology in
10 mL syringes containing 5 mL of solu-
tion marked only with trial identification
and randomisation numbers. The 10 mL
syringes with the test medicines were pre-
pared by a staff anaesthesiologist, who was
otherwise uninvolved in the study.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
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Rosseland 2013 (Continued)
Objective assessment of blood loss High risk Investigators evaluated blood loss with the
following formula: (0.75 x height in inches
x 50) plus (weight in pounds x 50) x ((pre-
delivery haematocrit measurement - post-
delivery haematocrit measurement)/prede-
livery haematocrit measurement)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered (ClinicalTrials.gov
NCT00977769)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source High risk The study was supported by funding from
Ferring Pharmaceuticals
Rozenberg 2015
Methods 2-arm placebo-controlled randomised trial.
Participants Between dates unspecified, 1721 parturients were randomised in a hospital setting in
France. The population comprised women of unspecified parity, unspecified whether
singleton or multiple pregnancy, at both high and low risk for PPH, who delivered by
vaginal delivery. Exclusion criteria comprised parturients undergoing emergency cae-
sarean section, or those with known hypersensitivity to prostaglandins
Interventions 400 mcg plus 10 IU of misoprostol plus oxytocin administered orally plus by an intra-
venous bolus (n = 863) versus 10 IU of oxytocin administered by an intravenous bolus
(n = 857)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, death, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
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Rozenberg 2015 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “The study excluded 57 women from the
misoprostol group and 61 from the placebo
group because they had caesareans.” The
study report did not specify whether exclu-
sions occurred before or after randomisa-
tion
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors excluded 119 study partici-
pants from the analysis because they expe-
rienced caesarean deliveries: it was unclear
from the study report whether these exclu-
sions occurred before or after randomisa-
tion
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Sadiq 2011
Methods 2-arm active-controlled randomised trial.
Participants Between November 2009 and September 2011, 1865 parturients were randomised in a
hospital setting in Nigeria. The population comprised women of parity 6 or less, a single-
ton pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients undergoing instrumental delivery, or those with diabetes, non-
cephalic presentation, anaemia, antepartum haemorrhage, multiple pregnancy, grand
multiparity (more than 6) or known allergy
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Sadiq 2011 (Continued)
Interventions 10 IU of oxytocin administered by an intravenous bolus (n = 900) versus 600 mcg of
misoprostol administered orally (n = 900)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, blood loss (mL), change in Hb level
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random assignments were generated by
dice-box.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators evaluated blood loss at deliv-
ery by collection with pre-calibrated kidney
dishes
Incomplete outcome data (attrition bias)
All outcomes
Low risk ”46 of the administered questionnaires were
invalidated leaving a total of 1819 valid
questionnaires (912 for oxytocin and 907
for misoprostol). The data were further re-
duced through a process of computer ran-
domisation so as to have [an] equal study
population in the 2medication groups: oxy-
tocin group (900 subjects) and misoprostol
group (900 subjects)”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Low risk The study was supported by funding from
the University of Maiduguri Teaching Hos-
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pital. Study medications were donated by
Emzor Pharmaceutical Industries
Samimi 2013
Methods 2-arm active-controlled double-blinded randomised trial.
Participants BetweenMarch 2011 and June 2011, 216 parturients were randomised in a hospital set-
ting in Iran. The population comprised women of parity 4 or less, a singleton pregnancy,
at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised
parturients with hypertension, pre-eclampsia, uterine rupture, cervical tear, asthma, car-
diovascular/renal/liver disorders, grand multiparity (not defined), fibroids or previous
PPH
Interventions 100 mcg of carbetocin administered intramuscularly (n = 109) versus 200 mcg plus 5
IU of ergometrine plus oxytocin administered intramuscularly (n = 107)
Outcomes The study recorded the following outcomes: morbidity, additional uterotonics, death,.
change in Hb level, nausea, vomiting, tachycardia, hypotension, shivering, abdominal
pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed using a ran-
dom number table.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients and medical personnel were
blinded to the type of drug.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk At 24 hours postpartum, blood samples
could not be collected from 16 women (9
in the carbetocin group and 7 in the er-
gometrine plus oxytocin group)
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Samimi 2013 (Continued)
Selective reporting (reporting bias) Low risk The study report matches the study proto-
col that was registered (Iranian registry of
clinical trials number 138810212854N2)
Intention to treat analysis High risk The authors excluded 16 study participants
from the analysis because postpartum Hb
measurements were not available
Funding source Unclear risk The study was supported by funding from
the Kashan University of Medical Sciences
(the institution of the authors)
Shrestha 2011
Methods 2-arm active-controlled randomised trial.
Participants Between 1st September 2009 and 28th February 2010, 200 parturients were randomised
in a hospital setting in Nepal. The population comprised women of unspecified parity,
a singleton pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion
criteria comprised parturients with polyhydramnios, chorioamnionitis, preterm labour,
previous caesarean, asthma, cardiac disorder or contraindication/hypersensitivity to the
use of prostaglandin and uterotonics
Interventions 1000 mcg of misoprostol administered rectally (n = 100) versus 10 IU of oxytocin
administered intramuscularly (n = 100)
Outcomes The study recorded the following outcomes: PPH at 500, morbidity, death, blood loss
(mL), change in Hb level, third-stage duration (min), fever, abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was randomly allocated as per
the lottery technique
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
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Objective assessment of blood loss Low risk Investigators evaluated blood loss in the
48 hours postpartum, by collection with
pre-weighed sterile pads and a calibrated
bucket. All the soaked drapes and pads were
weighed and the dry weights of these mate-
rials were subtracted to calculate blood loss
on the basis that 1 g is equivalent to 1 mL
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Singh 2009
Methods 4-arm active-controlled double-dummy randomised trial.
Participants Between dates unspecified, 300 parturients were randomised in a hospital setting in
India. The population comprised women of unspecified parity, a singleton pregnancy,
at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised
parturients undergoing augmentation of labour, or those with intrauterine death, an-
tepartum haemorrhage, multiple pregnancy, malpresentation, cardiac disorder, rhesus-
negative mother, hypertension, Hb less than 70 g/L or hypersensitivity/contraindication
to prostaglandins
Interventions 400 mcg or 600 mcg of misoprostol administered sublingually (n = 150) versus 5 IU of
oxytocin administered by an intravenous bolus (n = 75) versus 200 mcg of ergometrine
administered by an intravenous bolus (n = 75)
Outcomes The study recorded the following outcomes: PPH at 500, additional uterotonics, trans-
fusion, manual removal of placenta, blood loss (mL), third-stage duration (min), fever,
shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Drug packets were sealed and coded by the
same individual using a computer-gener-
ated random number chart
Allocation concealment (selection bias) Unclear risk Investigators used sealed drug packets.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was “double-blind”: active treat-
ments and placebo treatments were “iden-
tical” and investigators were “thus blinded.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators removed any linen soiled with
amniotic fluid, and placed a disposable and
absorbent pre-weighed linen saver sheet
with a pre-weighed polythene bag under
the mother to collect blood from the uter-
ine cavity. Any blood clots were expressed
from the vagina into the polythene bag,
which was then removed and weighed. A
fresh pre-weighed sanitary napkin was ap-
plied. Separate swabs were not included in
the final calculation (addition of the various
gravimetric measurements), that was per-
formed 1 hour after delivery. “The specific
gravity of blood being 1.08, the amount of
blood lost in mL was equal to the weight
in grams.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study re-
port (changes in Hb measurements were
unspecified beyond textual summary that
“all groups showed a slight decrease inmean
haemoglobin concentration 24 hours post-
partum [maximum decrease of 0.6 g/dL];
however, the difference was not significant
[ANOVA, P > 0.05]”)
288Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Singh 2009 (Continued)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Soltan 2007
Methods 4-arm active-controlled randomised trial.
Participants Between April 2002 and February 2003, 1200 parturients were randomised in a hospital
setting in Egypt. The population comprised women of unspecified parity, a singleton
pregnancy, at both high and low risk for PPH, who delivered by vaginal delivery. Exclu-
sion criteria comprised parturients undergoing caesarean section, or those with traumatic
PPH, blood disorders, chorioamnionitis, placenta praevia or placental abruption
Interventions 200 mcg of ergometrine administered intramuscularly (n = 300) versus 600 mcg to 1000
mcg of misoprostol administered sublingually (n = 900)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, manual removal of placenta, death, blood loss (mL)
, change in Hb level, third-stage duration (min), vomiting, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was computer-gener-
ated.
Allocation concealment (selection bias) Low risk Investigators used opaque, closed en-
velopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessor blinding was not reported.
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Objective assessment of blood loss Low risk Investigators evaluated blood loss by collec-
tion with a graduated plastic bag, and by
weighing towels, linen and gauzes
Incomplete outcome data (attrition bias)
All outcomes
High risk “144 women were excluded from analysis
because they were exposed to trauma to the
perineum, vagina or cervix during labour
and had traumatic excessive bleeding.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Sood 2012
Methods 2-arm placebo-controlled randomised trial.
Participants Between June 2003 and July 2005, 174 parturients were randomised in a hospital setting
in India. The population comprised women of unspecified parity, either singleton or
multiple pregnancy, at high risk for PPH, who delivered by either elective or emergency
caesarean. Exclusion criteria were not specified
Interventions 400 mcg plus 20 IU of misoprostol plus oxytocin administered sublingually plus by an
intravenous infusion (n = 90) versus 20 IU of oxytocin administered by an intravenous
infusion (n = 84)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, blood loss (mL), change in Hb level, nausea, vomiting, fever,
shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved by computer-
generated random numbers
Allocation concealment (selection bias) Low risk Investigators used sequentially-numbered,
opaque, sealed envelopes made at phar-
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macy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and caregivers were
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated
intraoperative blood loss by collection with
suction apparatus and sterile drapes before
irrigation, and by evaluating the blood in
abdominal swabs and gauzes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Stanton 2013
Methods 2-arm cluster controlled randomised trial.
Participants Between 21st April 2011 and 30th November 2012, 1586 parturients were randomised
in a community setting in Ghana. The population comprised women of unspecified
parity, either singleton or multiple pregnancy, at both high and low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria were not specified
Interventions 10 IU of oxytocin administered intramuscularly (n = 689) versus placebo or control (n
= 897)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity, death
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The 52 CHOs were randomly allocated
equally to either the intervention or the
control group; this allocation was stratified
by both district and distance (at least 10
km, or less than 10 km) to emergency ob-
stetric care. The randomisation sequence
was determined using Stata (version 12)
Allocation concealment (selection bias) Unclear risk .Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The random allocation was not masked.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Assessors were not blinded to treatment al-
locations.
Objective assessment of blood loss Low risk Investigators evaluated postpartum blood
loss by collection with a BRASS-V cal-
ibrated plastic drape placed under the
mother, who was asked to remain recum-
bent for 1 hour following delivery of the
baby, or for 2 hours if active bleeding per-
sisted. “Fluids, urine, and faeces were ex-
cluded from the blood loss measure by
sweeping them to the side and into a recep-
tacle.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “7 and 9 enrolled women in the oxytocin
and control arms, respectively, lacked a
blood-loss measure.”
Selective reporting (reporting bias) Low risk The study report matches the study pro-
tocol that was registered (ClinicalTrials.gov
NCT01108289)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the Bill and Melinda Gates Foundation
(public funding)
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Methods 2-arm active-controlled double-blinded randomised trial.
Participants Between January 2005 and April 2008, 370 parturients were randomised in a hospital
setting in Singapore. The population comprised women of unspecified parity, a single-
ton pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion crite-
ria comprised parturients undergoing elective caesarean section, or those with multiple
pregnancy, previous PPH, coagulopathy, coronary artery disease, hypertension or hyper-
sensitivity/contraindications for the use of Syntometrine or carbetocin
Interventions 100 mcg of carbetocin administered intramuscularly (n = 185) versus 500 mcg plus 5
IU of ergometrine plus oxytocin administered intramuscularly (n = 185)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional utero-
tonics, transfusion, manual removal of placenta, blood loss (mL), third-stage duration
(min), nausea, vomiting, headache, shivering, abdominal pain
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was blocked and stratified
by parity. The randomisation list with the
allocation of the mode of intervention was
forwarded from theBiostatisticsUnit to the
Department of Pharmacy at National Uni-
versityHospital, where the purchasedmed-
ications were kept
Allocation concealment (selection bias) Low risk Investigators used opaque packages made
at pharmacy.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The identities of the medications were
not known to the midwives, obstetricians
and the participants. Themedication codes
were only broken following completion of
the trial.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the vi-
sual estimation of attending obstetricians
and midwives
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Low risk The study protocol was registered 2 years
after beginning recruitment (ClinicalTrial.
gov NCT00499005)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the National Healthcare Group of Singa-
pore (public funding)
Sultana 2007
Methods 2-arm active-controlled randomised trial.
Participants Between January 2003 and December 2003, 400 parturients were randomised in a
hospital setting in Bangladesh. The population comprised women of unspecified parity,
unspecified whether singleton or multiple pregnancy, at low risk for PPH, who delivered
by vaginal delivery. Exclusion criteria comprised parturients with previous caesarean
Interventions 400 mcg of misoprostol administered orally (n = 210) versus 10 IU of oxytocin admin-
istered intramuscularly (n = 190)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta, shivering, abdominal pain
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the es-
timation of attending physicians after col-
lection in a plastic bowl
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Surbek 1999
Methods 2-arm placebo-controlled randomised trial.
Participants Between May 1997 and April 1998, 65 parturients were randomised in a Hospital set-
ting in Switzerland. The population comprised women of unspecified parity, a singleton
pregnancy, at both high and low risk for PPH, who delivered by vaginal delivery. Exclu-
sion criteria comprised parturients undergoing caesarean section, or those with multiple
pregnancy, pre-eclampsia, previous PPH or antepartum haemorrhage
Interventions 600 mcg of misoprostol administered orally (n = 31) versus placebo or control (n = 34)
Outcomes The study recorded the following outcomes: PPH at 500, additional uterotonics, blood
loss (mL), change in Hb level, third-stage duration (min), NNU admissions, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwas achievedusing random
tables.
295Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Surbek 1999 (Continued)
Allocation concealment (selection bias) Low risk Randomisationwas performedby the phar-
macy.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was “double-masked”: “for
proper masking, the study drugs were pre-
pared by the hospital pharmacy as 3 iden-
tical gelatine capsules.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the es-
timation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all
randomised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study report
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Tewatia 2014
Methods 2-arm active-controlled randomised trial.
Participants Between March 2010 and February 2011, 100 parturients were randomised in a hos-
pital setting in India. The population comprised women of parity 4 or less, a singleton
pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients with grand multiparity (more than 4), anaemia, malpresentation,
polyhydramnios, antepartum haemorrhage, liver/renal disorder, previous caesarean, pre-
vious PPH, uterine anomaly, traumatic PPH or contraindications to use misoprostol or
oxytocin
Interventions 10 IU of oxytocin administered by an intravenous infusion (n = 50) versus 600 mcg of
misoprostol administered sublingually (n = 50)
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Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, death, blood loss (mL), change in Hb level, third-
stage duration (min), nausea, vomiting. fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk .Randomisation was achieved using a com-
puter-generated random number sequence
Allocation concealment (selection bias) Unclear risk Investigators used sequentially-numbered,
opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Due to [the] nature of administration of
the drugs, [the] patient or clinical care team
could not be blinded. However, [the] statis-
tician was unaware of the group allocation.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators removed any linen soiled with
amniotic fluid, and placed a calibrated plas-
tic bag under the mother to collect blood
from the uterine cavity. After delivery of the
placenta, a pre-weighed padwas placed high
up in vagina until 1 hour afterwards. In cases
of episiotomy, a separate pad was applied to
the episiotomy site, and the fluid collected
by this pad was not included in blood loss
measurements
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
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Funding source Unclear risk Source(s) of funding for the study were not
reported.
Thilaganathan 1993
Methods 2-arm controlled randomised trial.
Participants Between January 1988 and February 1990, 193 parturients were randomised in a hospi-
tal setting in the UK. The population comprised women of parity 4 or less, a singleton
pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients undergoing induction or augmentation of labour or instrumen-
tal delivery, or those with grand multiparity (not defined), malpresentation, multiple
pregnancy, previous caesarean, previous PPH, antepartum haemorrhage, hypertension
in pregnancy, intrauterine death, preterm rupture of membranes, cervical lacerations or
third degree perineal tears
Interventions Placebo or control (n = 90) versus 500 mcg plus 5 IU of ergometrine plus oxytocin
administered intramuscularly (n = 103)
Outcomes The study recorded the following outcomes: additional uterotonics, transfusion, manual
removal of placenta, blood loss (mL), change in Hb level, third-stage duration (min)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was randomly allocated using standard
randomisation tables
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not blinded
to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the estima-
tion of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
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Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All those who were enrolled and randomly allo-
cated to treatment were included in the analysis,
in the groups to which they were randomised
Funding source Unclear risk The study was conducted without external fund-
ing.
Ugwu 2014
Methods 2-arm active-controlled randomised trial.
Participants Between 21st April 2011 and 31st March 2012, 120 parturients were randomised in
a hospital setting in Nigeria. The population comprised women of unspecified parity,
a singleton pregnancy, at high risk for PPH, who delivered by either elective or emer-
gency caesarean. Exclusion criteria comprised parturients requiring general anaesthesia,
or those with multiple pregnancy, placenta praevia, pre-eclampsia, eclampsia, undiag-
nosed vaginal bleeding, prolonged labour, prolonged obstructed labour, cardiac/renal/
liver disorders or fever
Interventions 400 mcg plus 20 IU of misoprostol plus oxytocin administered sublingually plus by an
intravenous infusion (n = 60) versus 20 IU of oxytocin administered by an intravenous
infusion (n = 60)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, death, blood loss (mL), change in Hb level, fever,
shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment allocations were generated by
random tables.
Allocation concealment (selection bias) Low risk Investigators used sequentially-numbered,
opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “There were no look-alike placebo tablets
for women who had oxytocin alone... The
obstetricians and the scrub nurses were un-
aware of which oxytocic was given to each
patient, as they were screened off during the
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surgery... No member of the obstetric team
had knowledge of which agent the patient
received”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk ”There were no look-alike placebo tablets
for women who had oxytocin alone... The
obstetricians and the scrub nurses were un-
aware of which oxytocic was given to each
patient, as they were screened off during the
surgery... No member of the obstetric team
had knowledge of which agent the patient
received”
Objective assessment of blood loss Low risk Investigators evaluated intraoperative and
postoperative blood loss by collection in a
suction bottle. Furthermore, soiled drapes,
abdominal packs and pieces of gauze were
weighed and the known dry weights sub-
tracted. Finally, vulva pads applied dur-
ing the 4 hours post-operation, were also
weighed and the known dry weights sub-
tracted. Measurements obtained by these 3
methods were added together.Weight mea-
surements were performed with a weighing
scale made in China, of total weighing ca-
pacity of 5 kg and graduations of 0.25 g. In-
vestigators considered that 1 g is equivalent
to 1 mL of blood
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification, but not all of the outcomes
projected by methodological descriptions
were reported as results in the study re-
port (cases of nausea, vomiting, diarrhoea,
headaches, fatigue, dizziness, chills, flatu-
lence and abdominal pain were omitted)
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
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Un Nisa 2012
Methods 2-arm active-controlled randomised trial.
Participants Between 1st January 2012 and 30th June 2012, 100 parturients were randomised in a
hospital setting in India. The population comprised women of parity 2 to 4, a single-
ton pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion crite-
ria comprised parturients with previous PPH, multiple pregnancy, previous caesarean,
macrosomia, pre-eclampsia, diabetes, cardiac/lung/bleeding/clotting disorders or taking
anticoagulants
Interventions 10 IU of oxytocin administered by an intravenous bolus (n = 50) versus 500 mcg plus 5
IU of ergometrine plus oxytocin administered intramuscularly (n = 50)
Outcomes The study recorded the following outcome: PPH at 500.
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study participants (patients) were divided
by a lottery system in the 2 groups, each
group comprising 50 patients
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss after the
delivery of baby “by squeezing the soaked
pads and quantifying the amount of blood
clots in a kidney tray of standard size to be
equal to 500 mL.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
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located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Uncu 2015
Methods 5-arm controlled randomised trial.
Participants Between dates unspecified, 248 parturients were randomised in a hospital setting in
Turkey. The population comprised women of parity 5 or less, a singleton pregnancy, at
both high and low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients undergoing caesarean section, or those with placenta praevia, pre-
vious PPH, antepartum haemorrhage, non-cephalic presentation, multiple pregnancy,
intrauterine death, grand multiparity (more than 5), fibroids, pre-eclampsia or antico-
agulation therapy
Interventions Placebo or control (n = 49) versus 400 mcg to 800 mcg of misoprostol administered
orally, vaginally or rectally (n = 199)
Outcomes The study recorded the following outcomes: additional uterotonics, transfusion, third-
stage duration (min), shivering, abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was generated by random tables.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and caregivers) was
not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not re-
ported.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were collected completely from all ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable for ver-
ification.
Intention to treat analysis Low risk All those who were enrolled and randomly allo-
cated to treatment were included in the analysis,
in the groups to which they were randomised
Funding source Unclear risk Source(s) of funding for the study were not re-
ported.
Vagge 2014
Methods 2-arm active-controlled randomised trial.
Participants Between dates unspecified, 200 parturients were randomised in a hospital setting in
India. The population comprised women of parity 4 or less, a singleton pregnancy,
at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria comprised
parturients undergoing caesarean section, or those with cardiac disorder in pregnancy,
uterine tumour in pregnancy, secondary PPH, grand multiparity (not defined), multiple
pregnancy, polyhydramnios, anaemia, coagulopathy, antepartum haemorrhage, previous
PPH, prolonged labour, precipitate labour or known allergic or hypersensitivity reaction
to prostaglandins
Interventions 10 IU of oxytocin administered by an intravenous infusion (n = 100) versus 800 mcg of
misoprostol administered rectally (n = 100)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, blood loss (mL), nausea, fever, shivering
Notes Contact with study authors for additional information: no. Additional data from authors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Investigators used simple random sampling.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study participants and caregivers were not
blinded to treatment allocations
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Unclear risk Methods of evaluating blood loss were not
reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Vaid 2009
Methods 3-arm active-controlled randomised trial.
Participants Over 10 months between dates unspecified, 200 parturients were randomised in a hos-
pital setting in India. The population comprised women of parity 4 or less, a singleton
pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria com-
prised parturients with grand multiparity (more than 4), multiple pregnancy, preterm
labour (less than 32 weeks), HELLP syndrome, polyhydramnios, coagulopathy, asthma,
cardiac/renal disorder, epilepsy, hypertension, Hb less than 80 g/L or known drug allergy
Interventions 400mcgofmisoprostol administered sublingually (n =66) versus 200mcgof ergometrine
administered intramuscularly (n = 67)
Outcomes The study recorded the following outcomes: PPH at 500, Additional uterotonics, trans-
fusion, manual removal of placenta, nausea, vomiting, fever, shivering, abdominal pain
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was allocated by a computer-
generated random number
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Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk After the drainage of amniotic fluid, inves-
tigators evaluated blood loss by collection
with a sterile calibrated BRASS-V drape
placed under the mother. The drape re-
mained in place for 1 hour. Furthermore,
“blood loss in gauze pieces was calculated
by subtracting the weight of dry gauze from
the weight of blood-soaked gauze pieces.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Verma 2006
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between 2005 and 2006, 200 parturients were randomised in a hospital setting in India.
The population comprised women of unspecified parity, unspecified whether singleton
or multiple pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion
criteria were not specified
Interventions 400 mcg of misoprostol administered sublingually (n = 100) versus 200 mcg of er-
gometrine administered intramuscularly (n = 100)
Outcomes The study recorded the following outcomes: PPH at 500, additional uterotonics, manual
removal of placenta, blood loss (mL), change in Hb level, third-stage duration (min),
nausea, fever, shivering
305Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Verma 2006 (Continued)
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence generation was
not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was “double-blind”: active treat-
ments and placebo treatments were “iden-
tical-looking.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators evaluated blood loss “accu-
rately with a specially designed calibrated
blood collection drape (BRASS-V drape).”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk It was unclear from the study report
whether all those who were enrolled and
randomly allocated to treatment were in-
cluded in the analysis, in the groups to
which they were randomised
Funding source Unclear risk Source(s) of funding for the study were un-
clear.
Vimala 2004
Methods 2-arm active-controlled randomised trial.
Participants Between October 2002 and January 2003, 120 parturients were randomised in a hos-
pital setting in India. The population comprised women of parity 5 or less, a singleton
pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients undergoing induction or augmentation of labour or caesarean
section, or those with preterm labour (less than 37 weeks), grand multiparity (more
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than 5), multiple pregnancy, hypertension in pregnancy, Hb less than 80 g/L or known
hypersensitivity to prostaglandins
Interventions 400mcgofmisoprostol administered sublingually (n =60) versus 200mcgof ergometrine
administered by an intravenous bolus (n = 60)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta, blood loss (mL), change in Hb
level, third-stage duration (min), nausea, vomiting, headache, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was allocated by random tables.
Allocation concealment (selection bias) Low risk Investigators used sequentially-numbered,
opaque, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Treatments were administered via different
routes and the authors did not report any
double dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss by the es-
timation of attending nurses and obstetri-
cians. After delivery of the baby, amniotic
fluid was allowed to drain away, and am-
niotic fluid-soaked bed linens were covered
with dry disposable ‘linen-savers’. A wedge-
shaped plastic bedpan was placed under the
mother for 1 hour. Blood and clots from
the bedpan were decanted into a measur-
ing cylinder and measured. Blood-soaked
swabs and linen-savers were weighed; the
known dry weights were subtracted, for the
weight of blood contained within them to
be added to the value indicated by the mea-
suring cylinder
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
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Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Vimala 2006
Methods 2-arm active-controlled randomised trial.
Participants Between August 2004 and April 2005, 100 parturients were randomised in a hospital
setting in India. The population comprised women of unspecified parity, a singleton
pregnancy, at high risk for PPH, who delivered by either elective or emergency caesarean.
Exclusion criteria comprised parturients with multiple pregnancy, antepartum haemor-
rhage, polyhydramnios, prolonged labour (more than 12 hours), previous more than 1
caesarean, previous uterine rupture, cardiac/liver/renal disorder, coagulopathy or Hb less
than 80 g/L
Interventions 400 mcg of misoprostol administered sublingually (n = 50) versus 20 IU of oxytocin
administered by an intravenous infusion (n = 50)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, blood loss (mL), change in Hb level, vomiting, headache,fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using com-
puter-generated random numbers
Allocation concealment (selection bias) Low risk Investigators used opaque, sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants and caregivers were not
blinded to treatment allocations
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk Investigators evaluated blood loss intraop-
eratively and in the first hour postopera-
tively “in a standard manner.” They mea-
sured the volume of blood in the suction
bottle, and weighed blood-soaked sponges
and linen savers. Then they added the
difference between dry and blood-soaked
weights of sponges and linen savers, to the
volume measured in the suction bottle
Incomplete outcome data (attrition bias)
All outcomes
Low risk Datawere collected completely fromall ran-
domised study participants
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
the Division of Reproductive Health and
Nutrition, Indian Council of Medical Re-
search (public funding)
Walley 2000
Methods 2-arm active-controlled double-dummy randomised trial.
Participants Between 15th June 1998 and 15th May 1999, 401 parturients were randomised in a
hospital setting in Ghana. The population comprised women of parity 5 or less, a single-
ton pregnancy, at low risk for PPH, who delivered by vaginal delivery. Exclusion criteria
comprised parturients undergoing induction or augmentation of labour or caesarean sec-
tion, or those with grand multiparity (more than 5), multiple pregnancy, preterm labour
(less than 32 weeks), hypertension in pregnancy, HELLP syndrome, polyhydramnios,
previous PPH, coagulopathy, precipitate labour, chorioamnionitis, Hb less than 80 g/L
or a known hypersensitivity to prostaglandins
Interventions 400 mcg of misoprostol administered orally (n = 203) versus 10 IU of oxytocin admin-
istered intramuscularly (n = 198)
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Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta, death, blood loss (mL), Change
in Hb level, third-stage duration (min), nausea, vomiting, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using com-
puter-generated random numbers
Allocation concealment (selection bias) Low risk Investigators used sequentially-numbered,
opaque packets made by administrative
staff
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The identity of the placebo and active
medications were concealed from care-
givers and participants.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss High risk Investigators evaluated blood loss by the es-
timation of attending physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of those women randomised, blood loss
measurements were unavailable in 3 cases,
and postpartum Hb samples were unavail-
able in 9 cases
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Low risk All those who were enrolled and randomly
allocated to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
MaterCare International and the Canadian
InternationalDevelopmentAgency (public
funding)
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Methods 2-arm active-controlled double-blinded randomised trial.
Participants Between dates unspecified, 58 parturients were randomised in a hospital setting in Aus-
tralia. The population comprised women of unspecified parity, either singleton or mul-
tiple pregnancy, at high risk for PPH, who delivered by emergency caesarean section.
Exclusion criteria comprised parturients undergoing elective caesarean section or requir-
ing general anaesthesia, or those with vascular/liver/renal disorders, preterm labour (less
than 37 weeks), placenta praevia, placental abruption, previous more than 2 caesareans
or an adverse reaction to carbetocin/oxytocin
Interventions 100 mcg of carbetocin administered by an intravenous bolus (n = 30) versus 5 IU of
oxytocin administered by an intravenous bolus (n = 28)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, blood loss (mL), change in Hb level
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Investigators used computer-generated
randomisation at pharmacy level, and none
of the operating or anaesthetic doctors had
access to this
Allocation concealment (selection bias) Low risk Randomisationwas performedby the phar-
macy.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was “double-blinded”: women
received “a blinded bolus of carbetocin” or
“a blinded oxytocin bolus.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Low risk Investigators
evaluated intra-operative blood loss by the
estimation of attending physicians. Excess
blood was collected in measuring container
by suction, and weighed together with any
swabs soaked in blood
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
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Selective reporting (reporting bias) Low risk The study report matches the study proto-
col that was registered prospectively (AC-
TRN 12612000466842)
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Low risk The study was supported by funding from
Frankston Hospital (the institution of the
authors)
Yuen 1995
Methods 2-arm active-controlled double-blinded randomised trial.
Participants Between February 1993 and March 1993, 1000 parturients were randomised in a hos-
pital setting in Hong Kong. The population comprised women of unspecified parity, a
singleton pregnancy, at both high and low risk for PPH, who delivered by vaginal de-
livery. Exclusion criteria comprised parturients requiring oxytocin infusion in the third
stage, or those with pre-eclampsia or cardiac disorder
Interventions 500 mcg plus 5 IU of ergometrine plus oxytocin administered intramuscularly (n = 496)
versus 10 IU of oxytocin administered intramuscularly (n = 495)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, morbidity,
additional uterotonics, transfusion, manual removal of placenta, death, change in Hb
level, nausea, vomiting, headache
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using com-
puter-generated random numbers
Allocation concealment (selection bias) Unclear risk Investigators used sequentially-numbered,
opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “When a patient entered the study, a nurs-
ing officer who was not involved in the
management of the patient drew up the
indicated medication and handed this to
312Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Yuen 1995 (Continued)
the patient’s attendants.” Study partici-
pants and caregivers were thus blinded to
treatment allocations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tions.
Objective assessment of blood loss Unclear risk Investigators evaluated blood loss during
delivery “by measuring the amount of
blood clots and weighing the towels used.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “9 [randomised participants] were ex-
cluded: 3 had a twin pregnancy, 1 had
blood transfusion during labour, and the
other 5 had unavailable records.”
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis High risk Not all study participants were included in
the analysis.
Funding source Unclear risk Source(s) of funding for the study were not
reported.
Zachariah 2006
Methods 3-arm active-controlled randomised trial.
Participants Over 8 months between dates unspecified, 2023 parturients were randomised in a hos-
pital setting in India. The population comprised women of unspecified parity, unspeci-
fied whether singleton or multiple pregnancy, at both high and low risk for PPH, who
delivered by vaginal delivery. Exclusion criteria comprised parturients undergoing cae-
sarean section, or those with asthma, cardiac disorder, rhesus factor incompatibility or
hypertension
Interventions 400 mcg of misoprostol administered orally (n = 730) versus 10 IU of oxytocin admin-
istered intramuscularly (n = 617) versus 200 mcg of ergometrine administered by an
intravenous bolus (n = 676)
Outcomes The study recorded the following outcomes: PPH at 500, PPH at 1000, additional
uterotonics, transfusion, manual removal of placenta, death, blood loss (mL), change in
Hb level, third-stage duration (min), nausea, vomiting, headache, fever, shivering
Notes Contactwith study authors for additional information: yes. Additional data fromauthors:
yes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using com-
puter-generated random numbers
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding (of study participants and care-
givers) was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessor blinding was not reported.
Objective assessment of blood loss Low risk After the drainage of amniotic fluid, inves-
tigators evaluated blood loss by collection
with a large sterile plastic bag placed under
the mother until she was transferred to the
postnatal department. The blood collected
in the plastic bag was then transferred to a
measuring jar. Mops were not used in the
labour room, and gauze pieces were counted
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study authors did not mention any in-
complete outcome data
Selective reporting (reporting bias) Unclear risk The protocol of the study was unavailable
for verification.
Intention to treat analysis Unclear risk The authors did not specify whether all
those who were enrolled and randomly al-
located to treatment were included in the
analysis, in the groups to which they were
randomised
Funding source Unclear risk Source(s) of funding for the study were not
reported.
ACTRN, Australian Clinical Trials Registration Number; ANOVA, one-way Analysis Of Variance; ASA I or II, ASA Physical Status
Classification System: ASA I represents a normal healthy patient, ASA II represents a patient with mild systemic disease; BMI, Body
Mass Index; cc, cubic centimetres;CHOs, community health officers; cm, centimetres;CTRI, Clinical Trials Registry of India;DIC,
Disseminated Intravascular Coagulopathy; dL, decilitres;EudraCT, EuropeanClinical Trials database; fL, femtolitres (measurement
of mean corpuscular volume); g, grams;Hb, Haemoglobin;HELLP syndrome, Hemolysis (destruction of red blood cells), Elevated
Liver enzymes (which indicate liver damage), and Low Platelet count; HIV, Human Immunodeficiency Virus; Hong Kong SAR,
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Hong Kong Special Adminstrative Region; IU, International Units; kg, kilograms; km, kilometres; L, litres;mcg, micrograms; mg,
milligrams; min, minutes; mL, millilitres; mmHG, millimetres of mercury (unit of pressure); mmol, millimoles; NCT, National
Clinical Trial (number); NEPU, National Perinatal Epidemiology Unit; NHS, National Health Service; nm, nanometres; NNU,
Neonatal Unit; PACTR, Pan African Clinical Trials Registry; PPH, Postpartum Haemorrhage; PROM, Premature Rupture Of
Membranes; RCOG, Royal College of Obstetricians and Gynaecologists; UK, United Kingdom; UNDP/UNFPA, United Nations
Development Programme/United Nations Population Fund; USA, United States of America;WHO, World Health Organization.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdel-Aleem 1993 Not eligible intervention
Abdel-Aleem 1997 Not eligible intervention
Abdel-Aleem 2013 Not eligible intervention
Abdollahy 2000 Not eligible intervention
Al-Harazi 2009 Same drug intervention both arms and only different route of misoprostol administration
Anandakrishnan 2013 Same drug intervention both arms and only different dose of carbetocin administration
Anjaneyulu 1988 Not eligible intervention
Anvaripour 2013 Intervention given after the third stage of labour
Athavale 1991 Not eligible intervention
Ayedi 2011a Same drug intervention both arms and only different dose of oxytocin administration
Ayedi 2011b Not eligible intervention
Aziz 2014 Quasi-randomised
Bader 2000 Not eligible intervention
Badhwar 1991 Not eligible intervention
Bai 2014 Not eligible uterotonic
Balki 2006 Same drug intervention both arms and only different dose of oxytocin administration
Banovska 2013 Not eligible intervention
Barbaro 1961 Not eligible intervention
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Baumgarten 1983 Not eligible uterotonic
Bhattacharya 1988 Not eligible uterotonic
Bhavana 2013 Not eligible intervention
Bider 1991 Not eligible intervention
Bider 1992 Not eligible intervention
Bisri 2011 Same drug intervention both arms and only different route of oxytocin administration
Biswas 2007 Not eligible uterotonic
Bivins 1993 Not eligible uterotonic
Blum 2010 Intervention for treatment of PPH
Bonham 1963 Quasi-randomised
Bonis 2012 Quasi-randomised
Cappiello 2006 Not eligible intervention
Carvalho 2004 Same drug intervention both arms and only different dose of oxytocin administration
Catanzarite 1990 Not eligible intervention
Chaplin 2009 Not eligible intervention
Chaudhuri 2014 Inappropriate population (excluded women who had PPH)
Chestnut 1987 Not eligible intervention
Chou 1994 Not eligible intervention
Chua 1995 Not eligible intervention
Chukudebelu 1963 Quasi-randomised
Cooper 2004 Same drug intervention both arms and only different dose of oxytocin administration
Cordovani 2012 Same drug intervention both arms and only different dose of carbetocin administration
Dagdeviren 2014 Same drug intervention both arms and only different route of oxytocin administration
Dahiya 1995 Not eligible intervention
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Daley 1951 Quasi-randomised
Daly 1999 Inappropriate population
Dao 2009 Intervention for treatment of PPH
Davies 2005 Same drug intervention both arms and only different route of oxytocin administration
De bonis 2012 Quasi-randomised
Dennehy 1998 Same drug intervention both arms and only different route of oxytocin administration
Devi 1988 Not eligible intervention
Diab 1999 Quasi-randomised
Dickinson 2009 Not eligible population (terminations 2nd trimester)
Dommisse 1980 Not randomised
Dong 2011 Not eligible intervention
Durocher 2012 Quasi-randomised
Dutta 2000 Quasi-randomised
Dweck 2000 Not eligible intervention
Dzuba 2012 Same drug intervention both arms and only different route of oxytocin administration
Elati 2011 Same drug intervention both arms and only different route of misoprostol administration
Erkkola 1984 Not eligible intervention
Farber 2013 Not eligible intervention
Farber 2015 Not eligible intervention
Fatemeh 2011 Same drug intervention both arms and only different route of oxytocin administration
Fawzy 2012 Treatment (not prevention) of PPH.
Forster 1957 Quasi-randomised
Francis 1965 Quasi-randomised
Friedman 1957 Quasi-randomised
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(Continued)
Fugo 1958 Quasi-randomised
Gai 2004 Not eligible intervention
George 2010 Same drug intervention both arms and only different route of oxytocin administration
Ghulmiyyah 2007 Not eligible intervention
Gobbur 2011 Not eligible intervention
Gohel 2007 Not eligible intervention
Goswami 2013 Not eligible intervention
Groeber 1960 Not eligible intervention
Gungorduk 2010a Same drug intervention both arms and only different route of oxytocin administration
Gungorduk 2010b Not eligible intervention
Gungorduk 2011 Not eligible intervention
Gungorduk 2013 Not eligible intervention
Gupta 2014 Not eligible intervention
Habek 2007 Not eligible intervention
Hacker 1979 Not randomised
Halder 2013 Not eligible intervention
Hoffman 2006 Not appropriate intervention (comparing timing of oxytocin)
Hofmeyr 2004 Intervention for treating PPH
Howard 1964 Not eligible intervention
Huh 2004 Same drug intervention both arms and only different route of oxytocin administration
Hunt 2013 Not eligible intervention
Häivä 1994 Quasi-randomised
Ilancheran 1990 Not randomised
Irons 1994 Inappropriate population (excluded women who had PPH)
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(Continued)
Jackson 2001 Not appropriate intervention (comparing timing of oxytocin)
Jiang 2001 Same drug intervention both arms and only different route of oxytocin administration
Jin 2000 Not eligible intervention
Jolivet 1978 Not eligible intervention (given oral ergometrine for 6 days)
Jonsson 2010 Same drug intervention both arms and only different route of oxytocin administration
Kashanian 2010 Ineligible population (excluded women with PPH)
Kemp 1963 Quasi-randomised
Khan 1997 Not eligible intervention
Khan 2003 Same drug intervention both arms and only different route of misoprostol administration
Khan 2012 Same drug intervention both arms and only different route of oxytocin administration
Khanun 2011 Same drug intervention both arms and only different route of misoprostol administration
Khurshid 2010 Not eligible intervention
Kikutani 2003a Innapropriate population
Kikutani 2003b Innapropriate population
King 2010 Same drug intervention both arms and only different route of oxytocin administration
Kintu 2012 Same drug intervention both arms and only different dose of oxytocin administration
Kiran 2012 Same drug intervention both arms and only different dose of oxytocin administration
Kore 2000 Not eligible intervention
Kovacheva 2015 Same drug intervention both arms and only different route of oxytocin administration
Kovavisarach 1998 Not eligible intervention
Kumar 2011 Not eligible intervention (carboprost)
Kushtagi 2006 Not eligible intervention (carboprost)
Lamont 2001 Not eligible intervention (carboprost)
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(Continued)
Le 2000 Not eligible intervention
Leader 2002 Not eligible population (2nd trimester)
Li 2002 Not eligible intervention
Li 2003 Not eligible intervention
Li 2011 Not eligible intervention
Lin 2009 Not eligible intervention
Liu 1997 Not eligible intervention
Liu 2002 Not eligible intervention
Luamprapas 1994 Not eligible intervention
Mangla 2012 Not eligible intervention
Mankuta 2006 Not eligible intervention
Mansouri 2011 Same drug intervention both arms and only different route of misoprostol administration
Martinez 2006 Not eligible intervention
McGinty 1956 Quasi-randomised
Miller 2009 Not eligible intervention
Mirghafourvand 2015 Not eligible intervention
Mollitt 2009 Same drug intervention both arms and only different route of oxytocin administration
Moore 1956 Same drug intervention both arms and only different type of the same drug
Movafegh 2011 Not eligible intervention
Muller 1996 Not randomised
Munishankarappa 2009 Same drug intervention both arms and only different route of oxytocin administration
Munn 2001 Same drug intervention both arms and only different route of oxytocin administration
Murphy 2009 Same drug intervention both arms and only different route of oxytocin administration
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Nankali 2013 Not eligible intervention
NCT01710566 2012 Study withdrawn
Nellore 2006 Not eligible intervention
Nelson 1983 Not eligible intervention
Newton 1961 Quasi-randomised
Nguyen-Lu 2013 Same drug intervention both arms and only different dose of carbetocin administration
Nieminen 1964 Not eligible intervention
Norchi 1988 Not eligible intervention
Oberbaum 2005 Not eligible intervention
Oguz 2014 Same drug intervention both arms and only different route and timing of oxytocin administration
Ozalp 2010 Not eligible intervention
Ozcan 1996 Not eligible intervention
Ozkaya 2005 Inappropriate population (excluded women who had PPH)
Padhy 2006 Not eligible intervention
Palacio 2011 Same drug intervention both arms and only different dose of oxytocin administration
Paull 1977 Same drug intervention both arms and only different doses of drug administration
Pei 1996 Not randomised
Perdiou 2009 Not eligible intervention
Phromboot 2010 Not eligible intervention
Pierre 1992 Quasi-randomised
Pinder 2002 Same drug intervention both arms and only different doses of drug administration
Pisani 2012 Quasi-randomised
Poeschmann 1991 Quasi-randomised
Porter 1991 Not eligible intervention
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Priya 2015 Inappropriate population (measured blood loss after the delivery of the placenta)
Puri 2012 Not eligible intervention
Qiu 1999 Not eligible population (2nd stage)
Quiroga 2009 Not eligible intervention
Rajwani 2000 Not eligible intervention
Reddy 1989 Not eligible intervention
Reddy 2001 Not eligible intervention
Rooney 1985 Quasi-randomised
Rosales-Ortiz 2013 Quasi-randomised
Rouse 2011 Same drug intervention both arms and only different doses of drug administration
Sadeghipour 2013 Not eligible intervention
Saito 2007 Qausi-randomised
Samuels 2005 Not eligible intervention
Sariganont 1999 Not randomised
Sarna 1997 Same drug intervention both arms and only different doses of drug administration
Sartain 2008 Same drug intervention both arms and only different doses of drug administration
Schaefer 2004 Same drug intervention both arms and only different timings of drug administration
Schemmer 2001 Same drug intervention both arms and only different timings of drug administration
Sekhavat 2009 Not eligible intervention
Sentilhes 2014 Not eligible intervention
Senturk 2013 Not eligible intervention
Shahid 2013 Not eligible intervention
Sharma 2014 Not randomised
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(Continued)
Sheehan 2011 Same drug intervention both arms and only different doses of drug administration
Shirazi 2013 Not eligible intervention
Shrestha 2007 Not eligible intervention
Singh 2005 Not eligible intervention
Siriwarakul 1991 Not eligible intervention
Soiva 1964 Quasi-randomised
Sorbe 1978 Quasi-randomised
Soriano 1995 Quasi-randomised
Stearn 1963 Quasi-randomised
Svanstrom 2008 Innapropriate population
Symes 1984 Innapropriate population
Taj 2014 Not eligible intervention
Takagi 1976 Not eligible intervention
Tanir 2009 Not eligible intervention
Tarabrin 2012 Not eligible intervention
Tariq 2015b Administered for treatment of PPH
Tehseen 2008 Not eligible intervention
Terry 1970 Not eligible intervention
Tessier 2000 Same drug intervention both arms and only different doses of drug administration
Tharakan 2008 Same drug intervention both arms and only different doses of drug administration
Thomas 2007 Same drug intervention both arms and only different doses of drug administration
Thornton 1988 Quasi-randomised
Tita 2012 Same drug intervention both arms and only different doses of drug administration
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Tripti 2006 Not eligible intervention
Tripti 2009 Not randomised
Tudor 2006 Not eligible intervention
Van den Enden 2009 Same drug intervention both arms and only different doses of drug administration
Van Selm 1995 Not eligible uterotonic
Vasegh 2005 Quasi-randomised
Vaughan 1974 Innapropriate population
Ventoskovskiy 1990 Not eligible intervention
Verghese 2008 Not eligible intervention
Vogel 2004 Not eligible outcomes
Wallace 2008 Same drug intervention both arms and only different regimen of oxytocin administration
Walraven 2005 Not eligible uterotonic (oral ergometrine)
Wang 2000 Not eligible intervention
Weeks 2013 Self-administered drug
Weihong 1998 Not eligible intervention
Weiss 1975 Not eligible outcomes
Wetta 2013 Same drug intervention both arms and only different doses of drug administration
Winikoff 2012 Same drug intervention both arms and only different doses of drug administration
Wong 2006 Same drug intervention both arms and only different doses of drug administration
Wright 2006 Not eligible intervention
Wu 2007 Not eligible intervention
Xu 2003 Not eligible intervention
Xu 2013 Not eligible intervention
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(Continued)
Yamaguchi 2011 Same drug intervention both arms and only different doses of drug administration
Yan 2000 Not eligible intervention
Yang 2001 Not eligible intervention
Young 1988 Not eligible intervention
Zamora 1999 Not eligible intervention
Zaporozhan 2013 Not eligible intervention
Zhao 1998 Not eligible intervention
Zhao 2003 Not eligible intervention
Zhou 1994 Same drug intervention both arms and only different doses of drug administration
PPH: postpartum haemorrhage
Characteristics of studies awaiting assessment [ordered by study ID]
Adanikin 2013
Methods
Participants
Interventions
Outcomes
Notes
Adhikari 2007
Methods
Participants
Interventions
Outcomes
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Adhikari 2007 (Continued)
Notes
Ahmed 2015
Methods
Participants
Interventions
Outcomes
Notes
Akinaga 2016
Methods
Participants
Interventions
Outcomes
Notes
Ali 2012
Methods
Participants
Interventions
Outcomes
Notes
Alli 2013
Methods
Participants
Interventions
Outcomes
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Alli 2013 (Continued)
Notes
Alwani 2014
Methods
Participants
Interventions
Outcomes
Notes
Ashwal 2016
Methods
Participants
Interventions
Outcomes
Notes
Asmat 2017
Methods
Participants
Interventions
Outcomes
Notes
Ayedi 2012
Methods
Participants
Interventions
Outcomes
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Ayedi 2012 (Continued)
Notes
Baig 2015
Methods
Participants
Interventions
Outcomes
Notes
Begum 2015
Methods Randomised trial.
Participants 100 women with singleton term pregnancy undergoing caesarean with spinal anaesthesia
Interventions 20 IU of oxytocin administered by an intravenous infusion or 400 mcg of misoprostol administered sublingually
Outcomes Additional uterotonics, blood loss (mL), change in Hb level, fever,.shivering
Notes Method of randomisation not clear and ’Risk of bias’ assessment is uncertain. Abstract only. Unable to contact authors
Beigi 2009
Methods Randomised trial.
Participants 542 nulliparous pregnant women
Interventions 20 IU of oxytocin administered intravenously or 400 mcg of misoprostol administered sublingually
Outcomes PPH (not defined), third-stage duration (min), headache, shivering
Notes Method of randomisation not clear and ’Risk of bias’ assessment is uncertain. Written in Persian and awaiting
translation
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Bhatti 2014
Methods Randomised trial.
Participants 120 women
Interventions 10 IU of oxytocin administered intramuscularly or 400 mcg of misoprostol administered sublingually
Outcomes PPH at 500. Blood loss (mL).
Notes Method of randomisation not clear and ’Risk of bias’ assessment is uncertain. Cannot obtain full text
Boopathi 2014
Methods
Participants
Interventions
Outcomes
Notes
Carrillo-Gaucin 2016
Methods
Participants
Interventions
Outcomes
Notes
Chalermpolprapa 2010
Methods
Participants
Interventions
Outcomes
Notes
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Chandhiok 2006
Methods Cluster-randomised trial.
Participants 1200 women from 30 health centres
Interventions 600 mcg of Methylergometrine administered intramuscularly or 600 mcg of misoprostol administered orally
Outcomes PPH at 500, third-stage duration (min).,additional uterotonics,transfusion, blood loss (mL)
Notes Method of randomisation not clear and ’Risk of bias’ assessment is uncertain. Require intracluster correlation coef-
ficient
Chatterjee 2000
Methods Randomised trial.
Participants 200 women
Interventions Not known dose of ergometrine administered intravenously or not known dose of misoprostol administered orally
Outcomes Additional uterotonics, PPH (not defined), third-stage duration (min), transfusion
Notes Method of randomisation not clear and ’Risk of bias’ assessment is uncertain. Abstract only. Unable to contact authors
Chatterjee 2016
Methods
Participants
Interventions
Outcomes
Notes
Chaudhuri 2016
Methods
Participants
Interventions
Outcomes
Notes
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Chou 2015
Methods
Participants
Interventions
Outcomes
Notes
Cordovani 2011
Methods
Participants
Interventions
Outcomes
Notes
Dabbaghi 2012
Methods
Participants
Interventions
Outcomes
Notes
Dagdeviren 2016
Methods
Participants
Interventions
Outcomes
Notes
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Del Angel-Garcia 2006
Methods Randomised trial.
Participants 152 women with no clear inclusion criteria
Interventions Not known dose of carbetocin of unknown route or not known dose of oxytocin of unknown route
Outcomes PPH (not defined).
Notes Method of randomisation not clear and ’Risk of bias’ assessment is uncertain. Abstract only. Unable to contact authors
Dell-Kuster 2016
Methods
Participants
Interventions
Outcomes
Notes
Dell-Kuster 2016a
Methods
Participants
Interventions
Outcomes
Notes
Dell-Kuster 2017
Methods
Participants
Interventions
Outcomes
Notes
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Deshpande 2016
Methods
Participants
Interventions
Outcomes
Notes
Diop 2016
Methods
Participants
Interventions
Outcomes
Notes
Dumoulin 1981
Methods Randomised trial.
Participants 1750 women
Interventions 5 IU of oxytocin administered intramuscularly then increased to 10 IU or ergometrine 500 mcg plus 5 IU of oxytocin
administered intramuscularly
Outcomes PPH at 500, blood loss (mL).
Notes Method of randomisation not clear and ’Risk of bias’ assessment is uncertain
Dutta 2016
Methods
Participants
Interventions
Outcomes
Notes
333Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Elbohoty 2016
Methods
Participants
Interventions
Outcomes
Notes
Fahmy 2015
Methods
Participants
Interventions
Outcomes
Notes
Fahmy 2016
Methods
Participants
Interventions
Outcomes
Notes
Fakour 2013
Methods
Participants
Interventions
Outcomes
Notes
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Frye 2015
Methods
Participants
Interventions
Outcomes
Notes
Fuks 2014
Methods Open-label randomised trial.
Participants 143 women with term singleton pregnancies
Interventions Not known dose of oxytocin of unknown route or Not known dose of oxytocin of unknown route plus 600 mcg of
misoprostol administered rectally
Outcomes Change in Hb level.
Notes Method of randomisation not clear and ’Risk of bias’ assessment is uncertain. Abstract only. Unable to contact authors
Ghulmiyyah 2017
Methods
Participants
Interventions
Outcomes
Notes
Gulmezoglu 2015
Methods
Participants
Interventions
Outcomes
Notes
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Hernandez-Castro 2016
Methods
Participants
Interventions
Outcomes
Notes
Islam 2008
Methods
Participants
Interventions
Outcomes
Notes
Jagielska 2015
Methods
Participants
Interventions
Outcomes
Notes
Jans 2017
Methods
Participants
Interventions
Outcomes
Notes
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Javadi 2015
Methods
Participants
Interventions
Outcomes
Notes
Kabir 2015
Methods
Participants
Interventions
Outcomes
Notes
Khan 2013
Methods
Participants
Interventions
Outcomes
Notes
Koen 2016
Methods
Participants
Interventions
Outcomes
Notes
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Liu 2015
Methods
Participants
Interventions
Outcomes
Notes
Liu 2016
Methods
Participants
Interventions
Outcomes
Notes
Maged 2015
Methods
Participants
Interventions
Outcomes
Notes
Maged 2017
Methods
Participants
Interventions
Outcomes
Notes
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Makvandi 2013
Methods
Participants
Interventions
Outcomes
Notes
Mirteimouri 2013
Methods
Participants
Interventions
Outcomes
Notes
Mockler 2015
Methods
Participants
Interventions
Outcomes
Notes
Modi 2014
Methods
Participants
Interventions
Outcomes
Notes
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Mohamadian 2013
Methods
Participants
Interventions
Outcomes
Notes
Mohamed 2015
Methods
Participants
Interventions
Outcomes
Notes
Murphy 2015
Methods
Participants
Interventions
Outcomes
Notes
Nankaly 2016
Methods
Participants
Interventions
Outcomes
Notes
340Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Narenji 2012
Methods
Participants
Interventions
Outcomes
Notes
Neri-Mejia 2016
Methods
Participants
Interventions
Outcomes
Notes
Ng 2004
Methods Double-blinded randomised trial.
Participants Not known how many women randomised
Interventions Not known dose of oxytocin administered intravenously or 400 mcg of misoprostol administered orally
Outcomes PPH at 500, PPH at 1000, additional uterotonics, transfusion, change in Hb level, blood loss (mL), fever, shivering
Notes Method of randomisation not clear and ’Risk of bias’ assessment is uncertain. Abstract only. Unable to contact authors
Nguyen-Lu 2015
Methods
Participants
Interventions
Outcomes
Notes
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Ononge 2015
Methods
Participants
Interventions
Outcomes
Notes
Othman 2016
Methods
Participants
Interventions
Outcomes
Notes
Pakniat 2015
Methods
Participants
Interventions
Outcomes
Notes
Patil 2013
Methods
Participants
Interventions
Outcomes
Notes
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Quibel 2016
Methods
Participants
Interventions
Outcomes
Notes
Rabow 2017
Methods
Participants
Interventions
Outcomes
Notes
Ragab 2016
Methods
Participants
Interventions
Outcomes
Notes
Raghavan 2016
Methods
Participants
Interventions
Outcomes
Notes
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Ray 2012
Methods
Participants
Interventions
Outcomes
Notes
Razali 2016
Methods
Participants
Interventions
Outcomes
Notes
Reyes 2011
Methods
Participants
Interventions
Outcomes
Notes
Rosales-Ortiz 2014
Methods
Participants
Interventions
Outcomes
Notes
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Sangkhomkhamhang 2012
Methods
Participants
Interventions
Outcomes
Notes
Sentilhes 2015
Methods
Participants
Interventions
Outcomes
Notes
Senturk 2016
Methods
Participants
Interventions
Outcomes
Notes
Shrestha 2008
Methods
Participants
Interventions
Outcomes
Notes
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Shrivasatava 2012
Methods Randomised trial.
Participants Not known how many women randomised
Interventions 200 mcg of Methylergometrine of unknown route or 400 mcg of misoprostol administered sublingually
Outcomes PPH (not defined), additional uterotonics, change in HB level, third-stage duration (min), blood loss (mL)
Notes Method of randomisation not clear and ’Risk of bias’ assessment is uncertain. Abstract only. Unable to contact authors
Soleimani 2014
Methods
Participants
Interventions
Outcomes
Notes
Sunil 2016
Methods
Participants
Interventions
Outcomes
Notes
Taheripanah 2017
Methods
Participants
Interventions
Outcomes
Notes
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Tali 2016
Methods
Participants
Interventions
Outcomes
Notes
Ugwu 2016
Methods
Participants
Interventions
Outcomes
Notes
Un 2012
Methods
Participants
Interventions
Outcomes
Notes
Vlassoff 2016
Methods
Participants
Interventions
Outcomes
Notes
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Voltolini 2012
Methods
Participants
Interventions
Outcomes
Notes
Weeks 2015
Methods
Participants
Interventions
Outcomes
Notes
Whigham 2016
Methods
Participants
Interventions
Outcomes
Notes
Winikoff 2016
Methods
Participants
Interventions
Outcomes
Notes
Hb, haemoglobin; IU, international unit;mcg, microgram; mL,: milliltre; PPH, postpartum haemorrhage
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Characteristics of ongoing studies [ordered by study ID]
Castro 2012
Trial name or title Buccal misoprostol during cesarean section for preventing postpartum hemorrhage
Methods Placebo-controlled randomised trial.
Participants 120 women undergoing an elective or emergency caesarean birth at 24 weeks of gestation or later with risk
factors for PPH
Interventions 400 mcg of misoprostol administered buccally or placebo
Outcomes PPH at 1000, additional uterotonics, transfusion.
Starting date February 2008, Updated 2012
Contact information Dr. Jose E. Gonzalez
Notes This study is shown as currently recruiting participants.
Diop 2011
Trial name or title Comparing misoprostol and oxytocin in UnijectTM for Postpartum Hemorrhage (PPH) Prevention in Mali
Methods Double-blinded randomised trial.
Participants 140 women with a pregnancy over 34 weeks and a risk factor for PPH
Interventions 100 mcg of carbetocin administered intravenously or 10 IU of oxytocin administered intravenously
Outcomes Change in Hb level, nausea, vomiting, fever, shivering.
Starting date Start date not known.
Contact information Milton Cesar Gomez Gomez
Notes This study is shown as not yet recruiting.
Diop 2012
Trial name or title Comparing misoprostol and oxytocin in Uniject for postpartum hemorrhage (PPH) prevention in Senegal
Methods Open-label cluster-randomised trial.
Participants 1365 women giving birth in community health centres with a trained study provider
Interventions 600 mcg of misoprostol administered orally or 10 IU of oxytocin administered intramuscularly
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Diop 2012 (Continued)
Outcomes Change in Hb level, nausea, vomiting, fever, shivering.
Starting date June 2012
Contact information Gynuity health projects
Notes This study is shown as completed.
Draycott 2014
Trial name or title Intramuscular oxytocics: a comparison study of intramuscular carbetocin, syntocinon and syntometrine for
the third stage of labour following vaginal birth (IMox)
Methods Randomised trial
Participants Women delivering vaginally, singleton pregnancy
Interventions One dose of 100 mcg intramuscular Carbetocin given for active management of the third stage of labour,
immediately after the birth of the baby
One dose of 10 IU intramuscular Syntocinon given for active management of the third stage of labour,
immediately after the birth of the baby
One dose of 500 mcg/5 IU intramuscular Syntometrine given for active management of the third stage of
labour, immediately after the birth of the baby
Outcomes Requirement for additional uterotonic drugs
Starting date February 2015
Contact information Tim Draycott, North Bristol NHS Trust/University of Bristol
Notes Study Chair:
Gomez 2011
Trial name or title Efficiency of carbetocin in the prevention of the postpartum haemorrhage: a clinical double-blinded ran-
domised study
Methods Open-label randomised trial.
Participants Women undergoing a vaginal birth at home with a trained study provider
Interventions 600 mcg of misoprostol administered orally or 10 IU of oxytocin administered intramuscularly
Outcomes PPH at 1000, additional uterotonics, transfusion, nausea, headache, abdominal pain
Starting date 15/07/2010
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Gomez 2011 (Continued)
Contact information Milton Cesar Gomez Gomez
Notes This study is shown as not yet recruiting.
Kalahroudi 2010a
Trial name or title Comparison of the effect of rectal misoprostol and syntometrin in prevention of postpartum hemorrhage
Methods Double-blinded randomised trial.
Participants 200 women with a singleton pregnancy undergoing a vaginal birth
Interventions 500 mcg of ergometrine plus 5 IU of oxytocin administered intramuscularly or 600 mcg of misoprostol
administered rectally
Outcomes Additional uterotonics, change in Hb level.
Starting date 21/4/2010
Contact information Dr. Mansoureh Samimi
Notes This study is shown as recruitment complete.
Kalahroudi 2010b
Trial name or title Comparison effect of carbetocine and syntometrin in prevention of postpartum hemorrhage
Methods Double-blinded randomised trial.
Participants 200 women with a singleton pregnancy undergoing a vaginal birth
Interventions 500 mcg of ergometrine plus 5 IU of oxytocin administered intramuscularly or 100 mcg of carbetocin
administered intramuscularly
Outcomes Additional uterotonics, change in Hb level.
Starting date 21/1/2010
Contact information Dr. Mansoureh Samimi
Notes This study is shown as recruitment complete.
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Moradi 2010
Trial name or title Comparison of misoprostol and oxytocin in reduction of postpartum hemorrhage
Methods Randomised trial.
Participants 300 women with singleton, term pregnancies.
Interventions 10 IU of oxytocin administered intravenously or 400 mcg of misoprostol administered orally
Outcomes Change in haemoglobin.
Starting date 22/12/2009
Contact information Simindokht Moradi
Notes This study is shown as recruitment complete.
Shahboodaghi 2013
Trial name or title Misoprostol versus oxytocin for prevention of post partum hemorrhage
Methods Double-dummy randomised trial.
Participants 400 women undergoing vaginal birth with a singleton pregnancy
Interventions 400 mcg misoprostol administered orally or 20 IU of oxytocin administered through an intravenous infusion
Outcomes Change in Hb level, vomiting, fever, shivering.
Starting date May 2013
Contact information Dr Minoo Rajaei
Notes This study is shown as ongoing, but not recruiting participants
Sweed 2014
Trial name or title Comparison between rectal& sublingual misoprostol before caesarian section to reduce intra& post-operative
blood loss
Methods Placebo-controlled randomised trial.
Participants 635 women undergoing elective caesarean with a singleton term pregnancy and only 1 previous caesarean
Interventions 400 mcg of misoprostol administered rectally or 400 mcg of misoprostol administered sublingually or placebo
Outcomes Change in Hb level, blood loss.
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Sweed 2014 (Continued)
Starting date February 2013
Contact information Mohamed S Sweed,
Notes This study is shown as completed.
Widmer 2016
Trial name or title Room temperature stable carbetocin for the prevention of postpartum haemorrhage during the third stage of
labour in women delivering vaginally
Methods Randomized, non-inferiority trial at 22 centres in 10 countries
Participants Women delivering vaginally, cervical dilatation equal to or less than 6cm, singleton pregnancy
Interventions Carbetocin RTS 100 micrograms solution for intramuscular (IM) injection to be administered once during
the third stage of labour
Oxytocin 10 IU solution for intramuscular (IM) injection to be administered once during the third stage of
labour
Outcomes The proportion of women with blood loss of 500 mL or more or the use of additional uterotonics at one
hour and up to two hours for women who continue to bleed after one hour
(composite primary outcome).
The blood loss will be measured with a plastic drape placed under the woman’s buttocks
Starting date July 2015
Contact information Mariana Widmer (widmerm@who.int)
Notes ACTRN12614000870651
Hb, haemoglobin; IU, international unit;mcg, microgram; PPH, postpartum haemorrhage; RTS, room temperature stable
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A P P E N D I C E S
Appendix 1. Search terms
ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP)
Third stage AND labo(u)r AND oxytocin
Third stage AND labo(u)r AND misoprostol
Third stage AND labo(u)r AND carbetocin
Third stage AND labo(u)r AND ergometrine
uterotonic* AND oxytocin
uterotonic* AND misoprostol
uterotonic* AND carbetocin
uterotonic* AND ergometrine
uterotonic* AND labo(u)r
uterotonic* AND h(a)emorrhage
h(a)emorrhage AND postpartum AND ergometrine
h(a)emorrhage AND postpartum AND oxytocin
h(a)emorrhage AND postpartum AND carbetocin
h(a)emorrhage AND postpartum AND misoprostol
Appendix 2. Network diagrams for secondary outcomes and subgroup analyses
Please see NIHR HTA report for all diagrams (link).
Appendix 3. Subgroup and sensitivity analyses for PPH ≥ 1000 mL
Please see NIHR HTA report for all diagrams (https://www.journalslibrary.nihr.ac.uk/programmes/hta/1413917/#/)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There are some differences between the published protocol for this review (Gallos 2015) and the full review, these are listed below.
Objectives
We have clarified the objectives of this review.
In our protocol the stated objectives were:We aim to assess the clinical effectiveness and side-effect profile of uterotonic drugs to prevent
PPH, and to generate a clinically useful ranking of available uterotonics according to their effectiveness and side-effects. We will explore
the effects according to various key prognostic and treatment factors. The population of interest is women following a vaginal birth or a
caesarean section in the hospital or the community setting. All uterotonic drugs considered by theWHO are eligible and the outcomes
include blood loss-related outcomes and side-effects.
In the review, our objectives are listed as:
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Primary
To identify the most effective uterotonic drug(s) to prevent postpartum haemorrhage (PPH) with a favourable side-effect profile, and
to generate a clinically useful ranking of all available uterotonics.
Secondary
To provide the relative effectiveness and side-effect profile of each drug for our primary outcomes within: a) Population subgroups (prior
risk of PPH, mode of birth and healthcare setting) and b) Treatment subgroups (different dosages, routes or regimens of administration
of each uterotonic drug).
Methods/types of agents
The text in this section has been edited to add sensitivity analyses that became necessary during the review and explain how we grouped
the agents for analysis.
In the protocol, this section stated:
We will consider trials of uterotonics described by WHO (WHO 2012) (oxytocin, ergometrine, misoprostol, carbetocin, or combina-
tions of uterotonics) administered prophylactically by healthcare professionals for preventing PPH via any systemic route (sublingual,
subcutaneous, intramuscular, rectal, oral, intravenous bolus and/or infusion) compared with another uterotonic or with placebo or no
treatment. If we identify in the included studies interventions that we are not aware of, we will consider them as eligible and include
them in the network after assessing their comparability with those named above. We will include trials in which non-pharmacologic
co-interventions such as controlled cord traction, cord clamping, or uterine massage was performed as a randomised intervention in all
arms of the trial. We will stratify all drugs according to mode of birth, prior risk of PPH, healthcare setting, specific dosage, regimen
and route, to detect inequalities in subgroups that could affect comparative effectiveness.
Figure 1 (in the published protocol) shows the overall network of eligible comparisons in the review at a drug level.
Multi-arm trials that compare different dosages, regimens or routes of one uterotonic drug, but also compare those versus another
uterotonic drug, will be included. Intervention arms of different dosages, regimens or routes of the same uterotonic drug will be merged
together for the global analysis of all outcomes and treated as separate independent comparisons only for the relevant subgroup analysis
according to dosage, regimen and route of drug administration, while taking into account the correlation between the comparisons.
We will exclude trials comparing exclusively different dosages, regimens or routes of administration of the same uterotonic drug. The
review will be restricted to studies evaluating uterotonic drugs administered systemically at the birth of the baby for preventing PPH.
Studies considering non-uterotonic drugs, uterotonic drugs administered locally (for example, via intraumbilical or intrauterine routes)
or at a later stage of delivery (for example, for the treatment of PPH or for retained placenta) will be excluded.
In our review this section now states:
Trials were eligible if they administered uterotonic agents of any dosage, route or regimen systemically following birth for preventing
PPH, and compared them against other uterotonic agents, placebo or no treatment. Trials evaluating uterotonic drugs administered
locally or not immediately after birth, or exclusively comparing different dosages, routes or regimens of the same uterotonic agent were
excluded. We included trials in which non-pharmacologic co-interventions such as controlled cord traction, cord clamping, or uterine
massage was performed as a randomised intervention in all arms of the trial and the effects of such co-interventions were tested through
a sensitivity analysis.
We classified drugs into oxytocin, carbetocin, misoprostol, ergometrine (included also ergonovine, methylergonovine), oxytocin plus
ergometrine (Syntometrine, oxytocin combined with ergometrine, ergonovine, or methylergonovine), and oxytocin plus misoprostol.
We excluded synthetic prostaglandin analogues of PGF2α (carboprost), and PGE2 (prostin, sulprostone), because these drugs are
usually used for treating (and not preventing) PPH, and are not currently recommended by the World Health Organization (WHO) as
alternatives (WHO 2012).
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Methods/search methods
The search methods have been updated in line with the current standard search methods text of Cochrane Pregnancy and Childbirth.
Methods/types of outcomes/secondary outcomes
We have edited the outcome ’clinical signs of blood loss’ to ’clinical signs of excessive blood loss (as defined by the trialists).’
Methods/investigation of heterogeneity and inconsistency and also subgroup analysis
We have edited the intervention subgroups for exploring heterogeneity and inconsistency and also subgroup analysis. In the protocol,
these sections stated:
Intervention: dose, regimen or route.
In our review these sections now state:
Intervention: Dose of misoprostol (≥ 600 mcg versus < 600 mcg), and regimen of oxytocin (bolus versus bolus plus infusion versus
infusion only).
Methods/investigation of heterogeneity and inconsistency and also subgroup analysis
We have carried out additional sensitivity analyses that became necessary during the conduct of the review. These are listed below:
1. Trials that also randomised participants to co-interventions such as uterine massage or controlled cord traction.
2. Trials with more than 10% missing data.
3. Trials published before 1990.
Analysis
Since publication of the protocol for this review, further methods became available to perform the analysis with a frequentist approach
in STATA. We changed our analysis for this reason to STATA rather than WinBUGS and a Bayesian environment.
’Summary of findings’ table
We have added a GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis,
which was not planned during the protocol stage as the methods for this only became available recently for network meta-analyses.
358Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
